





























Submitted for the degree of Ph.D. 
 








The candidate confirms that the work submitted is her own and that 
 
 appropriate credit has been given where reference has been made to the  
 
































Firstly, I would like to offer my sincerest gratitude to my supervisor, Dr. Rory 
Mitchell, who has supported me throughout my PhD with his patience, 
encouragement and knowledge. I could not have wished for a kinder supervisor. My 
warmest thanks to Dr. Louise Dickson, who has continuously offered enormous 
support, both on an academic and personal level, to Pam Holland, for her continuous 
supply of cells and good humour, and to Bobbie Rosie for patiently sharing her 
academic skills and experience - this is most valued. I would also like to thank 
Melanie Johnson, who provided me with the best possible start to my PhD. 
 
The informal support and encouragement of many friends has been indispensible, 
and in particular, for putting up with hours of my moaning, I would like to 
acknowledge Anita Norfolk and Christina Bruns.  My family have been a constant 
source of support during my postgradute years. Thanks to my father, James Barclay, 
for initially instilling in me a fascination for the natural world which started me on 
this path; to my sister, Lily Barclay, for always making me laugh when the going 
was tough; and to my mother, Nancy Barclay, whose love and support has been the 
foundation for me to see this through. Finally, to Andrew, who is probably even 
more pleased than me to see this thesis submitted, thankyou for your endless support, 








The 5-HT2A receptor (5-HT2AR) is implicated in neuropsychiatric disorders such as 
schizophrenia and is thought to mediate the actions of a number of hallucinogenic 
and antipsychotic drugs. Additionally, certain polymorphic variants of the receptor, 
such as an allele resulting in substitution of amino acid 452 histidine (H) with 
tyrosine (Y), have been linked to schizophrenia or altered therapeutic response to 
antipsychotics. The 5-HT2AR utilises various intracellular signalling pathways, 
including the activation of phospholipase C (PLC) and phospholipase D (PLD) via 
recruitment of the small G-protein ADP-Ribosylation Factor (ARF). This thesis 
focusses on protein:protein interactions and signalling mechanisms of the 5-HT2AR 
and H452Y-5-HT2AR receptor variant.  
 
Both ARF1 and PLD1 have previously been shown to bind to the carboxy-terminal 
tail (ct) of the 5-HT2AR. In chapter three it is demonstrated that the 5-HT2AR can 
activate PLD in an ARF-dependent manner, primarily through the PLD1 isoform. 
GST-fusion proteins of truncated and mutated variants of the receptor ct are used to 
show that ARF1 and PLD1 independently bind to distinct sites. Co-
immunoprecipitation, GST-fusion protein studies and PLD activity assays 
demonstrate that the introduction of the H452Y mutation decreases the physical 
interactions between the receptor and PLD1, as well as decreasing 5-HT2AR-
mediated PLD activation. In chapter four, potential mechanisms of wild-type and 
H452Y-5-HT2AR desensitisation are explored. It is shown that !-arrestin 2 (!-arr 2) 
confers a decrease in H452Y-5-HT2AR-mediated PLC activity, despite having no 
significant effect upon wild-type 5-HT2AR responses. The H452Y-5-HT2AR variant 
is also shown, by GST-fusion protein studies, to bind !-arr 2 more strongly. The 
H452Y-5-HT2AR additionally mediates increased levels of 5-HT-induced ERK 
phosphorylation compared to the wild type 5-HT2AR, potentially through increased 
scaffolding of ERK activation complexes by receptor-bound !-arr 2. Chapter five 
focusses on possible interactions of the 5-HT2AR with the Ca
2+
-binding proteins 
annexin A2, S100B and the annexin A2 partner p11, together with the functional 





studies show that annexin A2 binds specifically to the 5-HT2AR ct. Furthermore, 
annexin A2 (but not S100B or p11) is shown to result in an amplification of 5-
HT2AR-mediated PLC responses. 
 
These findings provide a greater insight into some of the signal transduction 
mechanisms of the 5-HT2AR and their perturbation in the H452Y polymorphic form 
of the receptor, and understanding of the molecular mechanisms underlying 
neuropsychiatric diseases in patient subgroups, potentially leading to improved 
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1.1 GPCR Structure 
The G protein-coupled receptor (GPCR) family constitutes one of the largest 
superfamilies of human proteins, and is the largest cell surface receptor family, with 
genes encoding functional GPCRs comprising more than 1% of the human genome 
(1,2). GPCRs are deployed within the plasma membrane and interact with 
extracellular ligands. These interactions induce conformational changes in the 
receptor, which are transmitted intracellularly. Thus GPCRs act to transfer signals 
across the cellular plasma membrane, activating G proteins and participating in 
protein:protein interactions. In this way GPCRs activate intracellular signal 
transduction pathways, ultimately resulting in a physiological response. Due to the 
variety of both potential receptor ligands and effector proteins, members of the 
GPCR superfamily demonstrate great functional diversity, acting to influence 
numerous physiological processes, such as cell growth and differentiation, 
metabolism, vision, smell and taste (3). Consequently, GPCRs are of immense 
pharmacological importance, with an estimated >50% of all clinical drugs in current 
use being targeted at these receptors (4,5). 
 
Although GPCRs exhibit diverse primary structures, and low sequence homology, 
experimental studies have determined a common basic architecture. They are thought 
to be composed of: an extracellular amino-terminus (N-terminus); 7 relatively 
hydrophobic "-helical transmembrane domains, linked by three intra- and three 





intracellular carboxy –terminal tail (C-terminus) (6). The "-helical transmembrane 
domains are thought to group together within cell membranes to form an anti-
clockwise orientated bundle, with the third transmembrane-spanning domain 
positioned towards the centre (7). Originally, structural GPCR models were based on 
the structure of bacteriorhodopsin, solved by NMR, electron diffraction and X ray-
based crystallography (8-11). This structure has since been demonstrated to be 
unrepresentative of the transmembrane domains of mammalian rhodopsin structures 
(12). Subsequent sequence homology studies of bacteriorhodopsin with other 
GPCRs suggested that these receptors do display some elements of a common basic 
structure, with the presence of 7 "-helical transmembrane-spanning domains (13-15). 
These studies were followed with the publication of several higher resolution 
rhodopsin structures (16,17). In 2000, the inactivated (11-cis-retinal) 3-dimensional 
structure of bovine rhodopsin was determined by X-ray crystallography to 2.8-
angstroms (7). This structure demonstrated a similar basic architecture to previous 
models, but with the addition of an eighth "-helical domain located distal to 
transmembrane-spanning "-helix 7, and orientated parallel to the membrane plane 
(7). Recently, in 2007, the first crystal structures of a non-rhodopsin receptor, the !2-
adrenergic receptor, were published (18-20). This was closely followed by the 
publication of the turkey !1-adrenergic receptor (21), and the human adenosine A2A 
receptor structure (22). Comparison of the solved structures has revealed the 
arrangement of the transmembrane helices to be loosely conserved between the three 
representative subclasses. However, dissimilarities between the models, such as the 
conformation of the extracellular regions, the position of ligand binding sites and the 





intracellular loop with a Glu residue of the sixth transmembrane domain (7,18,19) 
(21-23), have highlighted the limitations of using rhodopsin as a general GPCR 
model and the need for a greater array of solved GPCR structures. 
 
The GPCR superfamily has been classified into families using various techniques. 
The two most commonly used nomenclature systems, the A-F clan system and 
glutamate, rhodopsin, adhesion, frizzled/taste, secretin (GRAFS) system both 
categorise the GPCR superfamily based on the comparison of the 7 transmembrane 
domains of the receptors. The A-F clan system was developed using an informatics 
technique to analyse GPCRs of both vertebrates and invertebrates (24,25). Several 
conserved regions of alignment were used to generate a rhodopsin family fingerprint, 
which was used to scan the database, yielding GPCR families A-F (24). The GPCR 
superfamily has more recently been classified using the GRAFS system (26,27). 
Phylogenetic studies were used to categorise the superfamily into five human GPCR 
families, each containing members related by their presumed evolutionary origins, 
giving yield to glutamate, rhodopsin, adhesion protein, frizzled/taste 2 and secretin 
families (GRAFS) (27). The members of these families will be discussed in further 
detail below, using both GRAFS and A-F classification nomenclature. 
 
1.2 Rhodopsin-like family (Class-A) 
The rhodopsin-like family of receptors, otherwise known as Class-A receptors, 
comprise the largest family of GPCRs, with approximately 90% of known GPCRs 
being members of this group (28,29). Although many Class-A receptors are odorant 





structure and the physiological functions they may mediate (29). Rhodopsin-like 
receptors are divided into four subgroups. The " group contains the amine receptor 
group, which comprises 5-HT, dopamine, muscarinic, adrenergic and cannabinoid 
receptors among others. In addition the opsin, melatonin, prostaglandin and MECA 
(consisting of melanocortin, endothelial differentiation sphingolipid, cannabinoid 
and adenosine receptors) receptor groups are all contained within the " group. The ! 
group is primarily composed of peptide-binding receptors and contains neuropeptide 
Y receptors, oxytocin receptors and endothelin receptors. The # group comprises 
peptide- and lipid-binding receptors and includes the three opioid receptors, the AT1 
angiotensin receptor and the type 2 and 5 somatostatin receptors. Finally, the $ group 
comprises the olfactory receptors (the largest group of rhodopsin receptors), 
glycoprotein-binding receptors, the protease-activated receptors (PAR) and the 
leukotriene receptors (26,27,30-32).  
 
As the name suggests, receptors belonging to the rhodopsin-like group display 
significant sequence homology to the rhodopsin receptor (27). Rhodopsin-like 
GPCRs generally display relatively low sequence homology within the family, 
although they do typically express a few specific very highly conserved domains. 
The majority of class-A receptors contain a highly conserved structurally stabilising 
disulphide bond between Cyss of the second extracellular loop (e2) and the third 
transmembrane spanning helix (tm3) (33-36). A highly conserved motif, Asp-Arg-
Tyr (DRY), is located at the cytoplasmic face of the receptor, between the third 
transmembrane domain (tm3) and second intracellular loop (i2) (37). This motif is 





regulate agonist-induced conformational changes of the receptor, and subsequently 
the binding of the GPCR to the heterotrimeric G protein (38-43).  A conserved Asp-
Pro-xx-Tyr (NPxxY) motif is located at the junction between the base of 
transmembrane-spanning domain 7 (tm7) and the beginning of the C-terminal tail. 
The two amino acid residues found between Pro and Tyr tend to be hydrophobic 
(37). It has been proposed that the presence of the NPxxY domain interrupts the "-
helical structure of the seventh transmembrane domain by forming a flexible hinge 
region, thereby creating a structural perturbation that may have various potential 
functional roles (44). This domain has been reported to be required for the efficient 
internalisation of some receptors, such as the $-opioid receptor (45), the neurokinin-1 
receptor (46) and the vasopressin-II receptor (47). However, alternative studies have 
demonstrated that the angiotensin II type I receptor (48) and the gastrin-releasing 
peptide receptor (49) undergo internalisation independently of the NPxxY motif. The 
presence of the NPxxY motif has additionally been demonstrated to influence 
receptor signalling. Studies have shown that the motif may play a key role in receptor 
interactions with the small G protein ARF and possibly Rho, and subsequent ARF-
mediated signalling (50). Further signalling investigations have also revealed the 
involvement of the NPxxY motif in the activation of adenylyl cyclase, phospholipase 
C, MAP kinase and phosholipase D (50-53). Additionally, a conserved Cys of the 
carboxy-terminus is thought to undergo palmitoylation, thereby anchoring the 
carboxy-terminal tail domain at the cell membrane, creating a putative fourth 
intracellular loop. X-ray crystallography of the rhodopsin structure identified a short 
amphipathic "-helix existing parallel to the plane of the membrane, located between 





is thought to exist in many rhodopsin family GPCR structures and is suggested to be 
one of the GPCR regions involved in G protein coupling (7,54). 
 
The rhodopsin-like GPCR family includes two receptors for which the ligand-bound 
structures have now been solved to high resolution, thus providing insights into the 
mechanisms of GPCR ligand-binding and activation (7,18-20). The bovine rhodopsin 
receptor is known to be covalently bound to its ligand retinal, which is buried within 
a four-stranded !-sheet structure (55,56). Retinal undergoes isomerisation in 
response to light, inducing a conformational change in rhodopsin that brings about an 
association with the G protein transducin (57). When bound to the 11-cis retinal 
isomer (dark form of retinal), the receptor is known to be locked in an inactive form, 
held by an ionic interaction between Arg 135 of the DRY motif with the adjacent Glu 
134 and Glu 247 of tm6 (40,55,56). Ligand-activation induces a break in this 
interaction and a subsequent outwards movement of tm6 in relation to tm3 (55,58). 
In contrast, the !-adrenergic receptor binds diffusible ligands. The e2 forms an "-
helix stabilised by disulphide bonds, which reveals the ligand-binding site, making it 
accessible from the extracellular environment (18-20,55). Similarly to the rhodopsin 
receptor, the !-adrenergic receptor has an ionic interaction between the DRY motif 
of tm3 and tm6, although this interaction is not as strong in the !-adrenergic 
receptor, possibly decreasing the stability of the receptor (18-20,55).  
 
1.3 Secretin receptor family (Class-B) 
The class-B or secretin receptor family comprises 15 peptide-binding receptors, 





family are activated by peptide ligands of approximately 30-40 amino acids, such as 
hormones, neuropeptides and autocrine factors (60). The receptor family includes the 
calcitonin and calcitonin-like receptors, the corticotrophin–releasing hormone 
receptors, the glucagon receptor, the gastric inhibitory polypeptide receptor, the 
glucagon-like peptide receptors, the growth-hormone-releasing hormone receptor, 
the pituitary adenylyl cyclase-activating polypeptide receptor, the parathyroid 
hormone receptors, the secretin receptor and the vasoactive intestinal peptide 
receptors (59). Secretin family GPCRs have a large extracellular N-terminus, within 
which a large proportion of the receptor family sequence diversity exists. However, 
almost all members of the secretin family contain conserved Cys residues within the 
N-terminus, which form disulphide bridges, acting to stabilise the receptor (61). 
Some of these conserved Cys residues are also thought to be closely involved in 
ligand binding (62,63).  In addition, the e1 and e2 contain conserved Cys residues, 
which are also implicated in ligand binding (61,62). Although an exact mechanism 
has not been determined for the activation of class-B GPCRs, there are two popular 
theories. Dong et al proposed that agonist binding may induce a conformational 
change in the receptor, inducing the association of the N-terminus with tm6, acting to 
stabilise the receptor in its active conformation (64). Alternatively, the two-domain 
model proposes that class-B receptors bind ligand at the N-terminus, promoting 
interactions between the ligand and the transmembrane domain. This induces a 
conformational change in the receptor, increasing G protein interactions and thereby 
inducing the potential activation of downstream signalling pathways (65). Secretin 
family receptor-mediated signal transduction is reportedly initiated via interactions of 





control their downstream pathways (66,67).  However, secretin family receptors 
generally couple efficiently to Gs proteins as a common characteristic, thereby 
activating adenylyl cyclase  (66).  
 
1.4 Adhesion receptor family  (Class-B) 
The human adhesion receptor family is also a class-B clan member and contains 33 
human and 31 mouse GPCRs, which have been further subdivided to form 7 sub-
families. Although members of the adhesion receptor family also belong to the class-
B GPCR clan, they possess markedly different N-termini to secretin family GPCRs 
(32). The N-termini are long and can be composed of as many as a few thousand 
amino acid residues (68). They are diverse in terms of size and amino acid 
composition (26), but are commonly rich in Ser/Thr residues, resulting in high levels 
of glycoslyation (28,69). Adhesion family GPCR N-termini frequently contain 
several functional domains such as immunoglobulin, cadherin and laminin G 
domains, some of which are thought to be primarily responsible for the adhesive 
properties of these receptors (70). Nearly all members of the adhesion receptor 
family possess a conserved GPCR proteolytic site (GPS), within the extracellular 
regions of the receptor, adjacent to the transmembrane domain (71,72). It is 
reportedly involved in the proteolytic cleavage of receptor N-termini, to yield two 
non-covalently linked subunits (71,73).  This cleavage event is thought to be required 
for receptor folding and trafficking (74). 
 
The majority of adhesion family receptor members are orphan GPCRs, thus both the 





difficult to determine whether adhesion family GPCR members are linked to G 
proteins (73).  
 
1.5 Glutamate receptor family (Class-C) 
The class-C or glutamate family of GPCRs is composed of 22 receptors which are 
further subcategorised into 8 metabotropic glutamate, 1 calcium-sensing, 2 GABAB, 
3 taste, the GPRC6A and 7 orphan class C receptors (75). The N-terminus of 
glutamate family receptors is long, frequently containing more than 500 residues  
(76,77). It is involved in ligand recognition through a mechanism involving a 
conserved Venus Flytrap Module (VFTM) (76,78). With the exception of the GABA 
receptors, class-C glutamate family receptors express an additional conserved Cys-
rich domain that links the VFTM to the transmembrane-spanning domain (75). The 
ligand recognition site forms a cavity within the N-terminus, flanked by two folded 
lobe regions, stabilised by disulphide bonds to either side (79).  The lobes 
surrounding the ligand binding site are mobile and, in the absence of ligand, are 
proposed to oscillate between closed or open conformations. The presence of ligand 
is thought to stabilise the closed state of the ligand-binding region, thereby trapping a 
ligand such as glutamate at the binding site (80).  
 
The transmembrane helices are linked by short intra- and extracellular loops, of 
which e2 is the longest. e2 and e3 are reported to be involved in G protein binding 
and selectivity (75). As is consistent with the structure of rhodopsin, tm3 of class-C 
receptors is reported to be particularly hydrophobic, indicating that it is localised at 





structural studies, tm3 of glutamate receptors is linked via a disulphide bond to e2 
(7,75). An xPKxY motif, similar to the highly conserved NPxxY motif of rhodopsin-
like receptors is also conserved within tm7, which may be necessary for efficient 
coupling with G proteins (7,40,75). Additionally, members of the glutamate family 
receptors are also thought to express a putative eighth, amphipathic, helix, which is 
thought to be involved in G protein coupling (7,54,81). 
 
Many GPCRs can bind allosteric ligands, which regulate the activity of a receptor by 
interacting at binding sites distinct from the orthosteric ligand-binding site. The 
binding of an allosteric ligand acts to stabilize a particular receptor conformation, 
thereby altering the receptor binding affinity for the orthosteric ligand, and thus 
influencing receptor activity. Class-C receptors are putatively regulated by many 
positive and negative allosteric modulators (82,83). It has been reported that 
allosteric compounds may bind at the transmembrane helices of class-C receptors, as 
opposed to the N-terminus, in a crevice located within tm3, tm5, tm6 and tm7 (83). 
Class-C orthosteric ligand binding sites are known to consist of very highly 
conserved amino acid sequences, allowing little agonist-selectivity between the 
subtypes (84). It is thought that allosteric binding sites are less conserved, providing 
a potentially more specific therapeutic target (84). Both negative and positive class-C 
allosteric modulators have been developed for potential therapeutic purposes, 
including CDPPB, an antipsychotic that acts as an allosteric enhancer of the 
metabotropic glutamate 2 (mGlu2) receptor, and LY-354740, a positive allosteric 
regulator of both mGlu2 and mGlu3 receptors, currently undergoing clinical trials for 






Class-C receptors were the first GPCRs demonstrated to form functional in vivo 
dimers (85,86). Many members of the class-C receptor family are thought to form 
homodimers and/or heterodimers. The metabotropic glutamate receptors and 
calcium-sensing receptor have been identified in homodimeric form, linked by 
disulphide bonds and by direct interactions between the ligand binding domains 
(75,79,85). Subsequently, a metabotropic glutamate-calcium sensing receptor (mGlu-
CaSR) heterodimer was identified (87).  The GABAB receptor also forms a 
heterodimer, composed of the splice variants GABAB1 and GABAB2, linked via 
coiled-coil domains within the C-terminus (88) and also via interactions between the 
VFTM domains (89). It is suggested that GABAB function is dependent upon the 
formation of  GABAB1 and GABAB2 heterodimers (88).  
 
 
1.6 Frizzled / Taste 2 receptor family (class B) 
Although the frizzled and taste 2 receptor families comprise receptors that appear to 
have a diverse evolutionary history, the mammalian frizzled and taste 2 receptors are 
classified as one grouped under the GRAFS nomenclature system (27). However, 
under the A-F clan system the frizzled family, along with the adhesion family, were 
categorised as a part of the class-B secretin family (26). The frizzled family of 
GPCRs are receptors for Wnt glycoprotein ligands (32,90). Wnts are essential 
mediators of embryonic development, as well as being involved in many disease 
states (91,92). The family comprises only 11 human receptors, 10 frizzled receptors 





GPCR superfamily, frizzled receptors are composed of an extracellular N-terminus, 7 
transmembrane domains and an intracellular carboxy-terminus. The ligand-binding 
site is located within the N-terminus, and contains a Cys-rich domain (93). The C-
terminus of frizzled proteins appears not to contain the Cys residue required to form 
the putative fourth intracellular loop described in many GPCRs (94). However, many 
frizzled proteins have been determined to contain the C-terminal motif 
serine/threonine-Xxx-valine, recognised as a PDZ-binding domain, thereby 
providing a potential site for the scaffolding of signalling complexes (94,95).  As yet, 
the frizzled family of receptors have not been demonstrated to interact directly with 
G proteins, although data from signalling studies would suggest that frizzled 
receptors can signal via the Gi/o and Gq proteins (96).  
 
The taste 2 receptors are a family of bitter taste receptors, comprising 40-80 human 
and rodent GPCRs (97). Under the GRAFS nomenclature system, the taste 2 
receptors are categorised with the frizzled receptors. However, they have previously 
been classified under the clan system as a family distantly related to the rhodopsin 
receptor family, or as a novel separate family (98). They are thought to interact with 









Figure 1.1 Diagram illustrating the basic architecture of class-A, class-B and 
class-C GPCRs.  Structure of Class-A GPCRs (above), Class-B (middle) and 









1.7 G Proteins and signalling pathways 
The transduction of a signal resulting from GPCR ligand-activation is enabled by 
heterotrimeric G proteins. These highly conserved proteins are multi-subunit 
structures, composed of a G protein " subunit (G") and a G protein !# subunit (G!#) 
(99).  They are often described as ‘molecular switches’, as they switch from an 
inactive GDP bound state to an active GTP bound state in response to GPCR 
activation, with their transition to the inactive state facilitated by the intrinsic GTP-
ase activity of the G" subunit  (3). When in an active state, the G protein can interact 
with a plethora of downstream effector proteins, which are often enzymes, thereby 
promoting the transduction of the signal into the cell. There are 21 identified human 
G" subunits, encoded by 16 genes. These are classified into four groups based on 
sequence homology. There are only 6 G! subunits, encoded by 5 genes and 12 G# 
subunits (100). However, this provides the potential for a putative >1000 G protein 
heterotrimer combinations (3), although it is unlikely that this results in >1000 
functionally diverse heterotrimer combinations. Various receptors have been 
demonstrated to selectively use different heterotrimeric G protein combinations in 
the activation of particular signalling pathways (101,102). 
 
The G" subunit, (% 41kDa), contains a highly conserved guanine nucleotide-binding 
pocket, composed of both a helical and a GTPase domain (103). The GTPase domain 
is conserved throughout the entire G protein family. It acts to hydrolyse GTP, 
resulting in structural changes due to changes to the conformation of three flexible 





that acts as a lid, thereby trapping bound nucleotides at the nucleotide-binding pocket 
(103,104). The G! subunit (% 35 kDa) has an "-helical N-terminus which links to the 
N-terminal of the G# subunit via a coiled coil, the remaining major part of the G! 
subunit is composed of a seven bladed, !-sheet propeller structure (103).  The G# 
subunits are small, (%7-8 kDa), and are primarily "-helical in structure (3). The C-
terminal comprises a CAAx domain that undergoes post-translational isoprenylation 
at the Cys residue, and as a result, is important for membrane localisation (3,105). 
The G protein subunits interact with one another at various sites. G! and G# subunits 
form a tight heterodimer between the N- and C-termini of G# and the N-terminus and 
5th and 6th blades of the G! subunit (106). The heterotrimer is formed via interactions 
between the N-terminal and switch II domains of the G" subunit with G! (106). 
 
The type of G protein that a GPCR couples to determines the signalling pathway and 
thus physiological responses that receptor activation will promote. Both the G" and 
G!# subunits are capable of interacting with secondary effector proteins to regulate 
downstream signalling.  As previously mentioned, the mammalian G" subunits are 
categorised into 4 subgroups, dependent upon the effector protein they link to. The 
heterotrimeric G proteins are also classified into four groups, defined by their G" 
subunit, and thus by their associated signalling pathway (107). G"s proteins directly 
bind to adenylate cyclases, 12 transmembrane domain proteins that catalyse the 
cyclical conversion of cytoplasmic adenosine 5’ triphosphate (ATP) to cyclic 
adenosine 3’, 5’ monophosphate (cAMP) (107). The second messenger cAMP in 
turn interacts with and regulates secondary effector proteins, such as protein kinase 





responses, such as the activation of the transcription factor CREB, phosphorylase 
kinase, phosphodiesterases (negative regulators of cAMP production) and the 
opening of the L-type Ca2+ channel. cAMP also directly activates the cAMP- and 
AMP-regulated guanine nucleotide exchange factor, exchange protein activated by 
cyclic AMP (EPac1) which activates Rap1, ultimately resulting in the 
phosphorylation and activation of Mitogen-Activated Protein Kinase (ERK MAP 
Kinase) 1 and 2 (108). G"s-mediated GTP hydrolysis and thus de-activation is 
specifically and permanently blocked by cholera toxin, which has ADP-ribosylation 
enzymatic activity and acts to ribsoylate the G"s subunit, resulting in constitutive 
cAMP production.  
 
The Gi/o family is composed of the G"i1-3, the G"oa-b, G"z and the photoreceptor 
G"t G proteins. G"i/o subunits act to directly inhibit some adenylyl cyclase 
subtypes, thereby decreasing intracellular levels of cAMP.   However, both G" and 
G!# proteins can act as direct regulators of downstream signalling molecules in this 
pathway. Activated G!# subunits can directly interact with and thereby regulate K+ 
channels, neuronal N-type Ca2+ channels and some subtypes of phosphatidylinositol 
3-kinase (PI 3-K), phospholipase C-! (PLC-!) and adenylyl cyclases. The Gi/o 
pathway can be specifically inhibited by pertussis toxin, which catalyses the ADP-
ribosylation of G"i, G"o and G"t, thereby preventing GDP/GTP exchange and 
functionally effective G protein:receptor interaction. Thus this toxin has been an 






The Gq/11 family of G proteins comprises G"q, G"11 and G"14-16 G proteins. 
Both G" and G!# subunits of this pathway can activate PLC-!1-4, thereby 
promoting the hydrolysis of membrane-bound phosphatidylinositol 4, 5- 
bisphosphate (PIP2), to yield the second messengers inositol 1, 4, 5- trisphosphate 
(IP3) and diacylglycerol (DAG).  IP3 increases intracellular Ca
2+ concentrations by 
triggering the release of Ca2+ stores from the endoplasmic reticulum. Ca2+ is required 
for the activation of many signalling molecules, including classical protein kinase C 
(PKC) isoforms. Additionally, DAG acts to recruit various PKC isoforms to the 
membrane, which are subsequently activated. PKC influences many physiological 
responses via its activity as a positive and a negative regulator of a diverse array of 
downstream signalling molecules such as phospholipase D isoforms (109), MAP 
kinases, Raf1 and Ras (110),  the transcriptional activators c-fos, c-jun and NF&B 
(111) and the cyclin complex E/cdk2 (112).  
 
G"12 and G"13 of the G12/13 family were the most recently identified subfamily of 
G proteins. These ubiquitously expressed proteins were first reported to bind and 
activate Rho-specific guanine nucleotide exchange factors (113,114). Subsequent 
Rho activation in turn influences cellular growth and cytoskeletal rearrangements 
(115). Further to these studies, G"12 and/or G"13 have been reported to interact 
with a wide array of effector proteins, including Regulator of G protein Signalling 
(RGS) proteins, cadherins, Hsp90, PLD, c-Src and PKC (107,115).  G12/13 are 
involved in cell migration, proliferation and transformation, thus are of much interest 






As previously mentioned, G proteins act to communicate a signal from the 
membrane-bound GPCR to membrane-bound or intracellular second messengers. 
This is achieved via interactions between the G protein and the cytoplasmic face of 
the GPCR. There are various theories proposed to explain the formation of these 
interactions. It has been suggested that intracellularly localised G proteins may bind 
only to activated GPCRs (116,117). FRET studies have indicated that G proteins 
interact with "2A-adrenergic receptors in a random fashion via intracellular collisions 
(118). However, alternative FRET studies have suggested that G proteins and 
GPCRs may be ‘pre-coupled’ prior to agonist-activation of the receptor (116,119). 
Once ligand-bound, it has been proposed that the GPCR undergoes a conformational 
change, putatively involving movement of the second, third or sixth transmembrane 
helices, within the bundle of helices, to expose crucial residues on its cytoplasmic 
face, to which the G"-protein C-terminus binds (120,121). Residues in the loop 
linking "-helix 4 and !-sheet 6 of the G" subunit ("4-!6) and the G" N-terminal 
helix are also thought to be involved in interactions with the i3 or c-terminus of the 
receptor (122,123). The G!# subunit also independently binds the receptor, in 
addition to stabilising the G"-GPCR interface (124).  Receptor activation induces a 
conformational change in the G" subunit, thought to involve rearrangements of 
switch regions and/or the N-terminal helix around the nucleotide-binding pocket, that 
results in the exchange of bound GDP for GTP (125,126). This instigates the release 
of the G protein from the receptor, and the dissociation of the heterotrimeric G 
protein to yield the monomeric G" and heterodimeric G!# subunits.  Once 
dissociated from one another G" and G!# proteins are free to diffuse through the 





pathways.  Upon hydrolysis of GTP, G" re-associates with G!#, to reform the 
heterotrimeric G protein.  
 
1.8 Regulation of GPCR activation 
Once a GPCR has been activated, the subsequent signal is generally regulated in 
order to avoid constitutive signal transduction. This is achieved in a variety of ways; 
receptors may be desensitized, down-regulated, or regulated by intracellular proteins. 
Desensitisation can be homologous, whereby agonist-activated receptors display 
reduced signalling. Alternatively, heterologous desensitisation involves a decrease in 
receptor output, in response to the activation of another GPCR. Following ligand 
activation of GPCRs, it has been established that the receptor adopts a conformation 
that is generally susceptible to rapid phosphorylation by G protein-coupled receptor 
kinases (GRKs), at specific Ser and Thr residues within the third intracellular loop 
and C-terminal tail of the receptor (127). This phosphorylation event promotes the 
binding of arrestin isoforms, which recognise both specific phosphorylated GPCR 
residues and the active conformation of the receptor within the intracellular domains 
(127). Once bound, arrestin acts to induce homologous receptor desensitisation, by 
creating steric hindrance of GPCR:G protein interactions, which interrupts G protein 
guanine nucleotide exchange, thereby decreasing G protein-stimulated signal 
transduction (128). In addition, the binding of arrestin to GPCRs can also promote 
clathrin-dependant receptor internalisation (127). Arrestins have been found to bind 
both to clathrin (in vitro) and the AP-2 adaptor complex (129). The AP-2 complex 
also binds to clathrin, dynamin and Eps-15, which are all molecules involved in 





GPCR and the clathrin endocytic machinery. Subsequently, the receptor can be 
internalised via clathrin-coated pit formation, resulting in endocytosis (129). 
 
The mode of arrestin activation has been found to be both receptor and cell-type 
specific (130,131). The differential strength of arrestin interactions with different 
GPCRs (which is thought to be determined by particular groups of serine and 
threonine residues positioned in the carboxy-terminus of the GPCR) can have 
significant effects upon arrestin-initiated receptor down-regulation, resensitisation 
and various signal transduction pathways (132,133). Thus several GPCRs of the 
rhodopsin family have been classified as Class A or B, defined by their binding 
affinity for !-arrestin isoforms.  Class A receptors only form a transient interaction 
with arrestin (127). Following internalisation, the receptor–arrestin complex 
dissociates, liberating the GPCR, which is rapidly dephosphorylated and recycled to 
the plasma membrane (127). In contrast, Class B GPCRs have been found to form a 
stable interaction with arrestin, which does not readily dissociate following 
internalisation (127). This strong interaction is thought to hinder the recycling of the 
receptor to the plasma membrane and possibly promote receptor degradation (127). 
In addition, arrestins are thought to be capable of acting as scaffolds for various 
signalling proteins, including members of the ERK MAP kinase pathway (134-136), 
and consequently, they can act as mediators of ERK 1 / 2 activation (137).  
 
The RGS (Regulators of G protein Signalling) protein family comprises a group of      
proteins with intrinsic GTPase-activating protein (GAP) activity, related by common 





date, all of which contain a conserved 120-130 amino acid RGS domain that is 
thought to account for GAP activity at G"-GTP  (138-140). Thus by directly binding 
G" proteins, RGS proteins act to enhance the exchange of GTP for GDP by the 
activated G"-GTP protein, thereby promoting G" deactivation and sequestering 
signal transduction. The majority of RGS proteins are reported to confer GAP 
activity at G"i/o and G"q/11 proteins (140,141). However, an increase in G"s-GTP 
hydrolysis and a decrease in G"s-mediated signalling were reported in the presence 
of RGS-PX1 (141,142). Although RGS proteins typically act as inhibitors of GPCR 
signalling, some larger members of the RGS protein family are thought to act as 
scaffolds, thereby participating in multiprotein signalling complexes (140,143). 
Some RGS proteins are thought to selectively bind both particular G" and GPCR 
family members (140). In small RGS proteins, receptor selectivity is reportedly 
conferred via particular amino acids of the N-terminal region (141,144), whilst large 
RGS proteins are more likely to bind GPCRs via protein interaction domains 
(141,145).  
 
1.9 5-HT receptors 
5-hydroxytryptamine (5-HT) is a ubiquitous monoaminergic neurotransmitter found 
in animals, plants, fungi and unicellular organisms. In humans, it is found throughout 
the central nervous system (CNS) and in the gastrointestinal tract (GI) and is 
synthesized from the amino acid tryptophan, which is derived from the diet (146). 
Tryptophan is decarboxylated by the enzyme tryptophan decarboxylase, yielding 
tryptamine, which is futher hydroxylated by the enzyme tryptamine 5-hydroxylase, 





activity is terminated primarily via uptake from the synapse into the neuron, 
mediated by the serotonin transporter (SERT), and subsequent catabolism by 
monoamine oxidase (148). 5-HT activity is mediated by the 5-HT receptor family of 
Class A GPCRs. The 5-HT receptor family comprises 7 subfamilies of rhodopsin-
like receptors, which have since been further divided into 15 subtypes (149). With 
the exception of the ionotropic 5-HT3 receptor, members of the 5-HT receptor family 
are coupled to G proteins. 
 
The 5-HT1 subfamily is composed of the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F 
receptor sub-types (149). These receptors all bind the pertussis sensitive Gi/o 
proteins, thereby inhibiting adenylyl cyclase (AC) activation, cAMP formation and 
subsequently act as negative regulators of protein kinase A (PKA) (146). PKA is an 
important regulator of the transcription factor CREB-1 and Rap-1 (which is involved 
in ERK1/2 activation), thereby this receptor family can mediate the downstream 
regulation of genes such as c-fos and MAP kinase activation pathways. 5-HT1 
receptor signalling can be mediated through a wide range of additional downstream 
signalling proteins, including ERK, Akt, Janus Kinase, and p38 kinase (146). The 5-
HT2 subfamily of GPCRs is further divided into 3 sub-types, the 5-HT2A, 5-HT2B and 
5-HT2C receptor (149). Each of these receptors preferentially couples to Gq/11 
proteins, which activate PLC (150). Other pathways/second messengers that the 5-
HT2 GPCR subfamily can couple to include PLD, PLA2, AC, the Janus Kinase (JAK) 
pathway and the ERK pathway (50,151-155). The 5-HT3 receptor is a ligand-gated, 
cation selective ion channel, located both within the central and peripheral nervous 





central ion-conducting pore (156,157). Each subunit comprises an extracellular, 
transmembrane and intracellular domain. The agonist-binding site is located within 
the extracellular domain (156). Upon ligand-activation, the 5-HT3 cation channel 
opens, allowing an influx of Ca2+ and Na+ ions and efflux of K+ ions, resulting in a 
rapid depolarisation (156). The 5-HT5 subfamily of receptors are the least understood 
and studied of the 5-HT receptor family. The family is divided into two subtypes, 5-
HT5A and  5-HT5B (149).  Only the 5-HT5A receptor is expressed in the human, but 
both are expressed in the mouse and the rat (158,159). The 5-HT5A receptor has been 
demonstrated to couple to G proteins and appears to preferentially interact with the 
Gi/o protein (160).  Finally, members of the 5-HT4, 5-HT6 and 5-HT7 subfamilies all 
preferentially couple to the Gs protein, thereby activating adenylate cyclase and 
protein kinase A (161)}. However, they are categorised into separate receptor classes 
due to very low sequence homology (<35%) (149).  The 5-HT4 receptor exists as 10 
different C-terminal splice variants, although all variants demonstrate very similar 
coupling properties, and are all known to additionally couple to the G13 protein to 
activate the small G protein, Rho (146,162). The 5-HT7 receptor exists in 4 splice 
variants which are known to demonstrate differing patterns of internalisation, 
although all splice variants couple similarly and additionally couple to the G12 protein 
to also activate Rho (146).  
 
Via the activation of these receptors, 5-HT is involved in many central roles within 
the CNS, such as thermoregulation, emotion, sleep, appetite, motor function, 
cognition and the vomiting reflex. In addition, 5-HT is suspected to be involved in 





secretion of certain hormones from the pituitary gland (163). 5-HT is also reported to 
invoke physiological effects upon the GI tract (164-166). There is evidence to 
suggest that the 5-HT3 receptors are involved in the mediation of intestinal secretion, 
GI smooth muscle control and vomiting and 5-HT4 in the modulation of intestinal 
secretion, the stimulation of GI motility and GI smooth muscle relaxation/contraction 
(166). 5-HT has also been demonstrated to invoke numerous effects upon the 
cardiovascular system via its actions as a peripheral vasoconstrictor (167), and 
through indirect pathways mediated via the central nervous system (168). Thus, it is 
not surprising that 5-HT is thought to be involved in various patho-physiological 
states. The serotonergic system has been implicated in hypertension, GI conditions 
such as irritable bowel syndrome and nausea and psychiatric disorders including 
schizophrenia, anxiety disorders, obsessive-compulsive disorder, Alzheimer’s 
disease, depression, anorexia and addiction (166-169, 172).  As a result the 
serotonergic system is of much pharmaceutical interest, and the 5-HT receptors are 
the targets of many pharmacological studies and currently available drugs.   
 
The 5-HT2A receptor (5-HT2AR), a subtype of the 5-HT2 subfamily, has evoked much 
interest due to its suspected involvement in hallucinogenic effects of drugs such as 
lysergic acid diethylamide (LSD), psilocybin and mescaline (169-171) and also in 
antipsychotic drug activity (172-174). Additionally, recent research has indicated that 
expression patterns, and thus the distribution of the 5-HT2AR within the central 
nervous system, may differ in untreated patients afflicted with neuropathological 





suggests the involvement of the receptor in the pathology of neuropsychiatric 
phenotypes, such as schizophrenia.  
 
Consequently, the 5-HT family, and in particular the 5-HT2AR, have been the subject 
of many structural and functional research studies. The N-terminus of 5-HT2 family 
receptors tends to be poorly conserved, and in common with the majority of family A 
GPCRs, has not been demonstrated to have a clear functional role (175). 
Mutagenesis studies on various 5-HT family member tm2 regions have indicated that 
residues within this domain may be involved in ligand binding (176). Sealfon et al 
demonstrated that the 5-HT2AR second transmembrane domain (tm2) is also involved 
in conformational arrangements relevant to G protein coupling (175,177). It has also 
been proposed that tm2 may be important for the conformational changes seen 
during receptor activation (168,177). The residues of both the 1st intra- and extra-
cellular loops are poorly conserved throughout the 5-HT family, although they are 
always short, consisting of 6-7 residues (175). The 3rd trans-membrane spanning 
domain (tm3) contains several conserved residues, including the DRY motif and a 
Cys residue that serves to form a stabilising disulphide bond with a highly conserved 
Cys residue of the long 2nd extra-cellular loop. The Arg residue of the D/ERY motif 
in the 5-HT2AR is thought to be involved in receptor activation by forming an 
interaction with a Glu in tm6, that acts to stabilise the inactive receptor conformation 
(178,179).  Further mutagenesis studies using various 5-HT receptor sub-types have 
determined that this domain also includes residues essential for ligand-binding. Some 
studies have suggested that a highly conserved Asp residue of the 5-HT2 receptor 





interactions with the terminal amine moiety of various agonists, including 5-HT 
(180). In addition to facilitating optimal ligand binding, this residue is also thought to 
be involved in the targeting of the receptor to the membrane (181).  Residues of tm5 
are also thought to be involved in ligand binding and it has been proposed that 
binding of some ligands could induce a change in the orientation of tm5 (175). 
However, these interactions are suggested to be species specific; the rat and human 
5-HT2AR express an Ala and Ser residue at residue 242 of tm5 respectively, which is 
suggested to result in a higher affinity of N-1-substituted tryptamines at the rat 
receptor as opposed to the human receptor, and vice versa with respect to the binding 
of N-1-unsubstituted tryptamines (182). The 3rd intra-cellular loop (i3), although it is 
always relatively long, varies widely both in terms of its length and amino acid 
composition (175). With the exception of the rat and mouse 5-HT5AR, the third 
extracellular loop contains two highly conserved Cys residues, with the potential to 
form a disulphide bond. Signalling assays using chimeric receptor constructs and 
GST-fusion protein studies have determined i3 to be involved in G protein coupling 
(175,183,184). Experiments detecting signalling downstream of the  5-HT2AR, but 
substituting the 5-HT2A i3 with a 5-HT1B i3, resulted in the inhibition of adenylyl 
cyclase (AC) as opposed to the typical activation of PLC (184). This receptor domain 
has also been implicated in the binding of !-arrestins, calmodulin and small GTPases 
(185,186). tm6 and tm7 represent the trans-membrane spanning domains with the 
highest sequence homology among the 5-HT receptor family (175). Mutagenesis 
studies focused on 5-HT family receptor tm6 and tm7 domains suggest that residues 
of these domains are also involved in ligand binding (175,187,188). Further research 





possible involvement of tm6 residues in receptor conformation changes required for 
G protein-coupling (179). Many 5-HT receptors, including the 5-HT2AR express a 
highly conserved Cys in the proximal region of the C-terminal tail, close to the 
junction with tm7 (7). As previously discussed, this is a putative palmitoylation site, 
potentially giving rise to a 4th intracellular loop and acting to anchor an eighth 
cytoplasmic helix at the membrane (7). 5-HT receptor C-terminal domains have been 
implicated with a variety of functional roles. They are also thought to be involved in 
ligand binding and receptor activation, in addition to playing a putative role in 
targeting the receptor to various sites. PDZ-domain protein target motifs located at 
the distal region of 5-HT2 receptor C-terminal tails promote interactions with various 
signalling proteins, thereby influencing receptor trafficking and signalling (189,190). 
This motif has been demonstrated to be required for 5-HT2AR binding of the PDZ-
domain protein post-synaptic density 95 (PSD95) (189,190). PSD95 is a scaffolding 
protein, participating in the formation of multiprotein signalling complexes (189-
191). Co-expression of PSD95 and the 5-HT2AR has been shown to promote 5-HT-
induced inositol phosphate production (191).  The binding of PSD95 to the 5-HT2AR 
is also reported to result in an inhibition of agonist-mediated receptor internalisation 
(191). Additionally, the PDZ-protein recognition motif has been shown to be 
important for the dendritic targeting of the 5-HT2AR in cultured cortical pyramidal 
neurons (7,189,192).  
 
1.10 Main signalling pathways of the 5-HT2AR 
The 5-HT2AR is proposed to signal primarily through 3 distinct yet interconnected 





A2. The conventional 5-HT2AR-induced signal transduction pathway occurs via 
GPCR interaction with heterotrimeric G proteins of the Gq/11 group. The carboxy-
terminal part of the third intracellular loop (i3) of the receptor is thought to be 
responsible for forming direct interactions with the " subunit of the heterotrimeric 
Gq protein (G"q) (168). It has also been proposed that GPCR:G"q association may 
be facilitated by residues of the second and seventh transmembrane segments, which 
promote helix:helix interactions (177). The binding of the G protein to the GPCR 
promotes the replacement of GDP by GTP on the G protein " subunit, leading to 
dissociation of the " subunit from the !# subunits. G"q is then able to diffuse away 
and bind to phospholipase C (PLC), which it activates. The activation of PLC results 
in an increase of diacyl glycerol (DAG) and inositol phosphates and consequently the 
activation of protein kinase C (PKC) and a rise in intracellular Ca2+ levels. 
 
1.10.1 Phospholipase C 
In the 1950s a novel enzymatic activity was described that resulted in the 
incorporation of [32P] into phospholipids, following pancreatic acinar tissue 
stimulation by carbachol (193). Following subsequent studies, this enzyme was 
characterised as phospholipase C (PLC), a membrane bound enzyme, capable of 
catalysing the formation of inositol (1, 4, 5)-trisphosphate and 1, 2-diacylglycerol 
from the membrane phospholipid, phosphatidyl inositol (4, 5)-bisphosphate (PIP2) 
(194-198).  There are thirteen currently identified mammalian PLC isoforms, which 
are categorised into six groups and further divided into subtypes, to yield; four PLC! 
subtypes (1-4); two PLC# subtypes (1-2); three PLC$ subtypes (1, 3 & 4); PLC'; 





comprises: a pleckstrin homology (PH) containing N-terminal domain, of 
approximately 120 residues that interacts with the heads of the membrane 
phospholipids (200-202); four EF-hand motifs that provide a flexible linkage region 
to the enzyme’s catalytic core (203-205); the catalytic core, composed of an X and a 
Y domain, which contains the residues involved in the hydrolysis of 
phosphoinositols (203); and a C-terminal C2 domain (203,204).  Each sub-family 
also express its own characteristic regulatory domain, which acts to define the 
signalling pathway in which the protein will participate (199). The PLC# isoforms, 
composed of two Src homology 2 (SH2) domains and an Src homology 3 (SH3) 
domain, flanked to either side by a split PH domain (203) are reported to form 
interactions with PLD2 via the SH3 domain, thus acting as an intermediate between 
PLC and PLD signalling pathways (206). 
 
The C-termini of PLC! enzymes contain regulatory domains that form interactions 
with both activated GTP-bound G"q subunits (207,208), and in addition PDZ 
domain proteins (209), thereby potentially promoting the scaffolding of signalling 
complexes. Analysis of the crystal structure of PLC! has shown the C-terminus to 
exist as a long coiled coil structure, thereby exposing key residues involved in 
interactions with GTP-loaded G"q subunits (207,208). Active G"q is thought to be 
selective in its binding to PLC! isoforms, preferentially binding PLC!1, followed by 
PLC!4, then PLC!3 and finally PLC!2 (210,211).  The PLC! isoforms also contain 
an intrinsic GTPase-activating protein (GAP) functionality within their C-terminus, 
which acts to catalyse the hydrolysis of GTP on the active form of G"q to form the 





Gi/o proteins, are also capable of activating PLC! isoforms, but with approximately 
50-100 fold less potency than G"q (213). The G!# subunit forms interactions with 
the PH domain of PLC! N-terminal tails (214), and also with the catalytic domain of 
PLC!2 (215). PLC!3 and PLC!2 appear to be the only isozymes for which G!# 
subunits demonstrate a high affinity (216,217). It has been proposed that G"q and 
G!# subunits can simultaneously interact with PLC! isoforms, and demonstrated that 
G!# is incapable of activating PLC! in the absence of G"q (199,218). 
 
Following PLC activation, the enzyme acts to hydrolyse the membrane phospholipid 
phosphatidyl inositol (4, 5)-bisphosphate (PIP2), by catalysing its cleavage just 
before the phosphate group, thereby yielding 1, 2 diacylglycerol (1, 2-DAG) and (1, 
4, 5)-inositol triphosphate (1, 4, 5-IP3) (219,220). These are both important 
intracellular second messengers. 1, 4, 5-IP3 increases intracellular Ca
2+
 levels by 
diffusing into the cytosol and binding to InsP3 receptors, localised on the membranes 
of the endoplasmic reticulum (ER) and the sarcoplasmic reticulum (SR) (221,222). 
These receptors are ligand-gated Ca
2+
 channels, thus activation by 1, 4, 5-IP3
  results 
in the release of Ca
2+
 into the surrounding cytoplasm (221). The subsequent rise in 
intracellular Ca
2+
 concentration serves to activate the ryanodine receptor-operated 
channel on the SR, which leads to a further increase in the Ca
2+
, thereby acting to 
increase cellular depolarization (223,224). 1, 2-DAG stays at the membrane and 
induces the translocation of protein kinase C (PKC) isoforms to the membrane, 
which it then stimulates (221,225,226). This results in the activation of downstream 






1.10.2 Phospholipase A2 
5-HT2A receptor activation can also result in an increase in intracellular arachidonic 
acid (AA) levels. This increase in AA concentrations has previously been 
demonstrated to be phospholipase A2 (PLA2) dependent (227). Although there is 
some evidence showing that PLA2 activation can occur as a downstream effect of 
agonist-induced phospholipase C activity, it is now established that PLA2 activation 
and thus AA release largely occur as part of an independently activated signalling 
cascade (227).  The phospholipase A2 enzymes have been categorised into three 
groups (228), of which only one, cytosolic PLA2 is reported to undergo receptor-
mediated activation (229). The potential mechanisms of 5-HT2AR activation of PLA2 
were investigated by Kurrasch-Orbaugh et al (227).  Pre-incubations of NIH3T3-5-
HT2AR cells with pertussis toxin resulted in partial inhibition of 5-HT-induced AA 
release, thereby implicating the involvement of G"i/o proteins in this pathway (230). 
Inhibition of G!# (by the G!#-binding domain of the !-adrenergic receptor kinase), 
resulted in decreased 5-HT2AR-mediated AA release, in addition to an inhibition of 5-
HT2AR-mediated AA release seen following inhibition of MEK, with the specific 
inhibitor PD 098,059, thereby implicating involvement of both MEK-activated ERK 
1/2, and G!# in the PLA2 pathway (230).  In addition, selective inhibition of the 
G"12/13 subunit, Rho and p38 also resulted in a decrease in 5-HT2AR-mediated AA 
release (230).  Thus, two pathways have been implicated in the mediation of 5-HT2A 
receptor-activated PLA2 pathway; one involving G"12/13 activation of Rho and p38 
activation; and another involving the activation of ERK 1, 2, as a result of the 
activation of G"i/o and G!# subunits and subsequent activation of Ras and Raf. 
PLA2 is reportedly activated by the binding of Ca





the membrane and subsequent phosphorylation of a Ser at residue 505, reportedly by 
ERK 1/2 or p38 MAPK (231,232).  Following activation, cytosolic phospholipase A2 
induces AA release by hydrolysing AA-containing phospholipids at the sn-2 position 
(233,234). 
 
1.10.3 Phospholipase D 
There are two mammalian phosphatidylcholine-specific PLD isoforms, PLD1 and 
PLD2, encoded for by two PLD genes, both with two splice variants (235-237). 
Subcellular PLD localisation is reportedly isoform-dependent; PLD2 has been 
demonstrated to localise predominantly within lipid raft fractions at the plasma 
membrane (236,238,239), and is possibly associated with the Golgi apparatus (240). 
Alternatively, PLD1 is found throughout the cell, but typically localises to Golgi 
structures, the endoplasmic reticulum and the late endosomes (236,241). There have 
also been reports of PLD1 localisation at the plasma membrane, although the extent 
to which this occurs may be cell-type-dependent  (242,243) and it is further 
established that PLD1 can undergo translocation to the plasma membrane subsequent 
to GPCR activation (244). The enzymes also appear to demonstrate isoform-specific 
cellular functions; PLD1 is reportedly involved in agonist-induced secretion, actin 
reorganisation, cell adhesion and migration (199,245-247), whilst various studies 
have implicated PLD2 activity in the endocytosis and recycling of membrane 
receptors (241,248). 
 
Active PLD acts to hydrolyse phospholipids, primarily phosphatidyl choline 





(PA) and a free polar head group (choline). Whilst PLD-generated choline is used as 
a precursor for phosphatidyl choline regeneration, and can be used by cholinergic 
neurons for the synthesis of acetylcholine (249), phosphatidic acid (PA) is thought to 
be primarily responsible for PLD-mediated signalling, and is implicated in a diverse 
array of cellular functions, including the activation of the Ras/Raf/MEK/ERK 
cascade. There is evidence that PA acts to promote the translocation of the Ser/Thr 
kinase cRaf-1 to the cell membrane, where it can be activated by the membrane 
bound Ras (250-253), resulting in MEK phosphorylation and subsequent ERK 
activation. It has also been suggested that PA production may result in an increase in 
the production of endocytic vesicles, to which Ras-Raf complexes may attach, in 
addition to scaffolding proteins linked to MEK and ERK 1 / 2 (253). PA is 
additionally demonstrated to activate type I PI-4P 5-kinase, which is reportedly 
involved in actin polymerisation and subsequently, membrane ruffling (254-257).  
Furthermore, PA is shown to interact with (and have an essential role in the 
activation of) target of rapamycin, a mediator of translational regulation (258,259). 
PA has also been demonstrated to bind the small G protein ARF, kinesin and N-
ethylmaleimide-sensitive factor (260). 
 
PA can additionally be further metabolised to diacylglycerol (DAG) via phosphatidic 
acid phosphohydrolase (PAP)-catalysed dephosphorylation (261,262). Agonist 
activation of the M3 receptor has been demonstrated to result in a second, delayed 
period of DAG elevation following the original PLC-mediated DAG release, 
probably due to the relatively slow conversion of DAG from PA by PAP (263). 





(254). Contrary to previous thought (264), PA-generated DAG is also thought to be 
involved in the membrane translocation and subsequent activation of PKC isoforms 
(265,266). 
 
Furthermore, PA can also be converted to lysophosphatidic acid (LPA) via the 
actions of phospholipase A1 or A2  (267,268).  This metabolite can also be 
reconverted to the original PA, via lysophosphatidic acid acyltransferases catalysis 
(254). Although the complete range of molecular mechanisms through which LPA 
exerts its activity are not entirely understood, it is known to cause functional 
activation of various membrane-bound Edg family G protein-coupled receptors 
(269). LPA is  demonstrated to be involved in a myriad of physiological roles: it has 
been shown to display growth-factor-like activity and promote cellular proliferation 
(270); it is required for the activation of protein kinase D (271); and has additionally 
been established to activate PKC, inhibit the formation of cAMP and promote Ca2+ 
release via Edg family G protein activity (272).   
 
It is well established that the 5-HT2AR is also capable of activating alternative 
transduction pathways, including a pathway that involves the recruitment of the 
small G protein ADP-ribosylation factor (ARF), and the subsequent activation of 
phospholipase D (PLD) (50). Isolated cytosolic extracts found to be capable of 
activating PLD were identified as ARF proteins by Cockcroft et al, 1994 (273). It has 
now also been demonstrated that both ARF and RhoA function as activators of PLD 
in signal transduction pathways from many GPCRs, including the 5-HT2AR (50). 





downstream of the 5-HT2AR (274). The binding of ARF1 to the 5-HT2AR has been 
found to increase both when ARF1 is GTP-loaded and when the receptor is 
stimulated with 5-HT. GST-fusion protein constructs of 5-HT2AR domains have been 
used to illustrate that ARF1 appears to bind with the highest affinity to the C-
terminal domain, where residues 376–384 have been implicated in ARF1 coupling. I 
further demonstrate within this thesis that PLD binds to the distal regions of the C-
terminus, although the exact mechanism of PLD activation by ARF within the 
inferred receptor:ARF:PLD complex is unknown. This pathway is discussed  in 























Figure 1.2 5-HT2AR-mediated PLC activation and ARF-dependent PLD activation. Schematic 
diagram illustrating Gq/11 activation of PLC to generate inositol triphosphates and diacylglycerol and 






1.10.4 Ligand-directed signalling 
It is now widely established that the signalling pathway which an activated receptor 
mediates can be influenced by the structure of the bound ligand (275). Different 
ligands are thought to act to stabilise different conformational states of the receptor, 
thereby resulting in differential activation of the various secondary effector proteins.  
This phenomenon, termed agonist-directed trafficking of receptor stimulus, or 
functional selectivity, has been demonstrated using various receptor types, including 
!2-adrenergic (276), dopamine (277), µ-opioid (278-280) and the 5-HT2A receptors 
(281-283). Experiments investigating 5-HT2AR activation by a variety of agonists 
have provided evidence to suggest that IP accumulation and AA release occur at 
differing degrees dependent upon the ligand stimulating the receptor, indicating that 
there is a differential activation of PLC and PLA2 pathways (281-283). Additionally, 
the PLC and PLA2 pathways have actually been determined to have different 
‘receptor reserves’ (227). These studies demonstrated that PLA2 activation actually 
requires a much smaller proportion of activated 5-HT2AR than PLC activation needs, 
providing further evidence for the independent nature of PLA2 signalling (227). 
 
1.11 Serotonergic involvement in schizophrenia 
Schizophrenia is widely regarded to be a multi-factorial disease, with 
neurodevelopmental and dopaminergic disturbances being some of the most popular 
hypothosise. However, there is also strong support for the involvement of the 
serotonergic system. Following the discovery that serotonin receptors act as 





much research regarding the possible involvement of the serotonergic system with 
the disease state schizophrenia (170). The physiological effects induced by 
serotonergic hallucinogens such as LSD, are thought to present in a similar manner 
to symptoms those of a psychotic patient (286). Thus, it has been proposed that 
alterations in the functioning of the serotonergic system could result in the 
development of a psychotic disease state such as schizophrenia. Habituation and pre-
impulse inhibition are cognitive processes that allow the mind to focus on relevant 
stimuli by filtering out superfluous information (286). It has been proposed that 
schizophrenia may occur as a result of disruptions to these responses, which could 
potentially result in the development of psychotic symptoms (286,287). Serotonergic 
hallucinogens have also been shown to induce alterations of both habituation and 
preimpulse inhibition startle responses in mouse models (288). Thus further inferring 
that abnormalities of serotonergic systems could underlie some schizophrenia-
induced psychotic symptoms.  
 
In particular, the 5-HT2AR is of particular interest with regard to schizophrenia, due 
to the known agonist actions of hallucinogens such as LSD, mescaline, psylocibin as 
well as the antagonist actions of atypical psychotics at these receptors (284,285) 
(168,289). The localisation of the 5-HT2AR within the pre-frontal cortex has been 
found to be altered within schizophrenic patients and patients thought to be at risk of 
developing schizophrenia (172), and post-mortem studies have revealed there to be 
reduced 5-HT2AR binding sites in the prefrontal cortex of schizophrenia sufferers 





shown to increase following co-administration with additional antagonists of the 5-
HT2AR (286).  
 
 
1.12 Clozapine, an atypical antipsychotic with affinity for the 5-HT2AR 
Typical antipsychotics are well established to exert their effects by influencing the 
dopaminergic system (291). Conversely, atypical antipsychotics have relatively high 
affinity for 5-HT receptors, in particular the 5-HT2AR (292,293). These drugs are 
reported to exhibit a higher ratio of affinity and antagonism at serotonin receptors 
than at dopamine receptors (294-296).  The atypical antipsychotics are of much 
interest, as they are effective agents in the treatment of schizophrenia, and in 
particular the treatment of negative symptoms, but do not present the same risk of 
extrapyramidal side effects seen with the typical antipsychotics (291). Clozapine, 
developed in the 1960s, is the prototypical atypical antipsychotic (297). It was found 
to be effective in the psychotic, negative and cognitive treatment of schizophrenia 
and in particular was found to be unique in its effective treatment of previously 
treatment-resistant schizophrenic patients, in addition to evoking minimal 
extrapyramidal side effects (298). However, its use was restricted in the 1970s 
following the finding that the use of the drug could result in development of 
potentially fatal agranulocytosis (297). Clozapine acts as a competitive antagonist 
upon 5-HT2AR-initiated phospho-inositide (PI) turnover, mediated by PLC activation 
(293). It is reported to induce cortical 5-HT2 receptor downregulation in rats (292), 
and is also suggested to induce the in vitro internalisation of the 5-HT2AR, in addition 





not normally observed with receptor antagonists (299). Recent research has 
additionally implied that clozapine may contribute towards activation of the 
MEK/ERK MAP kinase pathway (300).  
 
1.13 Single Nucleotide Polymorphic (SNP) forms of the 5-HT2AR 
To date, 17 single nucleotide polymorphisms (SNPs) have been identified within the 
5-HT2AR gene, 9 within the promoter region and 7 within the coding region. Of the 
SNPs known to exist in the 5-HT2AR gene promoter, A1438G is the most widely 
studied, and different studies have looked at its association with seasonal affective 
disorder, Alzheimers disease, alcoholism and suicide, with a mixture of results in all 
cases. This SNP is in complete linkage disequilbrium with a non-coding T102C SNP, 
thus meta-analysis associations of one apply equally to the other. Of the 7 SNPs 
identified within the coding region of the 5-HT2AR gene, only 5 are non-
synonymous; T25N of the N-terminus, I197V of i2, and S421F, A447V and H452Y 
of the ct. Approximately 9% of individuals are reported to express the H452Y minor 
allele within the distal region of the 5-HT2ARct. Meta-analysis studies have 
concluded that there is a significant association between heterozygous expression of 
the Tyr 452 minor allele and a poor clozapine response in schizophrenic patients 
(301,302). An additional meta-analysis study did not report a significant association, 
but did identify the Tyr 452 allele to be expressed with a greater frequency among 
the clozapine resistant (303).  Heterozygous and homozygous expression of the Tyr 
452 allele has since been (304)linked to various neuropsychological disorders, such 
as attention deficit hyperactivity disorder (ADHD) (305), bipolar disorder (306), and 





His 452 individuals and eight heterozygous H452Y individuals determined there to 
be differences in the signalling of the Tyr 452 allele. Despite there being no 
significant differences in the levels of PKC isoforms, G!q/11 subunits or [125I]LSD 
binding between the two platelet groups, there was a significant difference in 5-HT-
stimulated Ca2+ mobilisation by the heterozygous H452Y platelets: the peak 
amplitude was smaller and the overall shape of the Ca2+ mobilisation peak was 
blunted, when compared to homozygous His 452 platelets (308). A further study has 
suggested that there is a substantial decrease in both PLC and PLD activation by 
NIH3T3 cells overexpressing the 452 Tyr variant of the 5-HT2AR, when compared to 
control, wild-type 5-HT2A receptor expressing cells (309). In addition, the wild-type 
5-HT2A receptor variant, was reported to undergo rapid desensitisation as a result of 
prolonged periods of incubation with 5-HT, prior to PLC assay (309). However, the 
H452Y variant of the receptor displayed a significantly reduced pattern of 
desensitisation when stimulated in an analogous manner (309).  It was thus suggested 
that the H452Y-5-HT2AR variant may exist in a partially desensitized state prior to 












    
 



































































































































































































































































































































Figure 1.3 H452Y polymorphic variant of the 5-HT2AR.  Diagram 
to illustrate the locus of the H452Y polymorphism (in red) within the 






1.14 Aims of the study 
It follows that due to the proposed involvement of the 5-HT2AR in pathophysiological 
disorders such as schizophrenia, its signalling mechanisms are of particular 
pharmacological interest. The aim of this thesis was to gain a further understanding 
of 5-HT2AR-mediated signal transduction, and to compare this to the signalling of a 
physiologically relevant polymorphic variant of the receptor (H452Y-5-HT2AR).   
Following suggestions that the H452Y polymorphism may influence Gq/11-mediated 
signalling downstream of the 5-HT2AR (308,309), it was proposed to further 
investigate this effect, comparing the desensitisation of Gq/11-mediated responses 
downstream of each receptor, and the potential effect of !-arrestin isoforms and Ca2+-
binding proteins on this pathway. However, the 5-HT2AR has also been shown to 
mediate signalling through less conventional and well-studied pathways, such as the 
ARF-dependent activation of PLD. Robertson et al, 2003 previously identified the 
active isoform involved in 5-HT2AR-mediated ARF-dependent PLD signalling to be 
ARF1, and the locus of its binding to be at the beginning of the 5-HT2ARct (274). 
Subsequent to these studies it was proposed to investigate which PLD isoforms are 
involved in this pathway, and in order to further understand the mechanism of ARF-
dependent PLD activation, to explore the dynamics and locus of PLD binding at the 
5-HT2ARct, in addition to examining any possible effects of the H452Y 






























2.0 Materials & Methods 
 
2.1 Preparation of mammalian cDNA 
2.1.1 Site-directed mutagenesis 
cDNAs of mutated receptor constructs were generated by colleagues in house using 
in vitro site-directed mutagenesis.  A brief outline of the protocol follows: the parent 
plasmid was denatured to yield two single stranded parent plasmids and incubated 
with a mutagenic and a selection primer (which contains a mutation in the 
recognition sequence for a restriction enzyme site). The two primers were 
simultaneously annealed to the single stranded DNA, and following elongation, 
ligated with T4 DNA ligase. Selected mutated and control  plasmids were 
transformed into mutS Escherichia Coli (E.Coli) strains (defective in mismatch 
repair) and DNA from the pooled bacterial population was isolated. Mutated 
plasmids were isolated based on resistance to a second restriction enzyme, 
introduced by the selection primer. The DNA was again transformed into bacterial 
cells, and as unmutated plasmids were digested during the second restriction digest, 
only mutated plasmids were transformed. cDNA was then recovered as described in 
section 2.1.3. p.45. 
 
2.1.2 Transformation of competent cells 
50 µl  of either BL21 (>10
6
 cfu/µg suspension) or JM109 (10
8
 cfu/µg suspension) 
competent strains of E.Coli were incubated with 1 µg of ampicillin-resistant plasmid 
cDNA for 20 min on ice. The cells were then heat shocked at 42°C for 45 s, prior to 
a further 10 min incubation on ice. 900 µl of sterile Luria Bertani (LB) broth (10 g/l 




bacto-tryptone, 5 g/l yeast extract, 10 g/l NaCl; pH 7.0) was then added to the cells 
and incubated at 37°C for approximately (~) 1 h. 100 µl of the cell suspension was 
then spread onto LB agar plates (LB broth, 1.5% bacto-agar w/v, 12.5 µg/ml 
ampicillin), which were incubated overnight at 37°C.  
 
2.1.3 Plasmid purification 
Plasmid purification was performed using the Qiagen HiSpeed Plasmid Maxi Kit. A 
single bacterial colony was selected and used to inoculate a starter culture of 3 ml 
LB-broth, supplemented with ampicillin (12.5 µg/ml) to ensure the selection of 
plasmid containing cells. The starter culture was then left to incubate with rotation 
for (~ 8 h, 37°C). Following incubation, 1 ml was added to 100 ml of LB-broth (with 
12.5 µg/ml ampicillin) and incubated (overnight, 37°C) in the shaking incubator. 
Bacterial cells were then harvested via centrifugation (15 min, 7000 g, 4°C). The 
supernatant was then removed and the remaining pellet resuspended in 10 ml Buffer 
P1 (Qiagen resuspension buffer; 50 mM Tris-Cl pH 8.0, 10 mM EDTA), containing 
100 µg/ml RNase A solution.  Cells were lysed with the addition of 10 ml Buffer P2 
(Qiagen lysis buffer; 200 mM NaOH, 1% SDS w/v). The solution was mixed 
thoroughly by inversion and incubated for 5 min after which 10 ml chilled Buffer P3 
(Qiagen neutralisation buffer; 3.0 M potassium acetate; pH 5.5) was added to prevent 
further cell lysis and the solution mixed thoroughly.  The lysate was poured into a 
QIAfilter cartridge and incubated at room temperature for 10 min, before being 
filtered into a HiSpeed maxi tip, previously equilibrated with 10 ml Buffer QBT 
(Qiagen equilibration buffer; 750 mM NaCl, 50 mM MOPS pH 7.0, 15% 
isopropanol v/v, 0.15% Triton X-100 v/v). After the lysate had passed through, the 




HiSpeed maxi tip was washed through with 60 ml Buffer QC (Qiagen wash buffer; 
1.0 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol v/v), and the DNA eluted into 
a 50 ml tube using 15 ml Buffer QF (Qiagen elution buffer; 1.25 M NaCl, 50 mM 
Tris HCl pH 8.5, 15% isopropanol v/v).   The DNA was precipitated by incubating 
the eluate with 10.5 ml isopropanol  (5 min, room temperature (RT)). The resulting 
DNA solution was transferred to a 30 ml syringe and filtered through a 
QIAprecipitator to isolate the DNA, which was subsequently washed using 2 ml 70% 
ethanol. The QIAprecipitator was left to dry before 1 ml Buffer TE (10 mM Tris Cl 
pH 8.5, 1 mM EDTA) was filtered through into a 1.5 ml Eppendorf, eluting the 
DNA. The DNA eluate was passed back through the QIAprecipitator to enable 
maximal DNA retrieval. 
 
2.1.4 Agarose gel analysis of DNA  
Agarose gel (1% agarose non-low melting point, concentrate standard Tris-borate-
EDTA buffer) was heated until melting point and ethidium bromide added to a final 
concentration of 0.5 µg/ml. The molten gel was allowed to cool before being poured 
to a depth of 3-5 mm into a sealed electrophoresis tank containing a comb positioned 
0.5-1.0 mm above the plate, in order to create sample wells. Once the gel was set it 
was covered with electrophoresis buffer (concentrate standard tris-borate-EDTA 
buffer). 10 µl DNA samples were then added to 1 µl loading buffer (0.4% 
bromophenol blue in glycerol) and loaded into the gel, which was run at 100 V (25-
30 mA, ~ 2-3 h), before being examined under a UV light. Approximate relative 
concentrations of DNA were estimated from band brightness. 
 




2.1.5 Spectrophotometric quantification of DNA concentration 
DNA concentrations were quantified when required by spectrophotometric analysis. 
5 µl of the appropriate DNA was added to a plastic cuvette containing 0.5 ml ddH2O 
and the solution mixed. The absorbance at 260 nm (A260) was determined using a 
spectrophotometer (Shimadzu UV-1201). DNA concentrations were calculated by 
multiplying the A260 reading by 100 to account for the dilution factor and then by 50, 
as an A260 of 1 corresponds to a DNA concentration of approximately 50 µg/ml. 
DNA samples were typically found to have a concentration between 0.5–1.0 µg/µl. 
 
2.2 Cell culture 
2.2.1 Cell maintenance 
COS7 cells (ECACC) were routinely cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco, Invitrogen, Paisley, UK), supplemented with 10% normal 
calf serum (Gibco), 100 units/ml penicillin (Gibco) and 100 µg/ml streptomycin 
(Gibco) and maintained at 37°C in a 5% CO2, 95% O2 humidified environment.  
 
C6 glioma cells (ECACC) were maintained in Ham’s F12 Medium (Sigma, Poole, 
Dorset, UK), supplemented with 10% foetal calf serum (Gibco) and 50 units/ml 
penicillin (Gibco) and 50 µg/ml streptomycin (Gibco) and kept at 37°C  (5% CO2, 
95% O2). 
 
Cells were passaged twice weekly when they had reached ~ 90% confluence. DMEM 
was removed by aspiration and cells were washed for 20 s in 20 ml pre-warmed 
HBSS (Gibco). Cells were then exposed to 10 ml trypsin-EDTA (0.05% trypsin, 




0.02% EDTA, 0.085% NaCl; Gibco) for 1 min, after which the trypsin-EDTA was 
removed and cells incubated at 37°C for 5 min. Following cell detatchment, cells 
were re-suspended in 8 ml DMEM and counted using a haemocytometer 
(Marienfeld). Cells were then seeded into flasks (75 or 175 cm
2
) or plates (12- or 24- 
well) (Greiner Bio-One, Gloucestershire, UK) at 21 x 10
5
, 45 x 10
5
, 1 x 10
5
 or 0.5 x 
10
5
, respectively.  
 
2.2.2 Cryopreservation of cultured cells 
Exponential phase cells were detached using trypsin-EDTA, as above, and re-
suspended in appropriate growth medium. Cells were centrifuged (200 g,  5  min), 
before the supernatant was removed and the pellet resuspended in DMEM 
supplemented with 10% DMSO. 1 ml aliquots were then frozen in an insulated box 
(-70°C, overnight), prior to transfer to liquid nitrogen (–140°C). 
 
2.2.3 Thawing of cryopreserved cells 
Aliquots of cells were removed from liquid nitrogen  (–140°C) and quickly defrosted 
in a water bath (37°C, 1 min). The cell suspension was transferred to 10 ml pre-
warmed DMEM supplemented with 10% normal calf serum (Gibco), 100 units/ml 
penicillin (Gibco) and 100 µg/ml streptomycin (Gibco)  in a 75 cm2 flask. Cells were 
incubated for 24 h, before the addition of fresh medium. 
 
2.2.4 Transient transfections 
Cells were grown to ~ 60% confluency, then transfected with the appropriate cDNA, 
generally in the pcDNA3.1 expression plasmid, using either Gene Juice Transfection 




Reagent (Novagen, Merck Biosciences, Nottingham, UK), or Fugene-6 Transfection 
Reagent (Roche, Charles Avenue, Burgess Hill, West Sussex, UK). Transfection 
reagents were used according to the manufacturers instructions, a 3:1 or 5:1 
transfection reagent:cDNA ratio was used for COS7 or C6 glioma cells respectively. 
Prior to cell transfection with 5-HT2A receptor cDNA, medium was removed from 
cells and replaced with DMEM containing 2% Ultroser G (USG; Pall Biosciences, 
Portsmouth, Hampshire, UK) in order to remove any traces of 5-HT present in 
normal serum. Transfection Reagent-cDNA complexes were incubated for ~ 15 min 
before being added to the cells in appropriate quantities; 5 or 10 µl of total cDNA 
was added to 75 or 175 cm
2
 flasks respectively and 0.33 or 0.7 µl of total cDNA was 
added to a single well of a 24 or 12 well plate respectively. Cells were then grown at 
37°C in a 5% CO2, 95% O2 humidified environment, before experimental use. 
Inositol phosphate and western blot studies were used to determine the optimal 
conditions for the transfection of COS7 cells using either Gene Juice Transfection 
Reagent, or Fugene-6 Transfection Reagent. Transfection of 1.0 x 10
5
 cells/well (of a 
12-well plate) for 48 hours was found to result in maximal expression of  both Flag-
tagged muscarinic 3 receptor and HA-tagged 5-HT2A receptor. These conditions were 
used for all experiments shown within this thesis.  
 
2.3 Preparation of cell extracts over-expressing proteins 
COS7 cells were seeded in 175 cm2 flasks and transfected with appropriate DNA as 
described in section 2.2.4 p48. Cells were quiesced approximately 4 h prior to 
harvest, after which they were washed once with Hanks’ Balanced Salt Solution 
(HBSS). Cells were then lysed in 2 ml extraction buffer (PBS pH 7.5, 20% glycerol 




w/v, 1.0% CHAPS w/v, 1.0% sodium deoxycholate w/v, 1 mM sodium 
orthovanadate, 1% v/v protease inhibitor cocktail set III; Calbiochem) on ice for 40 
min. Alternatively, cells over-expressing proteins which localised to cellular 
compartments were isolated with 2 ml buffer (PBS pH 7.5, 1 mM dithiothreitol, 1 
mM sodium orthovanadate, 1% v/v protease inhibitor cocktail set III; Calbiochem), 
followed by homogenisation (Ystral polytron)  (setting 3, ~ 15 s. Cell lysates were 
then centrifuged (20 min, 11,600 g, 4°C), before 250 µl aliquots of supernatant were 
taken and stored at   -40°C until use. 
 
2.4 Ligand binding experiments 
COS7 cells were seeded into 175 cm2 flasks and transfected with appropriate cDNA 
as outlined in section 2.2.1 p.47 and 2.2.4 p.48, respectively. Transfected cells were 
quiesced for 4 h prior to lysis. Cells were detached from the flask surface and 
harvested in ice cold ketanserin binding buffer (50 mM Tris, 5 mM MgCl2, 1 mM 
EGTA; pH 7.2) supplemented with 1:100 protease inhibitor cocktail set III 
(Calbiochem) and disrupted with an Ystral homogeniser (setting 3, ~ 15 s).  Cell 
lysates were transferred to a 2 ml skirted plastic vial and centrifuged (10 min, 2000 g,  
4°C ), to pellet nuclear debris. The supernatants were transferred to clean 2 ml vials 
and further centrifuged (30 min, 12,000 g, 4°C) to pellet cell membranes. The 
supernatant was removed and the pellet resuspended in 2 ml cold ketanserin buffer 
by trituration. The membranes were washed by centrifuging (15 min, 12,000 g, 4°C), 
before resuspension in 2 ml ketanserin buffer. The membrane suspension was mixed 
thoroughly by trituration until homogenous, and 100 µl aliquoted in triplicate into 1.5 
ml screw-topped Eppendorfs. Receptor expression was assessed by incubating 




membranes with 0.8 nM [3H]ketanserin (72.2 Ci/mmol) and a range of 
concentrations of unlabelled ketanserin (0.1-300 nM), or 10 µM mianserin to 
determine non-specific binding (total volume 0.5 ml, 60 min, 37°C). Binding was 
quenched by the addition of 1 ml ice-cold ketanserin binding buffer and membranes 
pelleted by centrifugation (20 min, 12,000 g, 4°C). Supernatant was removed by 
aspiration. The bottom of each Eppendorf tube was cut off and placed into 6 ml 
polyethylene vials, to which 4 ml of scintillation fluid (perkin-elmer) was added.  
Bound [3H]ketanserin was detected using a Beckman LS 5801 scintillation counter, 
on a 4 min per sample, [3H] disintegrations per min (DPM) programme. Homologous 
displacement of [3H]ketanserin binding by a series of concentrations of unlabelled 
ketanserin was assessed and used to evaluate receptor expression levels. 
 
2.5 Protein Assay 
The Pierce BCA Protein Assay Kit was used to determine protein concentrations of 
COS7 cell membrane preparations identical to those in ligand binding studies, as 
described in section 2.4. p.50. BSA standards were prepared by serially diluting a 2.0 
mg/ml BSA stock solution in ketanserin buffer to give a range of 0-2000 µg/ml final 
BSA concentrations. 25 µl membrane preparation was added in triplicates to a 96-
well plate. 200 µl BCA working reagent, (50:1, Reagent A:Reagent B) was added to 
each well and mixed by shaking for 30 s. The plate was incubated at 37°C for 30 
min, before being allowed to cool back to RT. Protein concentrations were 
determined by measuring absorbance at 562 nm, using a Thermo Varioskan Flash 
plate reader and unknowns were quantified by comparison with the concurrently run 
BSA standard curve. 
 




2.6 Cell Surface Biotinylation 
Procedures were based on the use of a membrane-impermeant covalent biotinylation 
agent (NH-SO4-biotin) and the capture of solubilised biotinylated proteins on 
(reversibly binding monomeric) agarose beads, following the manufacturers 
recommended protocols (Sigma and Pierce, respectively). COS7 cells were seeded 
into 175 cm2 flasks and transfected with appropriate cDNA as outlined in sections 
2.2.1. p.47 and 2.2.4. p.48, respectively. Medium was aspirated from the flasks and 
cells were washed with 10 ml PBS per flask at RT. PBS was removed by aspiration 
and flasks were put on ice to cool. Cells were incubated with 1 mM NH-SO4-biotin 
in PBS  (2 h, 4°C), before removal by aspiration and incubation with glycine (75 
mM) in PBS (10 min, 4°C) to quench the biotinylated agent and reduce non-specific 
binding. Glycine was removed by aspiration and cells washed with 5 ml ice cold 
PBS. Cell membranes were solubilised in 2 ml/flask solubilisation buffer (10% 
glycerol, 1% CHAPS, 0.5% deoxycholic acid, 1:100 protease inhibitor cocktail set 
III, PBS) and centrifuged (20 min, 12,000 g, 4°C). The combined supernatant from 2 
flasks was retrieved and 1.8 ml was transferred to 2 x 2 ml skirted vials. Aliquot ‘A’ 
was left on ice, whilst the other was incubated with monomeric avidin immobilised 
on agarose beads (1 h, 4°C) with rolling, to bind biotin. Monomeric avidin agarose 
beads were prepared in advance; beads supplied in suspension were centrifuged (30 
s, 12000 g, 4°C) and supernatant removed, before being washed x 2 in PBS. The 
beads were pelleted and incubated with 2 mM biotin in PBS (30 min, 4°C) with 
rolling, in order to displace any biotinylated proteins isolated from the membrane 
suspension. The bead solution was centrifuged (30 s, 12,000 g, 4°C) and supernatant 
removed and labelled ‘B’. Receptor expression was assessed by incubating 100 µl  




membranes ‘A’ and ‘B’ with 0.8 nM [3H]ketanserin (72.2 Ci/mmol) at 37°C, for 60 
min. Non-specific binding was determined by the addition of 10 µM mianserin. The 
binding reaction was terminated by the precipitation of proteins through the addition 
of 100 µl 0.05% bovine !-globulin in water and 900 µl 30% polyethylene glycol-
8000 in PBS at 4°C. After vigorous vortexing tubes were kept on ice for 15 min 
before centrifugation (20 min, 12,000 g, 4°C). The supernatant was completely 
removed by 2 rounds of aspiration. The bottom of the Eppendorf tubes were cut off 
and placed in 6 ml polyethylene vials, to which 4 ml of scintillation fluid was added.  
Bound [3H]ketanserin was detected using a Beckman LS 5801 scintillation counter, 
(4 min, [3H] DPM programme). 
 
2.7 GST-fusion protein studies 
2.7.1 Transformation of competent cells 
BL-21 RIL E. coli were transformed with plasmids encoding GST-fusion protein 
constructs as described in section 2.1.2. p.44. The transformed bacterial cells were 
plated onto 2 x YT plates (16 g/l bacto-tryptone, 10 g/l yeast extract, 5 g/l NaCl, 
1.5% bacto-agar w/v; pH 7.0), supplemented with 12.5 µg/ml ampicillin to ensure 
the selection of transformed cells. 
 
2.7.2 GST-fusion protein expression 
5 ml of 2 x YT broth (16 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl), supplemented 
with 12.5 µg/ml ampicillin, was inoculated with a single transformed BL-21 colony 
and incubated overnight with rotation at 37°C. 3 ml of the culture was added to 300 
ml pre-warmed 2 x YT broth, supplemented with 2% w/v sterile glucose and 12.5 




µg/ml ampicillin and incubated (2 h, 37°C), with shaking (200 rpm), until the cell 
culture had reached OD600 0.6-0.8. Isopropyl-!-D-thiogalactoside was then added to 
a final concentration of 0.5 mM, in order to induce protein expression. The cells were 
then incubated for a further 3 h  (37°C, 200 rpm).  
 
2.7.3 Glutathione-sepharose capture of GST-fusion proteins 
The cells were pelleted by centrifugation (10 min, 7500 g, 4°C), the supernatant 
removed and the pellet re-suspended in 6 ml ‘Bugbuster’ lysis reagent (Novagen) 
and left to lyse for 10 min at RT. The bacterial cell lysate was then centrifuged (25 
min, 11,600 g, 4°C) and 1 ml of the resulting supernatant added to 200 µl 
Glutathione-4B Sepharose bead suspension (pre-washed in PBS; pH 7.5). The beads 
lysate mixture was incubated with the lysate (30 min, 4°C) with rolling, to allow the 
GST fusion proteins to bind to the glutathione-conjugated beads. The beads were 
then pelleted and washed 4 x with a 1 ml volume of PBS, supplemented with 1% v/v 
protease inhibitors, cocktail set III. 200 µl of PBS and 200 µl of pre-prepared cell 
extracts over-expressing proteins of interest (section 2.3 p.48) were added to the 
beads and incubated overnight at 4°C. The beads were then pelleted washed 2 x in 
GST binding buffer (PBS pH 7.5, 20% glycerol w/v, 1.0% CHAPS w/v, 1.0% 
sodium deoxycholate w/v, 5 mM EDTA , 1% v/v protease inhibitors cocktail set III) 
and then 3 x in dilute GST binding buffer (1:20 dilution in PBS pH 7.5). Following 
the careful removal of the supernatant buffer, beads were resuspended in Laemmli 
buffer (50 mM Tris, 2% SDS w/v, 5% mercaptoethanol v/v, supplemented with 8 
mM urea) and boiled for 5 min. 
 




2.8 Co-immunoprecipitation  
COS7 cells were seeded into 75 cm
2
 or 175 cm
2
 flasks and transfected with 
appropriate cDNAs, as outlined in sections 2.2.1. p.47 and 2.2.4. p.48 respectively. 
Transfected cells were quiesced 4 h prior to lysis. Cells were washed with HBSS, 
before being solubilised in 1 ml/75 cm2 or 2 ml/175 cm2 of IP buffer, (20% glycerol, 
0.5% CHAPS, 0.5% deoxycholic acid, 1 mM sodium orthovanadate, 1:100 protease 
inhibitor cocktail set III, NaCl 150 mM, HEPES 20 mM; pH 7.4) for approximately 
40 min, with agitation. Flask contents were then scraped thoroughly, and the 
resulting cell lysates transferred to 1.5 ml Eppendorf tubes. Lysates were centrifuged 
(10 min, 11,500 g, 4ºC), after which supernatants were transferred to 1.5 ml 
Eppendorf tubes containing 20 µl Protein G-Sepharose 4B fast flow beads (diluted 
1:1 with IP buffer). The lysate/bead mixture was incubated (~ 45 min, 4ºC) with 
rolling, in order to pre-clear the lysate by capturing any endogenous proteins non-
specifically bound to protein-G beads. The beads were then pelleted by 
centrifugation (30 s, 12,000 g, 4ºC) and 470 µl of the pre-cleared supernatants were 
added to tubes containing 40 µl Protein G-Sepharose suspension and the appropriate 
primary antibody, or an equivalent concentration of species-specific, non-immune 
IgG as a negative control. Calcium chloride (1 mM) was also added to the tubes 
when using calcium-dependent antibodies. Lysates were left to incubate (overnight, 
4ºC) with rolling. 56 µl of the remaining lysate was added to 10 µl 2 x Laemmli 
buffer (50mM tris, 2% w/v sodium dodecyl sulphate, 5% v/v mercaptoethanol, 
supplemented with 8 M urea) and stored at -40ºC, to be used as an indication of total 
levels of protein expression. The beads were then pelleted by centrifugation (30 s, 
12,000 g, 4ºC) and the supernatant removed. The protein G beads were then washed 




3 x with 1 ml IP buffer. Following the final wash, 30 µl of 2 x Laemmli buffer/1 ml 
of original supernatant was added to the samples, which were then heated at 70 or 
100ºC (depending on protein content) for 5 min. 
 
2.9 Antibody cross-linking to protein G-sepharose 
In experiments to investigate co-immunoprecipitation of arrestins with HA-tagged 
wild-type and H452Y-5-HT2AR, the mouse monoclonal HA antibody (clone 12CA5, 
Roche) was covalently cross-linked to protein G-sepharose CL-4B beads prior to use 
to avoid IgG bands on Western blots obscuring the protein of interest. 180 µl beads 
were conjugated with 90 µg 12CA5 or non-immune mouse IgG as indicated and the 
solubilised extract was immunoprecipitated at a rate of 40 µl antibody-derivatised 
beads per 2 ml extract from 1 x 175 cm2 flask. Crosslinking was carried out 
according to the protocol supplied by Dynal/Invitrogen for crosslinking to protein G 
Dynabeads but with the beads being collected at each stage by brief centrifugation in 
a bench-top Eppendorf centrifuge rather than by magnet. Briefly, IgG binding was 
carried out for 40 min at room temperature in citrate-phosphate buffer pH 5.0 with 
rolling. After thorough washing in the same buffer and then 0.2 M triethanolamine 
pH 8.2, cross-linking was achieved with 20 mM freshly made dimethyl pimelimidate 
(DMP Pierce/Perbio) in triethanolamine buffer for 30 min at room temperature with 
rolling. Following quenching of remaining DMP with 50 mM Tris pH 7.5 for 15 min 
the derivatised beads were washed and then finally resuspended in PBS with 0.1% 
Tween-20 prior to use.  
 




2.10 SDS-PAGE and immunoblot 
Co-immunoprecipitation samples were added to 1 µl loading gel solution (0.04% w/v 
bromophenol blue in glycerol)/5 µl sample and the volume increased to 20 µl with 2 
x Laemmli buffer. The sample solutions were then mixed and centrifuged (30 s, 
12,000 g, 4ºC). A 4-12% Bis-Tris polyacrylamide gradient gel, designed to optimally 
separate proteins in the range 40-400  kDa, was rinsed thoroughly with ddH2O. The 
gel was placed into an X-cell Surelock Mini-cell and the tightly sealed inner and 
outer buffer chambers filled with running buffer, MOPS (50 mM MOPS, 50 mM 
Tris base, 1 mM EDTA, 0.1% w/v SDS; pH 7.7) or MES (50 mM MES, 50 mM Tris 
base, 1 mM EDTA, 0.1% w/v SDS; pH 7.3). 20 µl of the samples were loaded into 
the wells and 5 µl of pre-stained molecular weight marker protein solution was also 
loaded into the gel. The gel was then run for approximately 1 h at 200 V, thereby 
inducing separation of the sample proteins according to molecular weight.  
 
2.10.1 Western Blot 
The proteins on the gel were transferred to 0.2 µm pore polyvinylidene difluoride 
(PVDF) membranes by electroblotting. Prior to blotting membranes were cut and 
soaked in methanol for ~ 30 min, before being rinsed in ddH2O. Filter paper and 
blotting pads were pre-soaked in transfer buffer (bicine 500 mM, bis-tris 500 mM, 
EDTA 20.5 mM, chlorobutanol 1 mM; pH 7.2, supplemented with 10% methanol). 
Once the gel was run it was removed from the plastic cassette and placed on top of a 
pre-soaked piece of filter paper. The membrane was placed on top of the gel, over 
which a second piece of filter paper was placed and any air bubbles removed. The 
gel/membrane/filter paper bundle was placed in the blotting module between six pre-




soaked blotting pads, with the membrane closest to the anode core. The inner 
chamber of the blotting module was filled with transfer buffer and the outer chamber 
was filled with ddH2O. The blot was run at 30 V for 90-120 min. 
 
2.10.2 Immunoblotting 
The blot was then left to block in 5% Marvel PBS solution (overnight , 4ºC) and then 
removed from the block and washed in 0.1% Tween-20 PBS solution x 3. The blot 
was then exposed to 2 ml 1:250 rat monoclonal anti-HA tag antibody, conjugated to 
horseradish peroxidase (HRP) (3F10, Roche), diluted in 5% Marvel, 0.5% Tween 
PBS, for ~ 1 h, at RT. The blot was then washed 5 x in 0.1% Tween-20 PBS 
solution, after which the HA antibody bands were visualised by incubation of the 
blot with luminol (Cell Signalling Technology, New England Biolabs) for 1 min and 
exposure to ECL film (Amersham Biosciences, Buckinghamshire, UK).  
 
2.11 Cellular PLC activity assay 
2.11.1 Cell Labelling 
Prior to assay, 12-well plates of COS7 cells were transfected with appropriate 
cDNAs. When using 5-HT receptor cDNA, cells were maintained in DMEM with 
2% USG (to avoid 5-HT content of normal serum). Otherwise the DMEM was 
supplemented with 10% normal calf serum. 1 day prior to assay medium was 
removed from the plates by aspiration and replaced with 0.5 ml Earle’s balanced salt 
solution (EBSS), supplemented with 10 mM HEPES (pH 7.5), glucose (0.18%) and 
labelled with 1.5 µCi / well [3H]inositol (specific activity 18.5 Ci/mmole). Plates 
were then left to incubate at 37°C (5% CO2, 95% O2) for ~ 18 h. 




2.11.2 PLC Assay of cells transfected with 5-HT2A 
Immediately prior to assay, the cell medium was removed from the plates by 
aspiration and replaced with EBSS, supplemented with 10 mM HEPES (pH 7.5), 
glucose (0.18%) and bovine serum albumin (BSA) (0.2%). Lithium chloride was 
then added to each well to a final concentration of 10 mM and the plates left to 
incubate for 15 min prior to agonist incubation. For time-course assays, cells were 
stimulated with 5-HT (10 µM) for up to 3 h. Alternatively, for concentration-
response assays, cells were stimulated with a range of agonist concentrations 
(carbachol: up to 200 µM; 5-HT: up to 3 µM) for 3 h. Reactions were terminated by 
removal of the medium and the addition of 0.5 ml ice-cold formic acid (10 mM).  
 
2.11.3 Separation of [3H]inositol phosphates using anion exchange columns 
[3H]inositol phosphates were isolated by adding the PLC assay samples to 5 ml 
columns containing 1 ml Dowex anion exchange resin (1 x 8; formate form; 200-400 
mesh).  An increasing gradient of ammonium formate/formic acid were added to the 
resin to elute the [3H]inositol phosphates. Columns were initially washed through 
with 15 ml ddH2O, followed by 5 ml ammonium formate (50 mM). The [
3H]inositol 
phosphate samples were eluted into 20 ml Zinsser scintillation vials using 10 ml of 
ammonium formate (1.0 M)/formic acid (0.1 M). The columns were finally washed 
with 5 ml ammonium formate (2 M)/formic acid (0.1 M), followed by 15 ml ddH2O 
water, ready for re-use. 500 µl aliquots of the eluted samples were then transferred in 
duplicate to 6 ml polyethylene vials, to which 4 ml of scintillation fluid was added. 
Levels of [3H] were detected using a Beckman LS 5801 scintillation counter, (4 min, 
[3H] DPM programme).  




2.12 Cellular PLD Activity Assay 
2.12.1 Cell labelling 
72 h prior to assay 12-well plates of COS7 cells were transfected with appropriate 
cDNAs, as outlined in section 2.2.4 p.48, with USG used as a serum substitute when 
using 5-HT receptors, as outlined in section 2.11.1. p.58. Approximately 18 h prior 
to assay, cells were quiesced in DMEM (0.5 ml/well) containing [3H]palmitate 
(3µl/well; specific activity 47.5 Ci/mmol).  
 
2.12.2 PLD Assay 
Cells were incubated at  37°C (5% CO2, 95% O2) for ~ 18 h. Following incubation, 
the media was replaced with 0.5 ml/well MEM, containing HEPES (25 mM; pH 7.5), 
and fatty-acid free BSA (1.0% w/v) and the plates incubated (20 min, 37°C). 
Immediately prior to assay, butan-1-ol was added from a 600 mM MEM solution to a 
final concentration of 30 mM. Cells were then stimulated with agonist and incubated 
for 30 min. Reactions were terminated by the removal of assay medium and the 
addition of 500 µl ice-cold methanol/well.  
 
2.12.3 Separation of [3H] phosphatidyl butanol using solvent extraction and thin 
layer chromatography 
Membranes were scraped from the base of the wells and transferred into 2 ml glass 
vials, to which 500 µl chloroform and 400 µl ddH2O was added, yielding a final 
methanol/chloroform/water ratio of 5:5:4. Vials were sealed, mixed by vortex and 
left overnight at 4°C. Samples were then centrifuged (20 min, 5000 g, RT), to 
facilitate the separation of the samples into an upper aqueous layer and a lower 




organic layer. The aqueous layer was removed, after which 250 µl of the lower 
organic layer was transferred into a clean glass vial and allowed to evaporate 
overnight in a fume hood. Samples were resuspended in 50 µl of a 19:1 
chloroform:methanol solution and spotted onto lanes of LK5D thin layer 
chromatography plates, using a stream of nitrogen to dry the spots between sample 
loading. The plates were allowed to run for 1-1.5 h, in the organic phase of a running 
solvent mixture (ethyl acetate, 2,2,4-trimethylpentane, acetic acid, ddH2O, in the 
ratios 110:50:20:100). The area of the plate corresponding to the migration of 
[3H]phosphatidyl butanol ([3H]PtdBut), approximately 5 cm from the plate origin 
(previously identified using iodine staining of a phosphatidyl butanol standard 
(McCulloch, 1998)), was scraped from the plates in 6 x 0.5 cm bands and transferred 
to 6 ml polyethylene vials, into which 3.2 ml scintillation fluid was added. Levels of 
[3H] were detected using a Beckman LS 5801 scintillation counter, (4 min, [3H] DPM 
programme). 
 
2.13 Data Analysis 
All quantitative data was calculated as mean ± standard error of the mean (SEM), 
acquired from a number (n) of individual experiments. Statistical significance of 
differences where appropriate was evaluated by Wilcoxon test, Mann-Whitney U-test 
or one-paired T-test, with p < 0.05 selected as criterion for significance. The 
Graphpad Prism programme (Graphpad Software, CA, USA) was used to analyse 
and plot non-linear error-weighted curve fittings and to determine the concentration 
of a drug which could produce 50% of the maximum response (EC50 value), using 
the logistic Hill equation. 




Quantitative densitometry values were derived using the ScanAnalysis program 
(Biosoft, Cambridge, UK).    
 
2.14 Materials 
2.14.1 Chemicals and Reagents 
All chemicals and reagents were from Sigma Chemical Company (Poole, Dorset, 
UK), unless otherwise stated.  
 
2.14.2 Plasmids 
N-terminally haemaglutinnin tagged human phospholipase D1b (HA-PLD1) and 
mouse phospholipase D2 (HA-PLD2) in pCGN vector were a kind gift from Mike 
Frohman, State University of New York. C-terminally FLAG-tagged !-arrestin 1 
(FLAG-!arr1) and !-arrestin 2 (FLAG-!arr 2) in PcDNA3 were kindly gifted by 
Miles Houslay, University of Glasgow. !-arrestin 1 (!arr 1)  and !-arrestin 2 (!arr 2) 
in pCMV5 were kind gifts from the Lefkowitz lab, Duke Medical Centre. Human 
ARF1-HA ad ARF6-HA in plasmid pXS were kind gifts from Julie Donaldson, NIH. 
Plasmids encoding GST-fusion proteins of human 5-HT2AR C-terminal tail, 
truncations of the C-terminal tail, K385 variant of the C-terminal tail and third 
intracellular loop in pGEX-2T, in addition to the N-terminally FLAG tagged human 
M3 muscarinic receptor (sFM3), N-terminally Protein C- and HA-tagged human 5-
HT2A receptor and its N376D mutant form in pcDNA3.1 were created in collaboration 

































Phospholipase D (PLD) activity was initially demonstrated over 60 years ago in 
cabbage (310), although it was not until 1975 that it was first identified in mammals 
(311). PLD is now known to exist in fungi, plants, protozoa, bacteria and animals, 
thereby indicating its probably fundamental involvement in essential cellular 
functions (199). PLD activity is implicated in a wide range of physiological 
responses including endocytosis, exocytosis, secretion, vesicle trafficking, calcium 
mobilisation, cytoskeletal rearrangements and mitogenesis (199). Active PLD acts to 
hydrolyse phospholipids, primarily phosphatidyl choline (PtdCho), at the terminal 
phosphodiester bond, thereby producing phosphatidic acid (PA) and a free polar head 
group (choline).  
 
3.1.1 Phospholipase D Structure 
Phospholipase D enzymes contain several conserved motifs, including catalytic 
HxxxxKxD (HKD) sequences. Both PLD1 and PLD2 contain 2 HKD motifs, 
existing between residues 455-490 and 892-926 of the N- and C-terminal regions of 
the human PLD1 isoform, respectively (237). Mutagenesis studies during which Lys 
898 of PLD1 was replaced with an Arg yielded an inactive K898R PLD1 variant, 
highlighting the critical role of the HKD motif in catalytic activity (312). The 
equivalent mutation in PLD2, K758R, was also found to result in a similar loss of 
catalytic activity (312).  PLD activation is thought to require an association of the N- 
and C-termini and thus the two HKD domains, thereby forming an active catalytic 




centre (313). It has been further demonstrated that HKD association is an essential 
prerequisite for Ser/Thr phosphorylation of the N-terminus of PLD1 (314).  
 
Mammalian PLD1 and PLD2 isoforms also contain N-terminal Phox homology (PX) 
domains at residues 81-212 and 65-196, respectively (237,315). PX domains are 
conserved regions found in many proteins, which bind phosphoinositides and are 
involved in the targeting of proteins to membranes (316). Both PLD1 and PLD2 
function is thought to be dependent upon binding of the phosphoinositide PI-4,5P2 
(235-237,315). Moreover, the PX domains are also thought to be an essential 
prerequisite for effective PLD activity (317-319). These domains have been reported 
to form interactions wih PKC isoforms (320), in addition to being involved in the 
modulation of pleckstrin homology (PH) domain function (see below) (321). 
 
PLD isoforms additionally contain PH domains, thought to be involved in PLD 
translocation to the plasma membrane (322). The PH domains are found within 
residues 219-328 and 203-311 of PLD1 and PLD2, respectively (237). Both PLD 1 
and 2 isoforms undergo palmitoylation of two adjacent Cys residues (240-241 and 
223-224 respectively) within the PH domain, which acts to facilitate the association 
of the enzyme with membrane phosphoinositides (315,318,323).  
 
3.1.2 Regulation of phospholipase D isoforms 
Mammalian phospholipase D isoforms undergo functional modulation by several 
intracellular regulatory factors, including the small G proteins ADP-ribosylation 
factor (ARF) and Rho, phosphoinositides, PKC, and PKC-dependent 




phosphorylation. PKC-mediated PLD activation was recognised on account of the 
discovery that PKC- activating factors, such as phorbol esters, induce PLD activation 
(324,325). Further experiments determined that purified PKC extracts could induce 
PLD activation in a concentration-dependent manner in Chinese hamster lung 
fibroblast membranes (326). In 1996, recombinant and purified PKC! were shown to 
interact with and activate PLD1 synergistically with ARF (327). Moreover, PKC 
inhibitors such as staurosporine, bisindolylmaleimide and Ro31-8220 have been used 
to demonstrate that the agonist dependent-GPCR activation of PLD is dependent 
upon the activation of PKC in a variety of cell types (328-331). Although PKC 
isoforms have been demonstrated to activate the two PLD isoforms with similar 
potencies (109,332), PLD activation is thought to be PKC isoform specific; PKC! 
and PKC" are reported to be the primary PKC isoform activators of PLD (332,333). 
Furthermore, although PKC# has been previously demonstrated to be an equally 
effective activator of PLD in HL60 cells (334), it has additionally been implicated to 
act as a negative regulator of PLD1 in melanoma cell lines (335,336). PKC-mediated 
PLD regulation is thought to involve direct interactions and phosphorylation (254). 
However, phosphorylation-independent PLD activation by PKC has also been 
demonstrated (327), and has been reported to involve interactions within the N-
terminal PX domain of PLD1 (318). This was confirmed by the mutagenesis of 
human PLD1 at a GVPLE sequence at position 87 of the protein, (a non-
phosphorylatable motif), to yield PIM87 PLD1, which resulted in a loss of 
responsiveness to PKC (320).  
 




The small G protein, Rho, was first determined to be an activator of PLD in 
neutrophils, by Bowman et al in 1993 (337). Subsequently, RhoA, Rac1 and Cdc42 
have been identified as the primary Rho GTPase activators of PLD (235,337,338). 
Rho proteins have been demonstrated to form direct GTP-dependent interactions 
with purified PLD1 (235,334,339), and with the use of yeast two-hybrid assays, 
RhoA was further determined to bind residues 712-1074 of the human PLD1 C-
terminal tail domain (340). The subsequent point mutagenesis of PLD1 at residue 
870 from the original Ile to an Arg, although inducing no effect upon the expression 
or activation profile of PLD1, conferred insensitivity to regulation by Rho GTPases 
(341).  Furthermore Rho family GTPases are thought to be involved in the GPCR-
mediated activation of PLD: M3 muscarinic acetylcholine receptor-mediated PLD 
activation in HEK cells was attenuated with the addition of the specific Rho 
inhibitors toxin B from Clostridium difficile and C3 exoenzyme from Clostridium 
botulinum, thus suggesting the involvement of Rho in M3 receptor-mediated PLD 
activation (342). Rho-mediated activation of PLD has since been demonstrated to 
occur independently of Gq protein activation (50).  
 
ARF proteins, primarily ARF1 and ARF6, are able to directly activate PLD1, and to 
a lesser extent PLD2, in a GTP-dependent manner (235,237,343,344). ARFs are 
20kDa GTPases that form part of the Ras superfamily. There are 6 mammalian ARF 
proteins, categorised into 3 classes to yield: class I, comprising ARF1, ARF2, and 
ARF3; class II, containing ARF4 and ARF5; and class III, consisting of ARF6 (345). 
With the exception of ARF6 (which is largely associated with the plasma membrane 
and endosomes), the majority of ARF family members are typically localised in the 




cytosol.  However, ARF1 has been demonstrated to translocate to the membrane 
following activation of the M3 muscarinic receptor in COS7 cells (244), and in 
neutrophils (346,347).  
 
3.1.3 Regulation of phospholipase D isoforms by members of the ARF family 
ARF1-6 share several conserved structural features: all ARFs contain an N-terminal 
amphipathic helix, which is typically myristoylated at a Gly residue, following the 
removal of Met (345). It has been demonstrated that ARF1 myristoylation induces 
guanine nucleotide exchange factor (GEF)-dependent GDP-GTP exchange at 
physiological Mg2+ concentrations, in the presence of phospholipid vesicles (348).  
Although activated ARF (ARFGTP!S) can bind membrane phospholipids regardless of 
its myristoylation profile, ARFGDP is only capable of binding membrane 
phospholipids when myristolyated (349). Following myristolyated ARFGDP 
membrane association, the N-terminus associates with an interswitch domain. 
However, the N-terminal myristoyl group destabilises this interaction, allowing GTP 
access to the ARF-GTP binding site. Thus ARFGTP is formed and a more stable 
interaction occurs with the plasma membrane (348-350). ARF family proteins 
express an identical consensus sequence for GTP binding and hydrolysis. 
Conformational changes of this region following GTP binding are thought to result 
in the exposure of the myristoylated N-terminus, switch 1 (amino acids 41-51 of 
ARF1) and switch 2 (amino acids 68-81 of ARF1) regions, which are implicated in 
plasma membrane (348,351) and effector binding (345,352) respectively.  
 




ARF activation is regulated via ARF-guanine nucleotide exchange factors (ARF-
GEFs), which facilitate GDP-GTP exchange. These proteins all contain a Sec7 
domain that catalyses nucleotide exchange (351,353). ARF switch 1 and switch 2 
regions are thought to be responsible for associating with the Sec7 domain, which 
inserts residues into the GTP binding site, thereby disrupting the phosphate and Mg2+ 
binding sites and promoting nucleotide dissociation (351,353). ARF deactivation is 
facilitated by ARF-GTPase activating proteins (ARF-GAPs), which required a zinc 
finger motif and a conserved arginine residue within the GAP domain for maximal 
ARF-GTPase activity (354,355). 
 
ARF-mediated PLD activation was first demonstrated in permeabilised (cytosolic 
deficient) HL-60 granulocyte cells (356-358), although it was not until 1993 that the 
16 kDa PLD-activating cytosolic factor was characterised as ARF (273,359). Via the 
reconstitution of PLD activity in cytosol depleted HL60 cells by recombinant ARF1 
and the continued ARF dependence of PLD activity through several purification 
steps, these studies indicated that ARF proteins activate PLD in a direct manner 
(273,359). The N-terminal region of ARF1 has been isolated as an essential ARF 
domain for PLD activity, and is thus thought to be potentially involved in 
interactions with PLD (360). Furthermore the ARF binding site for PLD is reported 
to be distinct from regions required for activation of cholera toxin (361) and 
coatamer binding (360). The putative site within PLD for interaction with ARF 
remains unknown, although it is determined not to exist within the initial 325 amino 
acids of the N-terminus that are required for activation by PKC (318). 
 




The first evidence that ARF proteins were involved in GPCR-mediated PLD activity 
was provided in 1995 by Rumenapp et al; stable M3 muscarinic receptor-expressing 
HEK cells were incubated with the specific ARF-GEF-inhibitor brefeldin A (BFA), 
which was found to induce a decrease in carbachol-stimulated PLD activity, despite 
eliciting no effect upon receptor cell surface expression or G protein coupling (362). 
Furthermore, brefeldin A was determined not to act as a direct inhibitor of PLD 
(362). ARF has since been demonstrated to activate PLD in a variety of cell and 
receptor systems including: N-formylmethionyl-leucylphenylalanine (fMLP) receptor-
dependent PLD activity in human neutrophils (346); VPAC receptor-mediated PLD 
activation in CHO cells (363); somatostatin receptor-dependent PLD activation in 
clonal !-cells (364); and endothelin-1, angiotensin II, and platelet-derived growth 
factor receptor-mediated PLD responses in vascular smooth muscle A10 cells (365). 
Mitchell et al first demonstrated that ARF and Rho can associate with GPCRs to 
activate PLD via a mechanism independent of heterotrimeric G protein Gq/11 
activation in 1998 (50). Furthermore, the ARF/Rho-dependent receptor-mediated 
activation of PLD was found to be dependent upon the sequence existing at the 
junction between the 7th transmembrane domain and the carboxy-terminal tail of the 
receptor, within which the NPxxY motif is contained (50). Receptors containing an 
alternate DPxxY motif, were found to activate PLD in an apparently ARF/Rho–
independent manner (50). Moreover, mutation of the Asp to Asn conferred BFA/C3 
exoenzyme sensitivity onto PLD responses of previously insensitive receptors, such 
as the gonadotrophin releasing hormone receptor (GnRH), and the reciprocal 
mutation conferred insensitivity onto BFA/C3-sensitive receptors such as the 5-
HT2AR (50).  





Both ARF and PLD proteins have been demonstrated to form direct interactions with 
GPCRs in a variety of receptor and cellular contexts. ARF GTPases were first 
demonstrated to interact directly with GPCRs by co-immunoprecipitation of ARF1/3 
with the M3 receptor (50). The ARF binding site on the 5-HT2AR has been 
determined to exist within the initial 9 amino acids of the receptor C-terminal tail 
(274). PLD2 has been selectively co-immunoprecipitated with both the µ-opioid 
receptor (366), and metabotropic glutamate receptors (367). There is also evidence to 
suggest that PLD1, and to a lesser extent PLD2, can be co-immunoprecipitated with 
the M3 muscarinic receptor (unpublished observations).  The binding of PLD1 has 
been localised to the distal regions of the M3 muscarinic receptor C-terminal tail, 
with the use of a truncated receptor construct and GST-fusion proteins of M3 
muscarinic receptor domains (unpublished observations).  
 
It has been suggested that ARF and Rho act synergistically to activate PLD 
(346,368). Further studies that utilised a PKC-unresponsive PLD1 mutant 
demonstrated that PKC also displays synergistic activation of PLD1 with RhoA 
(320). However, the extent to which Rho, ARF and PKC can activate PLD is thought 
to depend upon the specific receptor and cell type setting (235,369). For example, 
following M3 muscarinic receptor activation in HEK-293 cells, both ARF1 and RhoA 
are demonstrated to undergo recruitment to the plasma membrane and independently 
activate PLD1 (199,362,370). Alternatively, in parallel experiments investigating 
PLD signalling in cardiomyocytes, PAR1 receptor-induced PLD stimulation was 
found to be PKC-independent and brefeldin A-sensitive, thus ARF-dependent, whilst 




endothelin-1 receptor-mediated PLD activity was determined to be ARF-independent 
(371).   
 
3.2 Results 
3.2.1 Identification of PLD isoforms utilised by the 5-HT2AR  
Various GPCRs have been demonstrated to interact with and activate phospholipase 
D isoforms, some of which are suggested to demonstrate PLD-isoform specific 
preferences (372). In order to elucidate which PLD isoforms mediate the 5-HT2AR 
response, COS7 cells were co-transfected with Protein C epitope-tagged 5-HT2AR 
(sPrC-5-HT2AR) and either control (empty pcDNA3.1 vector), wild-type HA tagged 
PLD1 or PLD2 (Figure 3.1a, 3.1b), or dominant-negative mutant (!-)PLD1 or PLD2 
isoforms (Figure 3.1c, 3.1d). !-PLD1 and !- PLD2 are catalytically inactive due to 
the replacement of the usual Lys (K) with an Arg (R) residue, at amino acid 898 
(PLD1 K898R) and 758 (PLD2 K758R), respectively, and thereby act to reduce the 
rate of substrate processing by the wild-type endogenous enzymes and hence block 
the effects of intracellular PLD signalling pathways (312,373). Cells were stimulated 
with 3 µM 5-HT for 0-10 minutes to assess PLD activity (Figure 3.1a, 3.1c), or 0-60 
minutes to investigate PLC activity (Figure 3.1b, 3.1d). PLD responses were 
measured via the quantification of tritiated phosphatidyl butanol production 
([3H]PtdBut), and PLC via tritiated inositol phosphate production ([3H]InsP). 
[3H]PtdBut or [3H]InsP production is illustrated as a fold of the respective 
unstimulated control. The control cells in Figure 3.1a (expressing 5-HT2AR plus 
empty vector) evoke an endogenous PLD response to approximately three-fold of the 
basal. Additional expression of recombinant PLD2 does not appear to significantly 




increase 5-HT2AR-mediated PLD activity above control responses, however, 
additional expression of recombinant PLD1 isoform is shown to significantly 
increase 5-HT2AR-mediated PLD activity over control responses at 2-10 min 5-HT 
incubation times (Figure 3.1a) (p <0.05, Wilcoxon test) to approximately eight-fold 
over basal, thus suggesting that 5-HT2AR-induced PLD activation is PLD1-
dependent. Neither PLD1 nor PLD2 responses in the corresponding PLC assay 
(Figure 3.1b) were found to significantly vary from control responses. Figure 3.1c 
demonstrates PLD responses in the presence of !- PLD1 and !- PLD2 constructs. !- 
PLD2 expression was not found to significantly influence 5-HT2AR-mediated PLD 
activity, however expression of the dominant negative PLD1 isoform (!- PLD1) was 
found to significantly inhibit [3H]PtdBut production when compared to control 
responses (p <0.05, Wilcoxon test), further implicating the involvement of the PLD1 
isoform in 5-HT2AR-mediated PLD activity. Both !
- PLD1 and !- PLD2 expression 
were demonstrated to have no significant effect upon corresponding 5-HT-induced 
PLC responses (Figure 3.1d). Pilot experiments indicated that [3H]PtdBut values in 
unstimulated COS7 cells transfected with the wild-type-5-HT2AR, H452Y-5-HT2AR 
(discussed later in chapter), or empty vector were not discernably increased through 
the duration of the assays. All plotted points represent means ± SEM, n = 8.  




                    




Figure 3.1 5-HT-induced PLD and PLC responses in COS7 cells co-transfected 
with 5-HT2AR and PLD1, PLD2, !
- PLD1 or ! - PLD2. PLD and PLC responses of 
COS7 cells co-transfected with 5-HT2AR and pcDNA3.1 as control (!), PLD1 (!) or 2 
(") isoforms (Figures a and b), or dominant negative mutant (!-) PLD1 (#) or 2 ($) 
isoforms, K898R-PLD1 or K758R-PLD2 respectively (Figures c and d). Cells were 
stimulated with 5-HT (3 µM) at a range of incubation times, PLD activity is 
represented by [3H]phosphatidyl butanol ([3H]PtdBut) production (Figures a and c). 
PLC activity is represented by [3H]inositol phosphate ([3H]InsP) production (Figures 
b and d). The points plotted represent means ± SEM, n = 4. Values for 5-HT-
induced [3H]Ptd But production in the presence of  wild-type PLD1 were significantly 
greater than control and those in the presence of !- PLD1 were significantly less 











3.2.2 Assessment of possible pathways mediating 5-HT2AR-evoked PLD activation  
A prominent role for ARF1 but not ARF6 in 5-HT2AR-mediated PLD responses was 
established by the use of dominant negative constructs in previous work from the lab 
to assess the input from different potential activating factors (274,374). To assess the 
dependence of 5-HT2AR-mediated PLD activity upon different potential activating 
factors, various inhibitory agents and dominant negative constructs were used. To 
investigate the influence of RhoA on 5-HT2AR-mediated PLD activity, the effects of 
[T19N] RhoA, a dominant negative RhoA construct, were investigated on 5-HT- and 
thrombin-stimulated PLD activity (Table 3.1). COS7 cells were triple-transfected 
with Protein-C-epitope tagged 5-HT2AR, PLD1 or pcDNA3.1 empty vector as control, 
and [T19N] RhoA or pcDNA3.1 control, and stimulated with either 3 µM 5-HT, or 0.5 
U/ml thrombin. Transfection with additional PLD1 evokes significantly higher 5-
HT-induced PLD responses than those seen with control. In the absence of the 
dominant negative [T19N] RhoA mutant 5-HT responses were amplified from 2.63 ± 
0.35 to 5.86 ± 0.97 fold of basal, and in the presence of mutant RhoA they were 
amplified from 2.72 ± 0.28 to 5.33 ±  0.69 fold of basal (p <0.05, Wilcoxon test). 
Thrombin, which is an activator of protease activated receptors (PAR)-1 and -4 (that 
can activate PLD in a Rho-dependent manner), also induced a significant increase in 
PLD activity above control in sPrC-5-HT2AR-transfected cells that was increased by 
transfection of wild-type PLD1. In the absence of [T19N] RhoA thrombin-evoked 
responses were amplified by PLD1 from 3.13 ± 0.42 to 4.72 ± 0.51 fold of basal (p 
<0.05, Wilcoxon test), but the addition of [T19N] RhoA conferred a significant 
reduction in PLD responses to 2.58 ± 0.37 fold of basal (p <0.05, Wilcoxon test), 
with no significant increase over control, which was 2.38 ± 0.39 fold of basal. All 




values are the mean of 6 separate results, displayed as mean ± SEM. These 
observations suggest lack of involvement of RhoA in 5-HT2AR-mediated PLD 
responses in COS7 cells whereas responses of a control receptor, the thrombin PAR-
1 R (which is known to engage closely in RhoA signalling) was clearly affected.  
 
The influence on PKC and Rho upon 5-HT2AR-regulated PLD activity was further 
investigated with the use of PIM87/IR-PLD1, a mutant PLD construct which exhibits 
a selective loss of responses to PKC! and Rho. COS7 cells were transfected with 
Protein C epitope-tagged 5-HT2AR (sPrc-5-HT2AR) and either pcDNA3.1 as a control, 
wild-type PLD1, or PIM87/IR-PLD1. Cells were then stimulated with either 3 µM 5-
HT, or 300 nM PDBu and assayed for PLD activity (Table 3.2). Both wild-type 
PLD1 and PIM87/IR-PLD1 cells demonstrated significantly increased 5-HT-induced 
PLD activity over control responses to 5-HT of 1.85 ± 0.10 fold increment over basal 
(p <0.05, Wilcoxon test), with the PIM87/IR-PLD1 construct conferring only slightly 
lower amplification of 5-HT-induced PLD responses when compared to wild-type 
PLD1 with responses of 5.27 ± 0.67 and 6.08 ± 0.58 fold increment over basal 
respectively. When incubated with PDBu, a potent protein kinase C activator, again a 
significant increase over control was seen in wild-type PLD1 expressing cells, at 
9.79 ± 0.88 compared to 4.64 ± 0.42 fold increment over unstimulated basal (p 
<0.05, Wilcoxon test), but PtdBut-induced PLD responses were not increased over 
control by PIM87/IR-PLD1 and were significantly lower than responses in the 
presence of wild-type PLD1 (p <0.05, Wilcoxon test). This suggests that neither Rho 
nor PKC are important in the amplification of 5-HT2AR-elicited PLD responses 




caused by additional wild-type PLD1 and therefore, by implication, that ARF may be 
a mediator. 
 
Table 3.3 shows the 5-HT-induced PLD activity of COS7 cells transfected with 
sPrC-5-HT2AR and either pcDNA3.1, as control, or wild-type PLD1 in the presence of 
the PLC and tyrosine kinase inhibitors U 73122 and AG 213. Neither inhibitor was 
found to reduce endogenous responses to 5-HT, or the amplified responses in the 
presence of additional PLD1 expression. 5-HT-induced PLD activity in controls, 
with U 73122 or with AG 213, was 2.43 ± 0.26, 3.11 ± 0.48 and 3.01 ± 0.33 fold of 
basal whereas corresponding responses in the presence of additional PLD1 were 4.91 
± 0.53, 5.40 ± 0.69 and 5.12 ± 0.78 fold of basal. All PLD1 expressing cells were 
found to evoke significantly higher PLD responses than control cells (p <0.05, 
Wilcoxon test). 
 
Table 3.4 demonstrates the 5-HT-induced PLD activity of COS7 cells transfected 
with sPrC-5-HT2AR and either pcDNA3.1, as control, or wild-type PLD1 and 
incubated with selected protein kinase C inhibitors or pertussis toxin. 
Bisindoylmaleimide 1 (BIM1), acts to block the PKC binding site for ATP, thereby 
inducing the kinase domain to adopt an open conformation, and rendering it inactive 
(375).  CGP 41251 is a derivative of staurosporine, and a structurally distinct protein 
kinase C inhibitor (376). Pertussis toxin acts to catalyze the ADP-ribosylation of Gi, 
Go and Gt alpha subunits, thereby preventing their downstream signalling. Again, 
none of the inhibitory agents acted to significantly reduce either control 5-HT2AR-
elicited PLD responses or their amplification in the presence of additional wild-type 




PLD1. Without additional PLD1, 5-HT-induced PLD responses for control, BIM1, 
CGP 41251 and pertussis toxin samples were 2.95 ±  0.33, 3.24 ±  0.39, 2.53 ± 0.61 
and 3.06 ±  0.44 fold of unstimulated basal. In the presence of additional PLD1 the 
corresponding responses were 6.82 ±  0.83, 6.13 ±  0.91, 7.01 ±  0.53  and 6.19 ±  
0.71 fold of basal. All PLD1 overexpressing cells were found to evoke significantly 
higher PLD responses than control cells (p <0.05, Wilcoxon test). All values are the 
mean of 6 separate results, displayed as mean ± SEM. In these experiments we could 
find no evidence for involvement of PKC of Gi/Go in 5-HT2AR-elicited PLD 
responses or their amplification in the presence of additional wild-type PLD1. 
 
Figure 3.2 illustrates 5-HT2AR- and gonadotrophin releasing hormone receptor 
(GnRHR)-mediated PLD responses in the presence/absence of PLD1 and 
[Q209L/D277N] G!q, a dominant negative G!q mutant construct, that acts to 
disrupt Gq coupling to PLC signalling pathways (377). [Q209L/D277N] G!q does 
not appear to confer any decrease in COS7 cell 5-HT2AR-mediated PLD responses, 
either in the presence or absence of wild-type PLD1, following stimulation with 3 
µM 5-HT. Control responses to 5-HT in the absence or presence of [Q209L/D277N] 
G!q and corresponding responses in the additional presence of extra PLD1 were 
3.13 ±  0.23, 2.90 ±  0.22, 8.12 ±  1.46 and 6.76  ± 0.56 fold of basal. In contrast, in 
cells transfected with the mouse GnRHR, GnRHR-mediated PLD responses were 
significantly decreased by [Q209L/D277N] G!q, both in the absence or presence of 
additional PLD1. Control responses to GnRH in the absence or presence of 
[Q209L/D277N] G!q and corresponding responses in the additional presence of 
extra PLD1 were 4.38 ± 0.45, 1.98 ± 0.12, 9.83 ± 1.07 and 4.84 ± 0.53 fold of basal 




respectively. Statistically significant increments in evoked PLD responses were seen 
due to additional PLD1 compared to vector alone in the case of both the 5-HT2AR 
and the GnRHR (p< 0.05, Wilcoxon test). [Q209L/D277N] G!q significantly 
attenuated facilitation of GnRHR but not 5-HT2AR-mediated PLD responses caused 
by additional wild-type PLD1 (p< 0.05, Wilcoxon test).  All values are the mean of 8 
independent results, displayed as mean ± SEM. These observation suggest that while 
Gq may play a role in PLD signalling by the GnRHR, this is not the case for the 5-
HT2AR. 
 
Previous work has established a strong inhibitory influence of dominant negative 
ARF1 ([T13N] ARF1) on 5-HT2AR-mediated PLD activation (274,374). Table 3.5 
illustrates the influence of the dominant negative [T31N] ARF1 construct upon 3 µM 
5-HT stimulated PLC activity. COS7 cells were triple transfected with sPrC-5-
HT2AR, PLD1 or pcDNA3.1 empty vector as control, and [T31N] ARF1 (that 
demonstrates a reduced affinity for GTP), or again, pcDNA3.1 control. Cells were 
stimulated with 5-HT and assayed for PLC activity. PLC responses are represented 
as [3H]inositol phosphate ([3H]InsP) production as fold of basal, unstimulated 
control. It is evident that transfection with PLD1, or dominant negative [T31N] 
ARF1 does not evoke any discernable or significant change in PLC activity 
(Wilcoxon test). Control 5-HT2AR-mediated PLC responses and those in the presence 
of [T31N] ARF1 were 2.69 ± 0.31 and 2.77 ± 0.35 fold of basal while corresponding 
values in the additional presence of extra wild-type PLD1 were 2.86 ± 0.40 and 2.53 
± 0.28 fold of basal respectively. All values are the mean of 8 independent results, 
displayed as mean ± SEM. 



















5-HT (3 µM) 
 
 
2.63 ± 0.35 
 
5.86 ± 0.97* 
 
5-HT (3 µM) 
+ [T19N] RhoA 
 
2.72 ± 0.28 
 
5.33 ± 0.69* 
 
thrombin (0.5 U/ml) 
 
 
3.13 ± 0.42 
 
4.72 ± 0.51* 
 
thrombin (0.5 U/ml) 
+ [T19N] RhoA 
 







Table 3.1 Effects of dominant negative RhoA construct on 5-HT2AR-mediated 
and thrombin/PARR-mediated PLD responses in the absence or presence of 
additional PLD1. PLD responses of COS7 cells co-transfected with sPrC-5-HT2AR 
and pcDNA3.1 or PLD1, in the presence or absence of the dominant negative 
[T19N]RhoA construct, following stimulation with either 3 µM 5-HT or 0.5 U/ml 
thrombin. * indicates response significantly greater than response in the absence of 
PLD1  and ! indicates response significantly less than response in the absence of 
[T19N]RhoA  (p< 0.05, Wilcoxon test). Values are means ± SEM from 6 separate 











Activator-induced [3H]PtdBut production (fold 

















5-HT (3 µM) 
 
1.85 ± 0.10 
 
             
6.08 ± 0.58 * 
 
5.27 ± 0.67 * 
 
PDBu (300 nM) 
 
4.64 ± 0.42 
 
 
9.79 ± 0.88 * 
 




Table 3.2 Effects of co-transfection of wild-type PLD1 or a PLD1 construct 
defective in activation by PKC or Rho (PIM87/IR-PLD1) on PLD responses to 5-
HT or phorbol 12, 13-dibutyrate (PDBu) in sPrC-5-HT2AR-expressing COS7 
cells. Values are means ± SEM, n - 3. Statistically significant increments in evoked 
PLD responses compared to vector alone and reduction compared to PLD1 wild-























sPrC-5-HT2AR + pcDNA3.1 
 
 
sPrC-5-HT2AR + PLD1 
 
5-HT (3 µM) 
 
 
2.43 ± 0.26 
 
4.91 ± 0.53* 
 
5-HT (3 µM) 
+ U 73122 (20 µM) 
 
3.11 ± 0.48  
 
5.40 ± 0.69* 
 
5-HT (3 µM) 
+ AG 213 (100 µM) 
 
3.01 ± 0.33 
 




Table 3.3 Effects of PLC and tyrosine kinase inhibitors on 5-HT2AR-mediated 
PLD responses in the presence or absence of additional PLD1. PLD responses 
of COS7 cells co-transfected with sPrC-5-HT2AR and pcDNA3.1 or PLD1 and 
stimulated with either 3 µM 5-HT alone, or in combination with 20 µM U 73122 or 
100 µM AG 213. All responses were found to be significantly greater in the presence 
of additional PLD1 (*p< 0.05, Wilcoxon test) but no significant inhibitory effects of U 






























5-HT (3 µM) 
 
 
2.95 ± 0.33 
 
6.82 ± 0.83* 
 
5-HT (3 µM) 
+ BIM1 (3 µM) 
 
3.24 ± 0.39 
 
6.13 ± 0.91* 
 
5-HT (3 µM) 
+ CGP 41251 (3 µM) 
 
2.53 ± 0.61 
 
7.01 ± 0.53* 
 
5-HT (3 µM) 
+ Ptx (200 ng/ml; 16 
h) 
 
3.06 ± 0.44 
 
6.19 ± 0.71* 
 
 
Table 3.4 Effects of protein kinase C inhibitors and pertussis toxin on sPrC-5-
HT2AR-mediated PLD responses in the absence or presence of additional 
PLD1. PLD responses of COS7 cells co-transfected with sPrC-5-HT2AR and 
pcDNA3.1 or PLD1 and stimulated with either 3 µM 5-HT alone, or in combination 
with, 3 µM BIM1, 3 µM CGP 41251 or 200 ng/ml pertussis toxin for 16 hours. All 
responses were found to be significantly greater in the presence of additional PLD1 






















Figure 3.2 5-HT/GnRH-induced PLD responses in the presence/absence of 
PLD1 and [Q209L/D277N] G!q. PLD responses of COS7 cells transfected with 5-
HT2AR or GnRHR, in the presence or absence of PLD1 and [Q209L/D277N] G!q, 
following stimulation with 3 µM 5-HT or 300 nM GnRH. * indicates response 
significantly greater than response in the absence of PLD1  and ! indicates 
response significantly reduced in the absence of [Q209L/D277N] G!q (p <0.05, 
Wilcoxon test). Values are means ± SEM, n = 4.  
 
  5-HT2AR        
5-HT 3 µM 
     GnRHR 
GnRH 300 nM 



















5-HT (3 µM) 
+ pcDNA3.1 
 
2.69 ± 0.31 
 
2.86 ± 0.40 
 
5-HT (3 µM) 
+ [T31N]ARF1 
 
2.77 ± 0.35 
 




Table 3.5 Effects of dominant negative ARF1 construct on 5-HT2AR-mediated 
PLC responses in the absence or presence of additional PLD1. The table 
illustrates the 5-HT-stimulated  PLC responses of COS7 cells triple-transfected with 
sPrC-5-HT2AR, pcDNA3.1 or PLD1 and pcDNA3.1 or the dominant negative [T31N] 
ARF1 construct. Values are means ± SEM from 8 separate determinations, n = 4. 
There were no statistically significant differences between responses (Wilcoxon 
test).  
 





3.2.3 PLD signalling pathway of the wild-type 5-HT2AR - co-immunoprecipitation 
experiments 
To further understand this signalling pathway, potential physical associations of the 
5-HT2AR and PLD isoforms were investigated; Figure 3.3 illustrates the results of co-
immunoprecipitation experiments in which HA-tagged PLD1 (HA-PLD1) or PLD2 
(HA-PLD2) constructs were investigated as potential interaction partners of the 
sPrC-5-HT2A receptor. COS7 cells were co-transfected with sPrC-5-HT2A receptor 
and either the HA-PLD1 isoform or the HA-PLD2 isoform. Mouse monoclonal 
HPC4 anti-PrC antibody (Roche) was used to isolate sPrC-5-HT2A receptor from cell 
lysates, along with any associated proteins. Non-immune mouse IgG was used as a 
control. Proteins were separated using gel electrophoresis and transferred to PVDF 
by Western blot. The resulting protein bands were identified by specific antibody and 
enhanced chemiluminescence; HA-PLD bands were detected using a rat monoclonal 
anti-HA HRP-conjugated antibody (clone 3F10, Roche) and sPrC-5-HT2AR was 
visualised with anti-PrC antibody (HPC4, Roche) and Chemicon anti-mouse 
secondary antibody conjugated to HRP. In Figure 3.3 HA-PLD isoform co-
immunoprecipitates can be seen in the bottom panel, sPrC-5-HT2AR 
immunoprecipitates in the middle panel and HA-PLD total lysate samples in the top 
panel (applicable to two adjacent lanes as appropriate). The band in the lower panel 
and first lane represents HA-PLD1 co-immunoprecipitate pulled down with anti-PrC 
antibody, and the adjacent band HA-PLD1 co-immunoprecipitate pulled down with 
control non-immune IgG. The obviously greater density of the band isolated with 
anti-PrC antibody indicates that HA-PLD1 specifically interacts with, and can be 
pulled down with the sPrC-5-HT2AR.  In contrast, lanes 3 and 4 represent anti-PrC 




and non-immune pull-downs of the HA-PLD2 isoform respectively. The high non-
immune HA-PLD2 pulldown seen in lane 4 suggests that co-immunoprecipitation of 
HA-PLD2 with the receptor lacks specificity. Both the receptor input (middle panel) 
and HA-PLD input (top panel) appear even.  
 
The results of the co-immunoprecipitation experiment shown in Figure 3.3 were 
quantified using Image J software to obtain densitometric measurements, and 
normalised, taking into account background levels, PLD input and receptor input. 
The mean results from such PLD pulldown experiments can be seen in Figure 3.4, 
shown as the scan densities of HA-PLD bands in arbitrary grey scale units. The 
specific scan density value for PLD1 associated with anti-PrC tag 
immunoprecipitates was found to be significantly greater than that for the control 
non-immune IgG co-immunoprecipitate (p <0.05, Wilcoxon test), indicating that 
HA-PLD1 specifically co-immunoprecipitates with the sPrC-5-HT2A receptor in 
cells. However, PLD2 control scan densities values were not found to be 
significantly different from the PLD2 co-immunoprecipitate values, thus not 
providing any indication of specific PLD2 co-immunoprecipitation with the sPrC-5-
HT2A receptor in vitro. All plotted points represent means ± SEM, n = 5.  











Figure 3.3 Co-immunoprecipitation of HA-PLD1 and HA-PLD2 with sPrC-
5HT2AR. Mouse monoclonal anti-PrC tag antibody (HPC4) was used to 
immunoprecipitate sPrC-5-HT2AR, along with any proteins attached to the receptor. 
Non-immune IgG was used as a control. HPC4 was also used to visualize 
immunoprecipitated sPrC-5-HT2AR. IgG bands from the immunoprecipitation are 
shown by arrows. HA-PLD1 and HA-PLD2 bands were visualised using rat 
monoclonal anti-HA HRP-conjugated antibody (clone 3F10, Roche). The levels of 
HA-PLD1 and 2 in co-immunoprecipitates are shown as well as PLD1 and 2 in 
inputs and receptor in immunoprecipitates. These observations were typical of 5 





















Figure 3.4 Quantification of HA-PLD1 co-immunoprecipitation with sPrC-5-
HT2A receptor. COS7 cells were co-transfected with sPrC-5HT2A and HA-PLD1 or 
HA-PLD2, and immunoprecipitation carried out as in Figure 3.3. The graph 
illustrates quantified scan densities of HA-PLD1 and HA-PLD2 pulled down by anti-
protein C tag antibody HPC4 and by control non-immune mouse IgG. The PLD1 
pull-down obtained via immunoprecipitation with anti-protein C antibody was found 
to be significantly greater than that using control non-immune IgG. Conversely, the 
PLD2 pull-down using anti-protein C antibody was not significantly increased over 
levels of PLD2 immunoprecipitated with control non-immune antibody. Values were 
obtained from a total of 5 experiments similar to that illustrated in Figure 3.3, n = 5 (! 









In previous experiments, the PLD-activating small G protein ARF1 has been shown 
to demonstrate an increased association with the 5-HT2AR following exposure with 5-
HT in the first 5 minutes, reducing thereafter (274). To assess whether the interaction 
of PLD1 with the receptor is dynamically regulated by 5-HT, HA-PLD1 was co-
immunoprecipitated with sPrC-5-HT2AR following increasing time periods of pre-
incubation with 5-HT. COS7 cells were transfected with protein C epitope-tagged 5-
HT2AR, and HA-tagged PLD1, and incubated with 10 µM 5-HT for 0-60 minutes. 
Mouse monoclonal anti-PrC antibody was used to isolate receptor with mouse non-
immune IgG for controls, and complexed PLD1 was identified by Western blot with 
HRP-linked rat monoclonal anti-HA antibody (clone HPC4). Figure 3.5 
demonstrates the quantification of band densities (arbitrary grey scale units), which 
were normalised to reflect receptor and PLD1 inputs, background and non-immune 
HA-PLD1 pull down densities and displayed as a ratio against control HA-PLD1 co-
immunoprecipitate in unstimulated cells. Normalised levels of HA-PLD1 co-
immunoprecipiting with the receptor after 5-HT incubation were not found to 
discernably vary from that of normalised control, with values ranging from  0.75 ± 
0.16 – 1.0 ± 0.02 fold of control. Values are from 3 independent experiments, results 
displayed as mean ± SEM.     













Figure 3.5 Quantification of levels of HA-PLD1 co-immunoprecipitated with 
wild-type 5-HT2AR pre-incubated with 10 µM 5-HT for 0-60 minutes. Graph 
represents normalised levels of HA-PLD1 co-immunoprecipitated with wild-type 5-
HT2AR taking into account receptor and PLD1 inputs, background and non-immune 
HA-PLD1 pull down densities. HA-PLD1 co-immunoprecipitation is represented as a 
ratio to basal control (no pre-incubation). There were no discernable differences in 
quantities of HA-PLD1 pulled-down by 5-HT2AR pre-incubated with 10 µM 5-HT for 
increasing periods of time between 0-60 minutes. Results displayed as mean ± 
SEM, n = 3. 




3.2.4 PLD signalling pathways of the 5-HT2AR-GST-fusion protein studies  
To further isolate the PLD interaction site on the 5-HT2AR, GST-fusion proteins of 
specific 5-HT2AR domains were used as bait for potential interactions of PLD1/2 in 
enriched lysates. PLD1- or 2-expressing COS7 cell lysates were incubated with GST 
alone as control, or with GST-fusion proteins of the 5-HT2AR carboxy-terminal tail 
(ct), third intracellular loop (i3), or a truncated variant of the carboxy-terminal tail, in 
which the initial nine amino acids are removed (K385ct). These initial nine amino 
acids (376-385), contain a conserved NPxxY motif which is implicated in ARF 
binding and isoform selectivity of interaction with the 5-HT2AR (274,374). GST-
receptor constructs and any complexed proteins were immobilised on Glutathione 
Sepharose-4B beads and any proteins captured from lysates by these constructs were 
isolated and separated by gel electrophoresis. HA-PLD bands were visualised using 
rat monoclonal anti-HA HRP-conjugated antibody (clone 3F10, Roche), and GST 
input detected with monoclonal mouse anti-GST antibody (Clone B-14 Santa Cruz) 
and HRP-linked secondary anti-mouse antibody (Chemicon).The results are 
illustrated in Figure 3.6a; HA-PLD1 at approximately 120 kDa (top panel) appears to 
demonstrate negligible interactions with the control construct (GST alone) (lane 1), 
and little interaction with the i3 construct (lane 4), but does appear to specifically 
interact with the C-terminal tail of the receptor (lane 2). Furthermore, this interaction 
does not appear to be inhibited in any way by the truncation of the initial 9 amino 
acids (lane 3); rather, PLD1 association with the K385-5-HT2ARct GST-fusion 
protein construct appears to be increased, indicating that residues 376-385 are not 
required for HA-PLD1 binding in vitro and may possibly act to partly restrict the 
interaction. Levels of HA-PLD2 captured with the GST-fusion protein constructs 




(middle panel) appear to follow a similar trend, although the differences between the 
various bands are less pronounced. GST inputs (bottom panel) appear to be 
reasonably well balanced, indicating that there is no bias of the results due to varying 
levels of construct input. Results of the subsequent densitometric analysis and 
quantification of the HA-PLD1 and HA-PLD2 protein bands seen in Figure 3.6a are 
represented in Figures 3.6b and 3.6c respectively. Statistical analysis of the results 
represented in Figure 3.6b determined levels of HA-PLD1 captured with GST-K385-
5-HT2ARct to be significantly greater than those captured with full length GST-5-
HT2ARct (p value 0.0217), and levels of HA-PLD1 captured with GST-5-HT2ARi3 to 
be significantly less than those captured with GST-5-HT2ARct (p value 0.0176). 
Statistical analysis of the complementary HA-PLD2 data illustrated in Figure 3.6c 
showed there to be no significant differences in levels of HA-PLD2 pulled down 
with the various constructs, possibly suggesting a degree of non-specific interaction 
by PLD2. 
 
The 5-HT2AR binding site for ARF1 has been previously determined to lie between 
residues 376-385 of the C-terminal tail and thus ARF binding to the K385-5-HT2ARct 
variant is significantly depleted. Thus Figure 3.6 indicates that PLD1 binds to the 
receptor at a region distinct from the ARF binding site. To further investigate this, 
GST-fusion protein constructs of the 5-HT2ARct were again used to assess whether 
the physical association of HA-PLD1 with the receptor C-terminus would influence 
ARF1-HA binding, or vice versa. Figure 3.7a and b illustrate the results of 
experiments in which GST-5-HT2ARct constructs were incubated with either HA-
PLD1 lysate/buffer (Figure 3.7a) or ARF1-HA lysate/buffer (Figure 3.7b) for 12 




hours, prior to being washed and undergoing a further 12 hour incubation with 
ARF1-HA lysate/buffer or HA-PLD1 lysate/buffer respectively. It is evident from 
Figure 3.7a that prior binding of HA-PLD1 to the C-terminal tail (upper panel, lanes 
1 and 3) does not appear to affect subsequent ARF1-HA binding (middle panel, lane 
3; compared to lane 2 control without PLD co-immunoprecipitation). The bound 
ARF1-HA levels appear to be equivalent and thus unaffected by receptor-bound HA-
PLD1 in vitro. Additionally, HA-PLD1 binding (top panel) did not appear to be 
displaced by the addition of, and subsequent GST-5-HT2ARct interactions with, 
ARF1-HA (lane 3). Furthermore, the corresponding experiment in Figure 3.7b 
demonstrates that HA-PLD1 binding to the 5-HT2ARct was not noticeably influenced 
by the prior binding of ARF1-HA (top panel, lane 3; compared to lane 2 control 
without ARF1-HA pre-incubation) and neither was ARF1-HA binding affected by 
the subsequent binding of HA-PLD1 (middle panel, lane 3). 
 
To further define the potential HA-PLD1 binding site on the 5-HT2ARct, a series of 
GST-fusion proteins of sequentially truncated variants of the 5-HT2ARct were used to 
capture HA-PLD1 and ARF1-HA lysate (Figure 3.8a). Full-length GST-5-HT2ARct 
and the C-terminally-truncated 5-HT2ARct GST-fusion protein variants, GST-(376-
470)5-HT2AR ct, GST-(376-438)5-HT2AR ct, and GST-(376-428)5-HT2ARc-
terminuswere incubated with lysates from COS7 cells transfected with HA-PLD1 or 
ARF1-HA. GST-fusion proteins and any associated proteins were immobilised on 
Glutathione-Sepharose-4B beads, before being isolated via gel electrophoresis and 
Western blotting; HA-PLD1 (~120kDa) and ARF1-HA  (~20kDa) were visualised 
using rat monoclonal HRP-linked anti-HA antibody (Roche). The density of the HA-




PLD1 bands indicate a decrease in HA-PLD1 binding to the C-terminal tail of the 
receptor as the distal region is progressively truncated. The results from 3 analogous 
experiments were quantified by scan densitometry; Figure 3.8b shows the mean ratio 
of HA-PLD1 captured by the truncated construct to that captured by the full-length 
GST-5-HT2ARct. Levels of HA-PLD1 captured by GST-(376-438)5-HT2ARct and 
GST-(376-428)5-HT2ARct were found to be significantly less than that captured by 
the full-length GST-5-HT2ARct (p <0.05, t-test). In contrast, the density of HA-ARF1 
bands shown in the lower panel of Figure 3.8a indicate that HA-ARF1 binding is 
unaffected by C-terminal truncations of the 5-HT2ARct. This is further corroborated 
by the densitometric quantification of 3 parallel experiments, represented in Figure 
3.8c as the mean ratio of ARF1-HA captured by construct to that captured by GST-5-
HT2ARct. Truncation of the distal region of the 5-HT2ARct was not found to result in 
any significant changes to ARF1-HA binding. 
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Figure 3.6 HA-PLD1 and 2 binding to GST-fusion proteins of particular domains 
of the 5-HT2AR. GST-fusion proteins of the 5-HT2ARct (ct), a truncated variant of the 5-
HT2ARct (K385ct) and the third intracellular loop (i3) were used as bait for potential 
interacting proteins in lysates of COS7 cells transfected with either HA-PLD1 or HA-
PLD2. The density of HA-PLD1 and 2 bands shown in part (a) were quantified and are 
shown as ratios of HA-PLD1 and 2 captured by the receptor domain constructs 
compared to GST alone in (b) and  (c), respectively. * or ! denote significantly greater 
or lesser levels of captured HA-PLD1 when compared to that captured with GST-5-

















Figure 3.7 Evidence for the lack of interaction between HA-PLD1 and ARF1-HA 
binding to the GST-5-HT2ARct tail construct. In these experiments, the GST-
fusion protein of the 5-HT2ARct was subjected to consecutive 12 hour incubations at 
4°C with COS7 cell extracts enriched in HA-PLD1 or ARF1-HA or appropriate buffer 
controls. Bound HA-PLD1 or ARF1-HA was then detected by SDS-PAGE and 
blotting with 3F10 HRP-conjugated anti-HA antibody. HA-PLD1 and ARF1-HA could 
be clearly distinguished by their different running positions at approximately 120 and 
20 kDa respectively. In the left panel (a) (PLD1 first incubation, ARF1 second 
incubation) it is seen that when PLD1 is already bound to the GST-5-HT2ARct 
construct the subsequent binding of ARF1 is neither facilitated nor inhibited. In the 
right panel (b) (ARF1 first incubation, PLD1 second incubation) it is seen that when 
ARF1 is already bound to the GST-5-HT2ARct construct the subsequent binding of 
PLD1 is neither facilitated nor inhibited. These results are typical of 3 independent 
experiments. 
a b 
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Figure 3.8 HA-PLD1 and HA-ARF1 binding to sequentially truncated GST-fusion 
protein constructs of the 5-HT2ARct. Figure (a) illustrates HA-PLD1 and ARF1-HA 
bound to sequentially truncated variants of the GST-5-HT2ARct. HA-PLD/ARF1-HA 
bands were scanned and quantified by densitometry, the scan densities for PLD1 and 
ARF1 are demonstrated as a fold of PLD1/ARF1 captured by the full-length carboxy-








3.2.5 PLD signalling pathway of the H452Y polymorphic variant of the 5-HT2AR – 
co-immunoprecipitation experiments  
The results from Figure 3.8 thus indicate that PLD1 requires residues 428-470 for 
efficient binding to the 5-HT2ARct. Interestingly, there is a clinically relevant 5-
HT2AR polymorphic variant, that codes within the distal region of the C-terminal tail, 
in which a Tyr replaces the normal His at residue 452 (H452Y). The minor variant 
allele is expressed by approximately 9% of the population (301,302) and previous 
studies have suggested that signalling by the H452Y variant of the receptor may 
differ from that of the H452 receptor (308,309). Thus, it was hypothesised that the 
H452Y mutation may alter PLD1 binding to the 5-HT2AR. Figure 3.9 illustrates the 
results of a typical co-immunoprecipitation experiment designed to identify any 
differences in the binding of PLD1 to the H452Y variant of the 5-HT2AR when 
compared to the wild-type form. COS7 cell lysates expressing either wild-type sPrC-
5-HT2A receptor and HA-PLD1, or H452Y variant sPrC-5-HT2AR and HA-PLD1, 
were immunoprecipitated with mouse monoclonal anti-PrC tag antibody (Roche, 
HPC4), or with non-immune mouse IgG, as a control. Following the separation of 
immunoprecipitated proteins by gel electrophoresis, HA-PLD1 associated with the 
receptor pull-down was assessed using rat monoclonal HRP-linked anti-HA (Roche, 
clone 3F10) and receptor input was determined with the use of mouse monoclonal 
anti-PrC tag antibody (HPC4, Roche) and anti-mouse HRP-linked antibody 
(Chemicon).  It can be seen that despite equivalent receptor (middle panel) and HA-
PLD1 inputs (top panel), noticeably less HA-PLD1 is co-immunoprecipitated with 
the H452Y-5-HT2AR variant (bottom panel, lane 2) than with the wild-type receptor 
(bottom panel, lane 1). Minimal HA-PLD1 immunoreactivity is seen in the control 




lanes (bottom panel, lanes 3 and 4), indicating that the result is specific to the sPrC-
5-HT2AR co-immunoprecipitation. The densitometric readings from three identical 
experiments were normalised, taking into account the values for specific co-
immunoprecipitated PLD1, receptor input and PLD1 input. The mean normalised 
value for PLD1 co-immunoprecipitated with the H452Y variant of the receptor was 
significantly lower, at just 44% of that for the wild-type sPrC-5-HT2AR (p value = 
0.0388, t-test).  
 
The equivalent experiment was performed with the HA-PLD2 isoform (Figure 3.10). 
HA-PLD2 appears to be pulled down with both receptor variants (bottom panel, 
lanes 1 and 2) although similar observations were made in the control pull-downs 
performed with non-immune mouse IgG (lanes 3 and 4) suggesting that any 
interaction of HA-PLD2 here was largely non-specific. This result was typical of 
three independent experiments. In the example illustrated the slightly greater 
apparent pulldown of HA-PLD2 in cells expressing the H452Y variant 5-HT2AR is 
probably due to greater input levels of receptor and HA-PLD2 inputs (middle and top 
panels, respectively). 
 
3.2.6 PLD signalling pathway of the H452Y polymorphic variant 5-HT2AR – GST-
fusion protein experiments 
The results from the co-immunoprecipitation experiment illustrated in Figure 3.9 
were further validated with the use of GST-fusion proteins of the wild-type H452 
and H452Y variants of the C-terminal tail of the 5-HT2AR. Either GST alone, GST-5-
HT2ARct, or GST-H452Y-5-HT2ARct constructs were incubated with lysate from 




COS7 cells expressing either HA-PLD1 or ARF1-HA, following immobilisation on 
glutathione Sepharose-4B beads. GST fusion proteins and any complexed proteins 
were then separated by gel electrophoresis and PLD1/ARF1 was detected with the 
use of rat monoclonal HRP-linked anti-HA antibody (Roche, clone 3F10).  Figure 
3.11a shows levels of HA-PLD1 captured; it is evident that the introduction of the 
H452Y mutation to the GST-5-HT2ARct (lane 3) results in a dramatic decrease in 
HA-PLD1 binding in vitro, despite similar levels of construct input (lower panel). To 
establish the specificity of the result, the same constructs were used to assess binding 
of ARF1-HA lysate (Figure 3.11b). There was no observable difference between 
ARF1-HA binding to the wild-type GST-5-HT2ARct and the GST-H452Y-5-
HT2ARct.  











Figure 3.9 Co-immunoprecipitation of HA-PLD1 with the wild-type sPrC-5-HT2A 
and the H452Y mutant form of the sPrC-5-HT2AR. COS7 cells were co-transfected 
with protein C-tagged wild-type or H452Y variant 5-HT2AR and HA-PLD1. Anti-
protein C tag antibody was used to immunoprecipitate the receptor. Non-immune 
mouse IgG was used as a control. The Figure shows levels of HA-PLD1 pulled 
down with both variants of receptor (co-IP), levels of sPrC-5HT2AR recovered in the 
immunoprecipitates (IP) and HA-PLD1 inputs (lysate). These results are typical of 3 
independent experiments. 















Figure 3.10 Co-immunoprecipitation of HA-PLD2 with the wild-type sPrC-5-
HT2A and the H452Y mutant form of the sPrC-5-HT2A receptor. COS7 cells were 
co-transfected with protein C-epitope tagged wild-type or H452Y variant 5-HT2AR 
and HA-PLD2. Anti-PrC tag antibody was used to immunoprecipitate the receptor. 
Non-immune mouse IgG was used as a control. The Figure shows levels of HA-
PLD2 pulled down with both variants of receptor (co-IP), levels of sPrC-5HT2AR 
forms recovered in the immunoprecipitates (IP) and HA-PLD2 inputs (lysate). These 











Figure 3.11 HA-PLD1 and ARF1-HA binding to GST fusion protein constructs 
of the C-terminal tail of the wild-type 5-HT2AR and the H452Y 5-HT2AR variant. 
HA-PLD1 or ARF1-HA-enriched COS7 cell lysates were incubated with either GST 
alone, wild-type 5-HT2AR or H452Y-5-HT2ARct GST-fusion protein constructs. GST-
fusion proteins, along with any further complexed proteins were isolated using 
glutathione beads. HA-PLD1 and ARF1-HA were separated and identified by 
Western blot and anti-HA HRP-conjugated antibody analysis. These results are 









3.2.7 PLD signalling pathway of the [H452Y] polymorphic variant 5-HT2AR – 
functional signalling studies 
To assess any functional implications of decreased PLD1 binding by the H452Y 5-
HT2AR, COS7 cells co-transfected with either wild-type PrC epitope-tagged 5-
HT2AR and empty pcDNA3.1 vector alone as a control, PLD1 or 2, or the H452Y 
variant of the PrC tagged 5-HT2AR with empty pcDNA3.1 vector alone as a control, 
PLD1 or 2, were stimulated with increasing concentrations of 5-HT and assayed for 
evoked PLD activity. Responses in Figure 3.12 are shown as 5-HT-induced 
[
3
H]PtdBut production as a fold increment over basal unstimulated control. Control 
responses of wild-type and H452Y receptor variants appear approximately equivalent 
with EC50 values of 3.82 ± 0.23 nM and 9.75 ± 0.31 nM and maximum response 
values of 2.14 ± 0.20 and 2.01 ± 0.20 fold increment over basal, respectively. In cells 
additionally expressing PLD2, 5-HT-induced PLD activation mediated by the wild-
type 5-HT2AR, or the H452Y 5-HT2AR, was similar to that in control cells with EC50 
values of 5.4 ± 0.36 nM and 12.67 ± 0.16 nM and maximum response values of 1.65 
± 0.26 and 1.76 ± 0.29 fold increment over basal, respectively. In COS7 cells 
expressing wild-type sPrc-5-HT2AR and PLD1, 5-HT induced significantly increased 
PLD responses over control, at 5-HT concentrations 3-3000 nM (*p <0.05, Wilcoxon 
test). 5-HT-induced PLD responses mediated by the H452Y-5-HT2AR in cells 
additionally expressing PLD1 were also significantly increased above control at 5-
HT concentration of 30-3000 nM (*p <0.05, Wilcoxon test). However, these 
responses were significantly lower than PLD responses evoked by the wild-type 5-
HT2AR and PLD1 expressing cells, at 5-HT concentrations 3-3000 nM (! p <0.05, 
Wilcoxon test), with maximum wild-type receptor responses in the presence of 




additional PLD1 reaching 7.02 ± 0.59 fold increment over basal, whereas 
corresponding H452Y-5-HT2AR responses only reached a maximum of 4.39 ± 0.30 
fold increment over basal.  
 
Complementary PLC assays (Figure 3.13) were performed in order to verify that the 
amplification of 5-HT-induced PLD activity seen in the presence of additional PLD1 
(Figure 3.12) was specific for that signalling pathway. COS7 cells were co-
transfected with either wild-type PrC-tagged 5-HT2AR and empty pcDNA3.1 vector 
alone as a control, PLD1 or 2, or the H452Y variant of the sPrC-5-HT2AR with empty 
pcDNA3.1 vector alone as a control, PLD1 or 2. It is evident that transfection of 
COS7 cells with either PLD isoform fails to induce a significant increase in 5-HT-
induced PLC activity mediated by either the wild-type 5-HT2AR (Figure 3.13a), or 
the H452Y-5-HT2AR (Figure 3.13b). 









Figure 3.12 5-HT-induced PLD responses of COS7 cells co-transfected with 
the wild-type or  H452Y mutant form of the 5-HT2AR and PLD1 or PLD2. COS7 
cells were co-transfected with either wild-type 5-HT2AR and vector alone as a control 
(!), PLD1 (!) or PLD2 ("), or the H452Y variant of the 5-HT2AR with vector alone 
as a control (!), PLD1(#) or PLD2 ($). Cells were stimulated with increasing 
concentrations of 5-HT for 20 min. [3H]PtdBut production was assayed to measure 
PLD activity. The points plotted represent means ± SEM, n = 4. Values for 5-HT-
induced [3H]PtdBut production were significantly greater in the presence of PLD1 
than vector control at 3-3000 nM 5-HT for the wild-type receptor and at 30-3000 nM 
5-HT for the H452Y variant form (*p <0.05, Wilcoxon test). The 5-HT-induced fold 
increment values for the H452Y variant in the presence of PLD1 were significantly 
less than corresponding values for the wild-type receptor at 3-3000 nM 5-HT (! p 















Figure 3.13 5-HT-induced PLC responses of COS7 cells co-transfected with 
the wild-type or  H452Y mutant form of the 5-HT2AR and PLD1 or PLD2. COS7 
cells were co-transfected in (a) with the wild-type 5-HT2A receptor and vector alone 
as a control (!), PLD1 (!) or PLD2 ("), or in (b) with the H452Y variant of the 5-
HT2AR with vector alone as a control (!), PLD1 (#) or PLD2 ($). Cells were 
stimulated with increasing concentrations of 5-HT for 180 min. [3H]InsP production 
was assayed to measure PLC activity. No significant differences in PLC responses 
were noted. The points plotted represent means ± SEM, n = 4.  
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3.2.8 PLD signalling pathway of the wild-type and H452Y variant 5-HT2AR – 
ligand-binding studies  
To determine whether the differences in PLD binding and activity could be a 
consequence of the uneven expression of wild-type and H452Y mutant 5-HT2AR or 
of differing ligand affinity, COS7 cells were transfected with either receptor variant 
and assayed by radioligand binding. Specific binding by wild-type or H452Y mutant 
5-HT2AR was determined by the incubation of COS7 cell membranes (microsomal 
fraction following removal of nuclei by low speed centrifugation, see section 2.4) 
with 0.8 nM of the selective 5-HT2AR ligand [
3H]ketanserin (72.2 Ci/mmol), in the 
presence of increasing concentrations of cold ketanserin (0.1-300 nM) and in the 
presence/absence of excess 10 µM mianserin to define non-specific binding. COS7 
cell membrane homogenates were additionally assayed for total protein concentration 
with the use of a Pierce BCA Protein Assay Kit. The KD (nM) and Bmax (pmol/mg 
protein) displayed in Figure 3.14 are calculated from a homologous displacement 
protocol with non-linear curve fitting to mean values from four separate 
determinations, using GraphPad Prism 4. The Bmax values calculated do not appear 
to be discernably different between the two receptor variants, indicating that the 
receptors demonstrate approximately equivalent maximal numbers of ligand binding 
sites in our experiments. Furthermore, the similar KD values represented in Figure 
3.14 indicate that there are no marked differences in ligand affinity between the wild-
type and H452Y variant 5-HT2AR. 
 
To assess whether the wild-type and H452Y variant receptors might differ in the 
extent to which they were expressed at the plasma membrane, receptors localised at 




the cell surface were isolated via extracellular biotinylation, solubilisation and 
reversible capture on monomeric avidin beads, prior to quantification by radio-ligand 
binding. COS7 cells were transfected with either wild-type or H452Y 5-HT2AR. Prior 
to lysis, cells were incubated with membrane-impermeant sulpho-NHS-biotin, which 
efficiently forms covalent bonds to exposed primary amine groups, such as those on 
Lys residues. Biotinylated proteins were captured with the use of monomeric avidin 
beads and eluted with 2mM biotin. Ligand binding on the solubilised receptor (both 
the eluate from monomeric avidin and samples of the initial lysate to assess total 
input of solubilised cellular receptor) was then carried out as described in section 2.6, 
with capture using a polyethylene glycol/bovine gamma globulin 
precipitation/centrifugation protocol. Total and non-specific cell-surface receptor 
expression were determined for both receptor variants and are displayed in Figure 
3.14. There was found to be no discernable difference in the cell-surface expression 
of the two receptor variants, indicating that differences in the proportionate cell 
surface expression do not contribute to the changes in cell signalling evident between 
the wild-type and H452Y variant 5-HT2AR. 
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Figure 3.14 Ligand binding to wild-type and H452Y mutant constructs of the 5-
HT2AR. Levels of expression of wild-type and H452Y-5-HT2AR were assessed by 
binding of the selective 5-HT2AR ligand [
3H]ketanserin in the absence/presence of 10 
µM mianserin, to define non-specific binding. Protein levels in COS7 cell 
homogenates were determined using a Pierce BCA Protein Assay Kit. A 
homologous displacement protocol was used (unlabelled ketanserin concentrations 
from 0.1-300 nM) with non-linear curve fitting to the data using GraphPad Prism 4. 
Curves were fitted to mean values from four separate determinations. 
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Figure 3.15 Ligand binding to biotinylated wild-type and H452Y-5-HT2AR. 
Levels of plasma membrane expression of wild-type and H452Y-5-HT2AR were 
assessed by binding of the selective 5-HT2AR ligand [
3H]ketanserin in the 
absence/presence of 10 µM mianserin, to define non-specific binding at biotinylated 
receptors captured with avidin beads.  





PLD1 and PLD2 enzymes demonstrate diverse cellular localisations, modes of 
regulation and intracellular functions. The present findings demonstrate a significant 
amplification of PLD responses mediated by the 5-HT2AR only in the presence of the 
PLD1 isoform, and additionally a significant decrease in PLD responses conferred by 
a negative mutant form of PLD1, but not PLD2. The lack of amplification of 5-HT 
induced PLC responses in the presence of either wild-type PLD isoform or of 
attenuation by corresponding negative mutant constructs demonstrates the specificity 
of the PLD1-evoked response. This indicates an isoform-specific functional role of 
PLD1 in 5-HT2AR-mediated PLD signalling.  Studies investigating 5-HT-mediated 
PLD signalling in pulmonary artery smooth muscle cells concluded that PLD 
activation was mediated by the 5-HT2AR, and that this primarily involved activation 
of the PLD1 isoform (378). However, it is likely that the mode of 5-HT2AR activation 
is also cell-type dependent, thus it should not be assumed that 5-HT2AR-mediated 
PLD activation is always PLD1-selective. PLD1 activation has previously been 
demonstrated to induce cellular effects, such as such as agonist-induced secretion, 
actin reorganisation, cell adhesion and migration (199,245-247), whereas PLD2 
activation downstream of the µ-opioid and glutamate receptors has been 
demonstrated to result in receptor endocytosis, a function apparently specific to the 
PLD2 isoform of the enzyme (248,379). Thus PLD1-selective activation could result 
in specific cellular responses, in addition to specific modes of regulation. 5-HT2AR-
induced PLD responses were previously demonstrated to be primarily ARF1-
mediated in COS7 cells, with ~ 50% reduction of PLD responses seen with the 
introduction of a dominant negative [T31N]ARF1 mutant (50,274,374). However, as 




previously discussed, the GPCR-mediated activation of PLD can be brought about 
via a range of signalling events, including the activation of protein kinase C, tyrosine 
kinases, PI 3-kinase, Gq or Gi proteins, RhoA and putatively following increasing 
intracellular Ca2+ levels (244). Thus various dominant negative constructs, drugs and 
toxins with inhibitory effects on these pathways were used to assess alternative 
influences upon 5-HT2AR-mediated PLD responses. However, none of the inhibitory 
agents produced significant reductions in PLD activity: the dominant negative 
Q209L/D277N-G!q construct caused only a minor (~ 15%) decrease in 5-HT2AR-
mediated PLD responses despite evoking a significant (~ 50%) reduction in GnRH 
receptor-mediated PLD activity as a control; the PLC inhibitor U 73122 and tyrosine 
kinase inhibitor AG 213 did not induce any reduction in PLD responses; the protein 
kinase C inhibitors CGP 41251 and bisindolylmaleimide 1 had little or no inhibitory 
effects upon 5-HT-induced PLD responses; inhibition of Gi/o with pertussis toxin or 
inhibition of RhoA-mediated pathways with the dominant negative [T19N]RhoA 
mutant induced only minimal reductions in PLD response; and finally, synergistic 
inhibition of RhoA and PKC-mediated PLD1 activation via the use of the PIM87/IR-
PLD1 construct attenuated the amplification of 5-HT2AR PLD responses by only 
around 15% compared to that achieved by wild-type PLD1. Therefore, the activation 
of PLD1 by 5-HT2AR appears to be primarily ARF-mediated, however, PKC and 
RhoA-mediated PLD activity may contribute to the residual 5-HT2AR-mediated PLD 
activity demonstrated by Johnson et al in COS7 cells expressing dominant negative 
ARF1 (374). Alternatively, the remaining PLD response could be a result of cellular 
adaptations resulting from the selective inhibition of ARF1 in 5-HT2AR-expressing 
COS7 cells. Although both PLD isoforms have previously been shown to to be 




capable of undergoing ARF-mediated activation, PLD1 is the primary PLD isoform 
involved in ARF-mediated PLD activation (199,247,332,380). There is evidence to 
suggest that PLD1 undergoes ARF-mediated activation by various GPCRs, including 
the M3 receptor (362) and the somatostatin receptor (364). However, PLD2 has also 
been reported to undergo GPCR-induced ARF-mediated activation, such as that 
mediated by the µ-opioid receptor (372).  
 
To further investigate the molecular arrangements underlying 5-HT2AR-mediated 
PLD activation, the potential physical interaction of the two PLD isoforms with the 
5-HT2AR was assessed by co-immunoprecipitation. Quantification of PLD2 co-
immunoprecipitation with sPrC-5-HT2AR demonstrated that the non-specific 
pulldown identified in non-immune IgG controls contributed approximately 95% of 
the levels of PLD2 that apparently co-immunoprecipitated with the receptor. 
Presumably, any interactions contributing to the control pull-down of PLD2, such as 
direct interactions with antibody or Protein G-Sepharose beads would also be a factor 
contributing to the apparent PLD2 co-immunoprecipitation with the receptor. In 
contrast, PLD1 co-immunoprecipitated specifically with the 5-HT2AR specific PrC 
tag antibody pulldowns, but not non-immune IgG controls. Thus, the specific co-
immunoprecipitation of PLD1 but not PLD2 with the sPrC-5-HT2A receptor further 
corroborates the selective involvement of the PLD1 receptor in 5-HT2AR-mediated 
PLD activity. Further evidence of PLD isoforms co-immunoprecipitating with 
GPCRs is limited, however, PLD2 has been co-immunoprecipitated with both the 
metabotropic glutamate receptors 1a and 5a (367) and the µ-opioid receptor, which 




was found to involve interactions with the N-terminal region of PLD and the C-
terminus of the  µ-opioid receptor (372).  
 
sPrC-5-HT2AR association with ARF1-HA has been shown to increase with 5-HT 
stimulation in a time- and concentration-dependent manner (274). Thus co-
immunoprecipitation experiments were used to characterize any dynamic changes in 
the binding of HA-PLD1 to sPrC-5-HT2A receptor. Stimulation with 1 µM 5-HT to a 
maximum of 1 hr did not, however, induce any significant changes in HA-PLD1 
association with the receptor, indicating that, in contrast to ARF1-HA, HA-PLD1 
does not appear to form a dynamic association with sPrC-5-HT2AR. However, there 
are various reports indicating that PLD1 activation can involve, or be subsequent to, 
PLD1 relocalisation: carbachol stimulation of COS7 cells overexpressing M3 
muscarinic receptor was found to induce the BFA-insensitive translocation of both 
ARF1 and PLD1 to the plasma membrane (244);  antigen-stimulation of RBL-2H3 
cells reportedly induces the co-localisation of PLD1b with Rac1, ARF6 and PKC! 
(381); and PLD1, but not PLD2 was found to translocate to the plasma membrane of 
cells incubated with the PLD1-activating cytokine TNF-!, in a time-dependent 
manner (382). Thus PLD1 availability in the plasma membrane may be dynamically 
regulated. It is possible that a sufficient pool may already be present to maintain 
PLD:5-HT2AR interactions, or that the binding or dissociation rate may be slow or 
limited by other factors.  
 
GST-fusion proteins of 5-HT2AR domains (ct, K385ct and i3) further defined the 
locus of PLD1 binding to the C-terminal tail domain of the receptor, at a point distal 




to the initial 9 amino acids. PLD2 binding was not detectably altered between any of 
the different receptor domains, further confirming the unspecificity of PLD2 binding 
by the 5-HT2AR. The 5-HT2AR third intracellular loop, which has been reported to 
bind arrestin isoforms and G-proteins (168) bound < 50% the amount of PLD1 that 
bound to the full-length receptor C-terminal tail. Removal of the initial 9 residues of 
the C-terminal domain appeared to increase PLD1 binding by approximately >50% 
of that seen with the full-length C-terminus. These initial 9 amino acids form part of 
an NPxxY motif (376-380) that has been implicated as a critical determinant of 
ARF-dependent signalling in rhodopsin family GPCRs (50). Residues 376-385 were 
further demonstrated to be essential for both the co-immunoprecipitation and 
isoform-selectivity of ARF isoforms by the 5-HT2AR. Thus these studies indicate that 
PLD1 binds at a distinct region from ARF, at a site more distal on the C-terminal tail. 
It has been suggested that residues Thr 381-Lys 385 of the 5-HT2AR may form a 
flexible hinge region to an adjacent eighth helical segment that is anchored to the 
membrane by a palmitoylated Cys (Cys 397) and runs parallel to the plane of the 
membrane (274). Increased levels of PLD1 binding introduced with the truncation of 
the C-terminal tail could be a result of conformational alterations of the receptor 
terminus subsequent to the removal of residues 376-384; for instance, changes 
resulting in the further exposure of sites involved in PLD interactions. However, due 
to the in vitro nature of the experiment and isolation of the C-terminus from the 
remainder of the receptor this may be unrepresentative of potential outcomes in the 
physiological state. Alternatively, it was considered that a reduction in ARF binding 
following removal of residues 376-385 (274), could be a factor of subsequent 
increased PLD1 binding levels. Thus GST-fusion proteins of the full-length 5-HT2AR 




C-terminal tail were used to assess the influence of prior binding of ARF1 to the 
receptor upon subsequent PLD1 binding to the receptor and, vice versa, the effects of 
prior binding of PLD1 to the receptor upon subsequent ARF1 binding. The lack of 
evident interruption or conversely, enhancement of the binding of ARF/PLD1 by 
prior occupancy with the other binding partner indicates that receptor-bound ARF1 
neither precludes nor is required for PLD1 binding. Furthermore, the apparent 
inability of either construct (ARF1/PLD1) to induce a dissociation of pre-bound 
construct (PLD1/ARF1 respectively) from the receptor further indicates that these 
constructs are binding to distinct sites of the receptor C-terminus. Thus these 
findings indicate that the binding of PLD1 and ARF1 by the 5-HT2AR are 
independent of one another. 
 
The PLD1 binding site on the 5-HT2AR was further defined with the use of sequential 
C-terminally-truncated GST-fusion proteins of the C-terminal tail. The truncations, 
(376-470, 376-438, 376-428) and the full-length C-terminal tail were found to bind 
HA-ARF1 with an approximately equivalent effectiveness, indicating that residues 
428-471 of the 5-HT2ARct are not a critical determinant of HA-ARF1 binding. 
Conversely, the loss of the terminal residue, Val 471 resulted in a small 
(approximately 30%) decrease in HA-PLD1 binding. Val 471 forms part of a VSCV 
motif that acts as a recognition site for PDZ domain proteins in the human 5-HT2A 
receptor. This canonical type I PDZ ligand has been demonstrated to bind a specific 
set of Post-synaptic density protein, Drosophila disc large tumor suppressor, and 
zonula occludens-1 protein (PDZ) proteins, including the multi-PDZ domain protein 
I (MUPP1), SAP97, channel interacting PDZ protein (CIPP) and post synaptic 




density-95 (PSD-95) (190,191). PDZ domain proteins often contain multiple PDZ 
domains, potentially enabling them to simultaneously interact with more than one 
binding partner, thereby facilitating a variety of protein-protein interactions and 
larger signalling complexes (383). Association of the PDZ domain protein PSD-95 
with the 5-HT2AR is reported to result in an increase in 5-HT-induced-PLC 
activation, which is ablated with the truncation of the 3 extreme 5-HT2ARct residues 
(Ser 469-Val 471) and corresponds to enhanced receptor retention at the cell surface 
(192). It is possible that a 5-HT2AR PDZ domain protein scaffolding complex could 
contribute to PLD assocation, and that this interaction is interrupted with the removal 
of the extreme C-terminal Val 471 residue, thus explaining the partial reduction in 
PLD association introduced with this truncation. The removal of a further 32 
residues to yield 376-438 5-HT2ARct however was found to result in a much more 
profound, approximately 70% loss of PLD association. The further loss of another 10 
residues with the 376-428 5-HT2ARct construct did not induce a discernably greater 
loss in PLD association than that seen with the GST-T438 5-HT2ARct construct, thus 
implying that key residues involved in PLD binding may be located between residues 
T438 and C470. A more precise definition of the binding site would require 
additional truncation constructs and an extensive array of single residue mutations. 
 
A clinically relevant single nucleotide polymorphism (SNP) exists at residue 452, 
located between residues 438-470, in the distal region of the 5-HT2ARct. This 
naturally occurring minor allele, involves the substitution of His 452 by Tyr 
(H452Y), and is known to be expressed by approximately 9% of the population 
(301). Meta-analysis studies have concluded that there is a significant association 




between the heterozygous expression of the H452Y minor allele and a resistance to 
clozapine, an atypical antipsychotic with high affinity for the 5-HT2AR (301). In 
addition, the H452Y SNP has been linked to poor memory, attention deficit 
hyperactivity disorder and biopolar disorder (307,384,385). Studies investigating 
signalling pathways downstream of the H452Y receptor have also concluded that 
expression of the minor allele results in a decrease in the speed and amplitude of 
agonist-stimulated intracellular calcium mobilisation in platelets (308). A subsequent 
study has suggested that both PLC and PLD activation may be decreased 
downstream of the H452Y receptor in association with enhanced desensitisation of 
the receptor (309). Due to the location of the coding substitution, which is positioned 
within the distal region of the 5-HT2ARct, it was hypothesised that the minor variant 
of the receptor might influence PLD interactions and signalling pathways. Co-
immunoprecipitation of HA-PLD1 with the H452Y variant of the sPrC-5-HT2AR 
showed clearly decreased interactions between PLD1 and the minor variant of the 
receptor when compared to the wild-type receptor. This was further confirmed in 
experiments to assess the binding of PLD1 to GST-fusion proteins of the wild-type 
5-HT2ARct and the H452Y variant. Again, levels of PLD1 captured with the H452Y 
receptor variant were greatly decreased. These data suggest that His 452 is a critical 
determinant of PLD binding, which is interrupted when it is substituted by Tyr. It is 
possible that the minor allele of the receptor adopts an alternative conformation, 
which obscures regions of the receptor necessary for the efficient binding of PLD. It 
is not obvious that the substitution of His, a polar positively charged amino acid with 
a hydropathy index of -3.2, by Tyrosine, a polar but neutrally charged amino acid 
with a hygropathy index of -1.3, would necessarily cause an altered conformational 




state in both the full-length receptor and in the truncated GST-fused C-terminal tail 
of the receptor, although unknown binding interactions with other residues could 
occur and be of importance here. Alternatively, His 452 could be directly involved in 
molecular interactions with PLD1, whereby the presence of the H452Y minor allele 
could result in a direct decrease in PLD1 interaction. 
 
Activation of PLD1 was also significantly decreased downstream of the H452Y 
variant of the receptor when compared to wild-type receptor, suggesting the 
functional importance of reduced PLD1 binding seen with the minor variant of the 
receptor. Both PLD2 activation and endogenous PLD responses did not appear to be 
altered in the H452Y variant of the receptor. The lack of detectable differences in 
endogenous PLD responses of the wild-type and H452Y variant receptor may 
possibly be because these responses are not large enough to be able to detect a 
significant decrease in the H452Y variant compared to the wild-type responses. The 
lack of any detectable differences between PLC responses of the wild-type and 
H452Y receptor indicates that differences in PLD signalling between these receptor 
forms are specific to that pathway, which accords with the observations of 
diminished PLD1 docking to the C-terminal tail domain of the H452Y variant. To 
ensure that differences in PLD responses were not as a result of uneven expression of 
the two receptor variants, overall or at the cell surface, the expression of the wild-
type sPrC-5-HT2AR and H452Y-sPrC-5-HT2AR, both within cellular microsomal 
membranes and at the cell surface, was quantified with radio-ligand binding and 
biotin-tag-selected radio-ligand binding, respectively. No significant differences 
were noted between expression or deployment of the two receptor forms. 





In conclusion, these experiments demonstrate for the first time that the 5-HT2AR 
directly binds PLD1 to its C-terminal tail at a locus in the distal tail importantly 
involving residues between 438 and 470, including residue 452, the site of a common 
and physiologically significant polymorphism, H452Y. The PLD1 binding site is 
independent of that for ARF1 in the proximal tail and the docking of the two ligands 
is dynamically independent. Both ARF1 and PLD1 however contribute important to 
an apparently heterotrimeric G protein-independent signalling pathway from the 5-
HT2AR, and the docking of PLD1 and amplification of functional signalling through 
this pathway by additional PLD1 are selectively disrupted in the H452Y. The work 
points to the existence of a functionally important 5-HT2AR/ARF1/PLD1 signalling 
complex and its specific disruption in the H452Y variant receptor, a distinction with 
potential physiological significance, for example in psychiatric disorders where the 






























4.0 Desensitisation of 5-HT2AR-mediated PLC responses and 
influences of the H452Y polymorphism 
 
4.1 Introduction 
4.1.1 Arrestin structure and function 
The mammalian arrestin family comprises 4 arrestin isoforms; arrestin-1, arrestin-2, 
arrestin-3 and arrestin-4. Arrestin-1 was the first arrestin isoform to be identified, in 
retinal extracts, and was originally named 48-kDa protein, or S antigen (386). 
Arrestin-2 and arrestin-3 are alternatively named !-arrestin 1 (!-arrestin1) and !-
arrestin 2 (!-arrestin2) respectively. Arrestin-4 is also termed cone arrestin or X-
arrestin. Mammalian arrestin-1 and arrestin-4, both of which are visual arrestins, are 
expressed within retinal rod and cone photoreceptors (387). These specialised 
proteins bind specifically to rhodopsin or cone cell pigments (387). Mammalian !-
arrestin 1 and !-arrestin 2 are expressed ubiquitously and act as negative regulators 
(388), adaptor proteins (389,390) and scaffolding proteins for many GPCRs (391).  
 
Crystallographic structural studies reveal a basic architecture that typifies arrestins, 
consisting of two antiparallel seven-stranded !-sheet sandwich domains (N- and C-
domains), residues 8-180 and 188-362 respectively in bovine visual arrestin, linked 
via a 12 residue long hinge region (127,387,392,393), and flanked to either end by an 
N- and C-terminal domain. The N-domain is connected to a small N-terminal "-
helix, and contains Src binding sites, in addition to a phosphate sensor domain 
thought to be essential for the selective binding to phosphorylated receptors (394). 
The C-domain contains an inositol hexakisphosphate InsP6 recognition site, and an 




RRSLHL MAP kinase recognition domain (394). Finally, the C-terminal domain of 
the non-visual arrestins contains regions responsible for forming interactions with the 
endocytic machinery (clathrin and AP-2) (387,392,393). At the centre of the structure 
is a polar core, composed of charged interactions of five solvent-excluded interacting 
charged residues of the N- and C-domains and C-terminus (Asp 30, Arg 175, Asp 
296, Asp 303 and Arg 382 in bovine visual arrestin) (395) (396) (127) (387).  
 
The mechanism by which arrestin preferentially binds activated, phosphorylated 
receptors is thought to require the simultaneous activation of two arrestin domains, 
the ‘phosphate sensor’ and an ‘activation sensor’ (394,397). The phosphate sensor is 
buried deep within the polar core of the protein and consists of an intra-molecular 
salt-bridge composed of a positively-charged residue (Arg 175 in bovine visual 
arrestin) of the N-domain and a negatively-charged residue (Asp 296 in bovine visual 
arrestin) of the C-domain (394,397). This salt-bridge is thought to lock the protein in 
an ‘inactive’ state that is unable to form high-affinity interactions with the receptor. 
Mutagenesis of both participating residues has been used to demonstrate that loss of 
the salt-bridge confers a corresponding loss of selectivity for phosphorylated 
receptors by arrestin (398).  Our understanding of arrestin structure without any 
stimulation is additionally supported by further intra-molecular interactions, 
including a ‘three-element interaction’, that exists between !-strand I and "-helix I in 
the N-domain and the C-terminal tail, and hydrophobic interactions between the N- and 
C-domains (394,397). The current model of arrestin activation (described using 
residue numbers of bovine visual arrestin) is thought to be a multi-step process 
involving various interaction sites: the arrestin ‘activation sensor’ is conjectured to 




bind regions of the receptor that change conformation upon activation, probably 
resulting in an inhibition of interactions existing between the two arrestin domains; 
additionally, Lys 14/15 of !-strand I reportedly associate with negatively charged 
receptor-bound phosphates, which acts to destabilize the three-element interaction, 
resulting in the dissociation and movement of the C-terminal tail and subsequent loss of 
Arg 382 from the polar core; meanwhile, Lys 14/15 are thought to facilitate the entry of 
the phosphates into the polar core, thereby allowing the association of Arg 175 with 
receptor-bound phosphates (394,397). Thus, the negatively-charged phosphates act to 
neutralise the positive charge of Arg 175, the salt-bridge breaks and the polar core is 
disrupted (394,397). Due to the additional loss of Arg 382 from the polar core, the 
remaining residues (Asp 30, Asp 296 and Asp 303) all become unopposed 
negatively-charged residues and thus repel each other, resulting in a conformational 
change in the orientation of the arrestin domains with relation to one another 
(394,397). This structural change introduces further receptor-binding sites to the 
active phosphorylated receptor, that engage in high-affinity semi-irreversible 
interactions with the receptor (394,397).   
 
 
4.1.2 GRK family kinases  
GPCR kinases (GRKs) act to phosphorylate Ser/Thr GPCR residues. The 
mammalian GRK family comprises 7 GRK isoforms that are categorised into 3 
subfamilies (399). GRK1 and 7, both of which are expressed exclusively within 
retinal cells form one sub-group - the visual GRK subfamily. The non-visual GRKs 
are divided into the remaining two subfamilies: the !-adrenergic receptor kinases 
subfamily, comprising GRK2 and GRK3; and the GRK4 subfamily, consisting of 




GRK4, GRK5 and GRK6 (399,400). GRK2, 3, 5 and 6 are all expressed 
ubiquitously, whilst GRK4 is primarily expressed in the testes (401). The non-visual 
GRKs have a common basic architecture, displaying a highly conserved N-terminus 
of approximately 185 residues, connected to a central, well-conserved catalytic 
domain of approximately 270 amino acid residues, and terminating in a C-terminal 
tail of variable length (105-230 amino acid residues) (399). The N-terminal domain 
is thought to be involved in receptor recognition and exhibits a Regulator of G 
protein Signalling (RGS) homology domain, which in the case of GRK2 and GRK3, 
is thought to be involved in the regulation of G protein coupling (400,402-404). 
Other N-terminal regions are reported to be involved in membrane targeting and 
where the GRK4 subgroup is concerned, binding phosphatidylinositol (4, 5)-
bisphosphate (399,405,406), which is thought to result in an increase in the catalytic 
kinase activity of the GRK (399,405,406). Specific binding sites expressed on the 
GRK C-terminus are thought to be important for both GRK localisation and agonist-
dependent translocation, thus influencing GRK function (127,399,407-410). GRK2 
and 3 possess both PH domains and G!" subunit binding domains, which interact 
with phosphoinositides and !" subunits of heterotrimeric G proteins respectively, 
thereby inducing GRK translocation to the plasma membrane (127).  Both GRK4 and 
6 contain C-terminal cysteine residues that undergo palmitoylation and anchor the 
GRK to the plasma membrane, whereas GRK5 contains a C-terminal sequence of 46 
basic amino acids that interact with phospholipids at the membrane, again localising 
the protein to the plasma membrane (127). 
 




In addition to acting as receptor kinases, GRKs have been demonstrated to interact 
with a diverse array of signalling and trafficking proteins, including PI-3 kinase, G 
protein-coupled receptor kinase interactor (GIT) proteins, caveolin, clathrin, Hsp90, 
calcium-binding proteins and G!q and G"# subunits (399). Thus, in addition to being 
regulated by binding partners such as caveolin, calmodulin, actin and Akt, GRKs 
may also be directly involved in alternative cellular processes such as inhibition of 
ERK and PLC-" activation via interactions with MEK1 and Gq/11, respectively 
(399).   
 
4.1.3 GRKs and arrestins in GPCR desensitisation  
The classical mode of homologous desensitisation follows GPCR agonist-activation, 
which yields free G"# subunits. It is thought that these "# subunits interact with 
GRK2/3 proteins, which results in GRK2/3 translocation to membrane-bound 
receptors (411). Once localised at the receptor, GRK mediates the phosphorylation of 
the agonist-activated receptor at Ser/Thr residues generally of the C-terminal tail or 
3rd intracellular loop (412). GRK2 and 3 have been identified as the isoforms 
primarily involved in agonist-dependent receptor phosphorylation (413-415): Ren et 
al used small interfering RNA sequences (siRNAs) specific to the only widely 
expressed GRKs, GRK2, -3, -5, and -6 to investigate GRK isoform-specific 
regulation of the vasopressin-2 receptor (V2R), GRK2 and -3 were determined to be 
primarily responsible for V2R phosphorylation and inhibition of Gs-mediated cAMP 
responses (415). Furthermore, H1 histamine receptor desensitisation has been 
demonstrated to be GRK2-, but not GRK5-dependent (416). However, there is 
growing evidence to implicate members of the GRK4 subfamily in regulating events 




that moderate GPCR signalling. GRK4 is implicated in the regulation of various 
GPCRs in specific tissues at which it is expressed relatively highly, such as 
desensitisation of the type 1a metabotropic glutamate receptor in Purkinje cells (417). 
GRK5 is now known to be able to phosphorylate numerous GPCRs when 
coexpressed with receptor (401), but is also demonstrated to regulate endogenously 
expressed vasoactive intestinal polypeptide type I (VPAC1) receptors (418). 
Endogenously expressed GRK5 is further reported to regulate thrombin-induced 
signalling in endothelial cells (419). Additionally, GRK6 is implicated in the 
regulation of various GPCRs; it is thought to induce !-adrenoceptor desensitisation 
in uterine smooth muscle cells (420), and its overexpression has been shown to result 
in increased phosphorylation of the M3 muscarinic receptor in SH-SY5Y 
neuroblastoma cells (421).   
 
Receptor activation and subsequent GRK-mediated phosphorylation results in the 
recruitment of !-arrestin isoforms to the plasma membrane (412). The subsequent 
binding of !-arrestin by agonist-activated receptor induces a conformational change 
in the !-arrestin (422). Phosphate moieties of the receptor disrupt the delicate ionic 
equilibrium of the !-arrestin central polar core (387,412,414,422) and subsequently, 
interactions between the phosphate sensor region and the C-terminus are broken, 
resulting in the dissociation of the N- and C-termini and a likely rearrangement of the 
N- and C-domains (387,412,414,422). This yields the ‘active’ !-arrestin 
conformation, which binds the receptor with high affinity. !-arrestin is conjectured to 
bind at such a position as to sterically hinder receptor:G protein interactions, thereby 




preventing G protein re-association and resulting in the termination of G protein-
mediated signalling (394).  
 
Heterologous desensitisation occurs downstream of GPCR phosphorylation by 
second-messenger-dependent kinases such as cyclic-AMP dependent kinase (PKA) 
and protein kinase C (PKC) (127,423). These kinases also phosphorylate GPCRs at 
Ser/Thr  residues of the intracellular loops and C-terminal tail (127,423).  
Conversely, agonist-activation of the receptor is not a prerequisite for receptor 
phosphorylation in this system (127,423). Thus, a receptor may become desensitized 
as the result of PKA/PKC activation by an alternative receptor, hence the use of the 
term ‘heterologous desensitisation’ (127,423). Various GPCR sub-types, such as the 
D2 dopamine receptor (424) and the !-opioid receptor (425) have been demonstrated 
to associate with "-arrestins following phosphorylation by PKC (426).  PKC and 
PKA have also been demonstrated to phosphorylate and activate GRK2, thereby 
increasing its ability to phosphorylate and desensitize specific receptors (426).  
 
4.1.4 Arrestins in GPCR internalisation  
"-arrestin  isoforms are additionally implicated as mediators of  the internalisation of 
many GPCRs, by facilitating receptor linkage to clathrin-coated vesicles (390). 
Following the binding of agonist-activated receptor by "-arrestin isoforms and the 
subsequent dissociation of the "-arrestin C-termini from the polar core, binding sites 
for AP2 and clathrin situated on the "-arrestin C-terminal tail are revealed 
(387,412,414,422). Clathrin, a trimeric protein and the primary constituent of 
clathrin-coated pits, is able to self-polymerise into a lattice to surround the receptor-




containing vesicle via a cage-like structure. AP-2, an adaptor protein, forms a 
complex by linking to the clathrin molecules and associating with accessory proteins, 
such as dynamin (which facilitates the fission of vesicles from a membrane) and 
EPS-15 (which is thought to facilitate the AP180 adaptor protein-mediated assembly 
of clathrin) (427)) to facilitate internalisation (428). Once the clathrin-coated pit is 
assembled, it pinches off from the membrane, mediated by dynamin, and the clathrin 
coat disassembles to leave the vesicle  (429).  
 
!-arrestin isoforms bind, via an LIEF sequence within residues 374-377 of the 
carboxy-terminal tail, to residues 89-100 of the N-terminal domain of the clathrin 
heavy chain (127,430,431). The interaction with clathrin can be regulated via 
phosphorylation of the !-arrestin 1 Ser 412 residue by ERK MAP kinase (430,432). 
Phospho-Ser 412  !-arrestin 1, although still capable of binding receptor is unable to 
bind clathrin. However, upon !-arrestin 1 recruitment to the membrane, a 
phosphatase catalyses the dephosphorylation of the protein, thereby promoting 
clathrin-mediated receptor internalisation (430,432).  Interestingly, no equivalent 
residue is present in !-arrestin 2, exemplifying differential regulatory potential of !-
arrestin 1 and !-arrestin 2. 
 
!-arrestin isoforms have also been demonstrated to bind, via an RxR sequence, to the 
!2 adaptin subunit of the AP-2 complex (127), an interaction that has been shown to 
be independent of clathrin binding (430). A further factor that may promote 
arrestin:AP-2 mediated events may be phosphoinositide 3-kinase (PI 3-kinase); GRK 
isoforms have been demonstrated to form cytosolic complexes with PI 3-kinase upon 




agonist stimulation of the !-adrenergic receptor, resulting in the GRK-mediated 
agonist-dependent translocation of PI 3-kinase to the plasma membrane (433-435). 
Subsequently, phosphatidylinositol 3,4,5-phosphate species are generated in a PI 3-
kinase-dependent manner at the plasma membrane, that in turn are thought to 
increase AP-2 recruitment to the membrane (433-435).   
 
Following internalisation, GPCRs demonstrate two distinct intracellular trafficking 
patterns dependent upon their interactions with !-arrestin isoforms (436). GPCRs 
have been classified as class A or class B receptors, based upon their !-arrestin 
binding characteristics (437). Class A receptors include the µ-opioid, endothelin A, 
dopamine D1A, !2 adrenergic and "1B adrenergic receptors (127,435). Class A 
receptors form transient interactions with !-arrestin isoforms, but bind !-arrestin 2 
with higher affinity than !-arrestin 1 (127). This relatively weak interaction 
putatively occurs as a result of the transient ubiquitination state of !-arrestins that are 
complexed to class A receptors (435,437,438). Following internalisation of class A 
GPCRs, the receptor:!-arrestin complex dissociates and the receptor is thought to be 
rapidly recycled back to the plasma membrane representing resensitisation (127,436). 
However, class B receptors, such as neurotensin 1, vasopressin type-2, angiotensin II 
type-1a, thyrotropin-releasing hormone and neurokinin NK-1 receptors, demonstrate 
a more stable, prolonged interaction with !-arrestin isoforms and bind with 
approximately equal affinities to !-arrestin 1 and !-arrestin 2 (127). Following 
internalisation, !-arrestin does not dissociate from class B receptors and the complex 
is targeted to endocytic vesicles (127,436). The recycling of class B receptors back to 
the plasma membrane is much slower and it has been suggested that stable GPCR:!-




arrestin interactions may promote degradation of the receptor (127,436).  It has been 
demonstrated, using the dopamine D2 and D3 receptors, that both the DRY motif 
(within the second intracellular loop) and the C-terminal tail of GPCRs determine the 
strength of !-arrestin interactions (439). 
 
4.1.5 Arrestin-dependent signalling  
In addition to facilitating the scaffolding of complexes involved in receptor 
endocytosis, !-arrestin isoforms have also been shown to act as scaffolds for multi-
component signalling complexes (132,133,137,440-443). It has been proposed that 
upon activation, !-arrestin isoforms may adopt diverse conformations, depending 
upon the phosphorylation profile of the bound receptor (444). Thus, the array of 
potential !-arrestin binding partners and hence, the resulting functional output, may 
be influenced by the initial pattern of phosphorylated sites on the GPCR (444).  !-
arrestin-dependent signal transduction was first demonstrated in !2-adrenergic 
receptor-mediated MAP kinase activation, by means of its inhibition following the 
expression of dominant negative mutant !-arrestin constructs in HEK293 cells (443). 
Subsequent studies have led to the identification of many GPCRs that can signal in a 
!-arrestin-dependent manner, including the gonadotrophin-releasing hormone, 
angiotensin II type I,  vasopressin 2, parathyroid hormone receptors and 5-HT2AR 
(132,133,137,440-442,445). !-arrestins have been demonstrated to link GPCRs to 
various signalling complexes involving Src family tyrosine kinases, ERK1/2 and 
JNK3 (446,447) . The scaffolding of Src by !-arrestins is thought to be important for 
several processes: it has been demonstrated to be involved in the tyrosine 
phosphorylation of dynamin, which is potentially a prerequisite for receptor 




endocytosis (127,448,449); it is implicated in the stimulation of neutrophil 
degranulation (127); and it is additionally thought to be one route for activation of 
the ERK MAP kinase cascade (127,448,449). MAP kinase cascades are thought to be 
activated via the scaffolding and subsequent activation of upstream enzymes required 
for MAP kinase activation (435). Arrestin-dependent ERK 1/2 activation, 
downstream of both ligand activated !2-adrenergic receptor and gonadotrophin-
releasing hormone receptors, appears to result in a delayed, sustained response, when 
compared to G protein-dependent phospho-ERK signals (133,450). The strength of 
the arrestin:GPCR interaction is thought to have a significant influence upon the 
efficiency of ERK 1/2 phosphorylation and thus ERK 1/2 activation (131). Thus, it 
follows that stably interfaced arrestin:Class-B GPCR complexes induce greater ERK 
1/2 phosphorylation than weaker, more transient arrestin:Class-A GPCR complexes 
(131). 
 
!-arrestin 1 and !-arrestin 2 have also been demonstrated to promote the 
desensitisation of particular GPCRs by acting as scaffolds for enzymes that inhibit 
specific signalling pathways. !-arrestin isoforms have been implicated in the 
translocation and scaffolding of phosphodiesterases (PDEs) to activated !2-
adrenergic receptors at the plasma membrane (435,451).  The localization of PDEs at 
the receptor results in the degradation of the second messenger cAMP, which further 
results in the inhibition of cAMP dependent-PKA activation (435). Furthermore, 
subsequent to the binding of activated M1 muscarinic receptors, !-arrestin isoforms 
have been demonstrated to interact with diacylglycerol kinases (DGKs) (435,452). 
DGKs act to catalyze the ATP-dependent conversion of diacylglycerol (DAG), to 




phosphatidic acid (PA) (452). Thus the !-arrestin mediated recruitment of DGK to 
the activated receptor results in a decrease in DAG signalling, and yet promotes 
signal transduction downstream of the signalling molecule PA (452).   
 
4.1.6 Involvement of GRKs and arrestins in 5-HT2AR regulation 
Various studies have investigated regulation of 5-HT2AR signalling. Desensitisation 
mechanisms are thought to be cell-specific, ligand-specific and receptor-specific 
(130,170,174,292,453,454),  thus there is no standard pattern of 5-HT2AR 
desensitisation.  Putative desensitisation-related phosphorylation sites were identified 
by the sequential mutagenesis of Ser/Thr residues of the intracellular regions of the 
5-HT2AR expressed in HEK293 cells (455). Only the mutagenesis of Ser 188 in the 
second intracellular loop and Ser 421 of the C-terminal tail was found to inhibit 
agonist-mediated desensitisation, thus suggesting that these Ser residues may 
undergo phosphorylation by kinases, potentially including GRKs (455).  However, 
when HEK293 cells were induced to overexpress GRK2 and GRK5, or catalytically 
inactive GRK2 (GRK2-K220R) together with the 5-HT2AR, and stimulated with 
quipazine, desensitisation was unaffected, indicating that GRK2 and GRK5 appear 
not to be involved in quipazine-induced 5-HT2AR desensitisation in HEK293 cells 
(130). GFP-tagged 5-HT2AR expressed in HEK293 cells has also been demonstrated 
to internalise independently of !-arrestin 1 and !-arrestin 2 (456). Furthermore, the 
systematic mutagenesis of protein kinase C consensus phosphorylation sites within 
the cytoplasmic domains of the 5-HT2AR was shown to have no effect upon 5-HT-
induced desensitisation (455). However, PKC activation is reportedly involved in 5-




HT2AR desensitisation and internalisation (457,458) (459), although the effects of 
PKC activation are thought to be cell-dependent (292,454,458).  
 
In an attempt to elucidate arrestin binding sites in the 5-HT2AR, Gelber et al used 
GST-fusion proteins of the 5-HT2AR third intracellular loop to evaluate binding of 
arrestin isoforms (186). Visual arrestin, !-arrestin 1 and !-arrestin 2 were found to 
interact with i3 of the 5-HT2AR with seemingly equivalent affinities (186). The 5-
HT2AR has surprisingly been demonstrated to undergo internalisation via an 
endosomal pathway in response to incubation with both agonists and antagonists, in 
vitro and in vivo (299,460). It has been suggested that the therapeutic effects of some 
typical and atypical antipsychotics may in part be due to the potentiation of 5-HT2AR 
internalisation and redistribution (172,292,299,460). It appears that the 5-HT2AR is 
capable of undergoing desensitisation and internalisation via diverse mechanisms, 
potentially dictated by cell-type or agonist-type (130,170,174,292,453,454). A study 
by Bhatnagar et al suggested that the 5-HT2AR internalises in an arrestin-independent, 
but dynamin-dependent manner in HEK293 cells (456). This study was corroborated 
by further observations that the overexpression of a truncation mutant of !-arrestin 1 
(319-418), that blocks 5-HT2AR endocytosis in HEK293 cells, had no discernable 
effect upon agonist-mediated 5-HT2AR desensitisation, although overexpression of a 
dominant-negative mutant of dynamin (DynK44A) was also determined not to 
influence desensitisation of the receptor (130). However, overexpression of the same 
arrestin and dynamin mutant constructs in C6 glioma cells acted to potentiate 
desensitisation, putatively by inhibiting the resensitisation of receptors, thus implying 
that both dynamin and !-arrestin 1 are required for 5-HT2AR internalisation in C6 




glioma cells (130).  Furthermore, the expression of a constitutively active !-arrestin 1 
mutant (R169E) in HEK293 cells co-transfected with 5-HT2AR resulted in the 
agonist-independent desensitisation and internalisation of the receptor, suggesting 





4.2.1 Desensitisation of 5-HT2AR PLC signalling and the influence of arrestins 
Previous studies have suggested that the H452Y-5HT2AR may exist in a partially pre-
desensitised state, demonstrating PLC responses that resemble the reduced agonist-
induced PLC activity seen with wild-type receptors presensitised with 10- or 30- 
minute exposures to 5-HT in NIH3T3 cells (309). Additionally, platelets of H452Y 
heterozygotes were found to demonstrate reduced Ca2+ mobilisation (308).  To 
further investigate this possibility here, COS7 cells were transfected with either 5-
HT2AR or H452Y-5-HT2AR and assayed to assess whether the H452Y mutation 
confers any alteration to the time-course of 5-HT-induced PLC activation responses 
(Figure 4.1a). The H452Y mutation was not found to cause any significant time-
dependent alteration in 10 µM 5-HT-induced PLC activation represented as [3H]InsP 
production shown as a fold of basal; 5-HT2AR-mediated PLC responses reached a 
maximum of ~ 6.2 ± 0.39 fold of basal control, whilst H452Y-5-HT2AR-mediated 
PLC responses reached a maximum of ~ 6.6 ± 0.57 fold of basal control. Basal 
values were not discernably different between cells expressing the two variants of the 
5-HT2AR. PLC responses for both receptor variants were found to desensitise in these 




experiments between approximately 140 and 180 min of agonist incubation with no 
detectable difference between the receptor variants. Pilot experiments indicated that 
[3H]InsP values in unstimulated COS7 cells transfected with the wild-type-5-HT2AR, 
H452Y-5-HT2AR  or empty vector were not discernably increased through the 
duration of the assays.  
 
To further investigate 5-HT2AR desensitisation in a different cell type that may 
contain additional relevant proteins, C6 glioma cells (which endogenously express 5-
HT2AR at low levels), were transfected with either pcDNA3.1 vector as a control, 
wild-type 5-HT2AR, or H452Y-5-HT2AR, stimulated with 10 µM 5-HT for between 0-
180 min and assayed for PLC responses (Figure 4.1b). The endogenous 5-HT2AR 
produced a maximum response of approximately 3.8 ± 0.13 fold of basal; this was 
increased to approximately 5.6 ± 0.31  and 6.1 ± 0.43 fold of basal with additional 
expression of wild-type 5-HT2AR and H452Y-5-HT2AR, respectively. Evidently, the 
H452Y substitution also did not appear to confer any alterations to agonist-
stimulated PLC activity compared to the wild-type receptor in C6 glioma cells. 
Although PLC responses in the control cells appeared to undergo desensitisation 
between 140-180 min of 5-HT-stimulation, there was no apparent reduction in the 
rate of either wild-type 5-HT2AR or H452Y-5-HT2AR-mediated PLC responses within 
the maximum 180 minute 5-HT incubation.  
 
To further investigate the desensitisation of wild-type- and H452Y-5-HT2AR-
mediated PLC activity by means of an alternative protocol, COS7 cells were 
transfected with either 5-HT2AR (Figure 4.2a) or H452Y-5HT2AR (Figure 4.2b) and 




pre-treated with 10 µM 5-HT plus 10 µM pargyline (monoamine oxidase inhibitor; to 
prevent 5-HT breakdown) for increasing periods of time between 0–30 min.  After 
washing twice and addition of lithium to prevent inositol phosphate recycling, cells 
were then either stimulated for 30 min with 10 µM 5-HT, 1 µM ritanserin (a 5HT2AR 
antagonist, to expose any potential effect of residual un-eluted 5-HT), or not 
stimulated at all, with 10 µM pargyline present in each case. Pre-incubation for up to 
30 min with 10 µM 5-HT  did not induce any significant changes to PLC responses 
mediated by either the 5-HT2AR or H452Y-5HT2AR in COS7 cells under any of the 
three conditions, when compared to cells that had not been pre-stimulated.  









Figure 4.1 Time-dependent 5-HT-stimulated PLC responses of (a) COS7 cells 
and (b) C6 glioma cells transfected with wild-type HA-5-HT2A R or H452Y HA-5-
HT2A R. Graphs illustrate the 0-180 minute time-course of 10 µM 5-HT-stimulated 
PLC responses. (a) shows COS7 cells transfected with HA-tagged wild-type-5-
HT2AR (!) or HA-tagged H452Y-5-HT2AR ("). (b) shows C6 glioma cells (which 
endogenously express 5-HT2AR), transfected with pcDNA3.1 vector (!) (as control), 
wild-type 5-HT2AR (!), or H452Y variant  5-HT2AR ("). PLC activity is measured as 
[3H]inositol phosphate ([3H]InsP) production. Values are means ± SEM, n = 3 and 4, 
in (a) and (b) respectively. No significant differences between responses of the wild-












Figure 4.2 PLC responses of COS7 cells transfected with HA-5-HT2AR or 
H452Y HA-5-HT2AR that had been pre-stimulated with 10 µM 5-HT for up to 30 
min. PLC responses are shown of COS7 cells transfected with either (a) wild-type 
or (b) H452Y variant 5-HT2AR. Prior to assay, cells were pre-incubated for 0-30 min 
with 10 µM 5-HT in addition to 10 µM pargyline (which inhibits 5-HT breakdown).  
Subsequently, after washing and addition of lithium, cells were incubated for 30 min 
with 10 µM 5-HT (! or " respectively), 1 µM ritanserin (5-HT2AR antagonist) for 30 
min (# or $ respectively), or not stimulated at all (! or " respectively) with 10 µM 
pargyline present in each case. PLC activity is measured as [3H]InsP production 









To further investigate the desensitisation profiles of wild-type- and H452Y-5-
HT2AR-mediated PLC responses with respect to potential involvement of arrestins, 
COS7 cells were co-transfected with complements of wild-type-5-HT2AR plus 
pcDNA3.1 or !-arrestin 1 (Figure 4.3a) and H452Y-5-HT2AR plus pcDNA3.1 or !-
arrestin 1 (Figure 4.3b). The time-course of PLC activation was investigated to a 
maximum 180 min 5-HT-incubation. !-arrestin 1 was not found to induce any 
significant alteration in the time-course of wild-type- or H452Y-5-HT2AR-mediated 
PLC responses, with all maximum responses (at 180 min time point) being very 
similar and lying within the range of  5.54 ± 0.26 - 6.47 ± 0.06 fold of basal 
responses.  
 
COS7 cells were additionally assayed to determine the potential effects of the  !-
arrestin 2 isoform on wild-type- and H452Y-5-HT2AR-mediated PLC responses. 
COS7 cells were co-transfected with complements of wild type 5-HT2AR plus 
pcDNA3.1 or !-arrestin 2 (Figure 4.4a), and H452Y-5-HT2AR plus pcDNA3.1 or !-
arrestin 2 (Figure 4.4b). Again, the time course of PLC activation was investigated to 
a maximum 180 min 5-HT  incubation. !-arrestin 2 was not found to induce any 
significant alteration in wild-type 5-HT2AR-mediated PLC responses from 0-180 min 
with maximum values lying between  6.1 ± 0.36 and 6.5 ± 0.39 fold of basal. 
However, the addition of !-arrestin 2 was found to evoke a significant decrease in 
H452Y-5-HT2AR-mediated PLC responses at 100-180 min 5-HT stimulation (p<0.05 
by Wilcoxon test), with maximum wild-type- and H452Y-5-HT2AR-mediated PLC 
responses reaching 6.83 ± 0.22 and 4.67 ± 0.07 fold of basal respectively.  






COS7 cells expressing wild-type-5-HT2AR plus control pcDNA3.1 vector, or !-
arrestin 2 (Figure 4.5a), and H452Y-5-HT2AR plus control pcDNA3.1 vector or !-
arrestin 2 (Figure 4.5b), were further investigated to assess  PLC responses 
throughout a range of 5-HT concentrations, from 1-10,000 nM. !-arrestin 2 did not 
evoke any discernable change in the 5-HT-induced PLC responses of wild type 5-
HT2AR-expressing COS7 cells, with EC50 values for 5-HT2AR plus pcDNA3.1 
transfected cells and 5-HT2AR plus !-arrestin 2 transfected cells of 8.36 ± 0.44 nM 
and 10.02 ± 0.98 nM respectively and corresponding Emax values of 3.89 ± 0.79 
fold of basal and 3.66 ± 0.38 fold of basal respectively. However, H452Y-5-HT2AR-
expressing COS7 cells co-transfected with !-arrestin 2 demonstrated significantly 
decreased levels of 5-HT-induced PLC activity compared to pcDNA3.1 controls. 
Levels of PLC activity elicited by 5-HT concentrations 100-10,000 nM from H452Y-
5-HT2AR plus !-arrestin2-expressing cells were found to be significantly less than 
control, (* p<0.05 by Wilcoxon test), with maximum wild-type and H452Y-5-
HT2AR-mediated [
3H]InsP production reaching 4.07 ± 0.54 and 2.83 ± 0.32 fold of 
basal, respectively. EC50 values for H452Y-5-HT2AR plus pcDNA3.1  and H452Y-5-
HT2AR plus !-arrestin 2-expressing cells were not significantly different, being 9.44  
± 0.65 nM and 8.98 ± 0.68 nM respectively. 
 











Figure 4.3 5-HT-induced PLC responses of COS7 cells co-transfected with wild 
type or H452Y variants of HA-5-HT2AR and !-arrestin 1, or empty plasmid as a 
control. PLC responses are shown of COS7 cells transfected with HA-tagged wild-
type (a) or H452Y (b) variants of the 5-HT2AR together with !-arrestin 1 (! or " 
respectively) or pcDNA3.1 vector as a control (! or " respectively). Cells were 
stimulated with 10 µM 5-HT for 0-180 min. PLC activity is measured as [3H]InsP 
production. The points plotted represent means ± SEM, n = 4. No significant effects 
of !-arrestin 1 were detected.  
a 
b 








Figure 4.4 5-HT-induced PLC responses of COS7 cells co-transfected with wild 
type or H452Y variants of HA-5HT2AR and !-arrestin 2, or empty plasmid as a 
control. PLC responses are shown of COS7 cells co-transfected with HA-tagged 
wild-type (a) or H452Y (b) variants of the 5-HT2AR plus !-arrestin 2 (!or "  
respectively) or pcDNA3.1 vector as a control (! or " respectively). Cells were 
stimulated with 10 µM 5-HT for 0-180 min. PLC activity is measured as [3H]InsP 
production. !-arrestin 2 caused a significant decrease in the H452Y-5-HT2AR 
signalling response between 100-180 min agonist-incubation, despite conferring no 
alteration to wild-type 5-HT2AR-mediated PLC responses,  with asterisks denoting 
significance (" p <0.05, Wilcoxon test).  The points plotted represent means ± SEM, 
n = 4. 
a 
b 








Figure 4.5 Effect of !-arrestin 2 on the concentration-dependence of 5-HT-
induced PLC activation in COS7 cells transfected with wild-type or H452Y 
variant 5-HT2AR. PLC responses of COS7 cells transfected with HA-tagged wild-
type (a) or H452Y (b) variants of the 5-HT2AR together with !-arrestin 2 (!or " 
respectively) or pcDNA3.1 vector as a control (! or " respectively). Cells were 
stimulated with 1-10,000 nM 5-HT for 180 min. PLC activity is measured as [3H]InsP 
production. !-arrestin 2 caused a significant decrease in the H452Y-5-HT2AR 
signalling response between 100-10,000 nM despite conferring no alteration to wild-
type 5-HT2AR-mediated PLC responses, with asterisks denoting significance (" p 
<0.05, Wilcoxon test).  All values are the means ± SEM, n = 3.  
a 
b 




4.2.2 Arrestin interaction with the 5-HT2AR  
It has been previously reported that !-arrestin 2 (like !-arrestin 1 and visual arrestin) 
associates with the third intracellular loop of the 5-HT2AR (5-HT2ARi3) (186). 
However, the C-terminally located H452Y polymorphism was observed to influence 
the effects of !-arrestin 2 on PLC signalling. We thus investigated potential physical 
interactions of FLAG-tagged !-arrestin 2 with GST-fusion proteins of both the third 
intracellular loop of the wild-type receptor (GST-5-HT2ARi3) and the carboxy 
terminal tail of the wild-type receptor (GST-5-HT2ARct) (Figure 4.6a). In addition, 
we further compared interactions of  FLAG-tagged !-arrestin 2 with GST-5-HT2ARct 
and the corresponding H452Y variant 5-HT2AR construct (GST-H452Y-5-HT2ARct) 
(Figure 4.6b). GST-receptor constructs were incubated with lysates from !-arrestin 2 
overexpressing COS7 cells, before being immobilized on glutathione Sepharose-4B 
beads and the captured proteins separated by gel electrophoresis. FLAG-!-arrestin 2  
bands were visualised using rabbit polyclonal anti-FLAG (Affinity Bioreagents) and 
HRP-linked anti-rabbit secondary antibody (Chemicon), and GST inputs were 
detected with mouse monoclonal anti-GST antibody (Clone B-14, Santa Cruz) and 
HRP-linked anti-mouse secondary antibody (Chemicon). The results of Figure 4.6a 
indicate that FLAG-!-arrestin 2 binds with a greater affinity to the C-terminal tail of 
the receptor construct (GST-5-HT2ARct) (third lane), when compared to the third 
intracellular loop of the receptor construct (GST-5-HT2ARi3) (middle lane), despite 
similar or lower input levels of the c-terminus construct (running at approximately 40 
kDa and 36 kDa respectively for c-terminal and i3 constructs). Furthermore, the 
introduction of the H452Y substitution to the GST-fusion protein construct of the 5-
HT2ARct appears to confer a marked increase in binding of FLAG-!-arrestin2 




(Figure 4.6b), despite similar input levels of constructs, which is consistent with the 
functional studies descried above. 
 
In an attempt to further investigate the cellular association of !-arrestin 2 with the 5-
HT2AR and H452Y-5-HT2AR, COS7 cells were co-transfected with either wild-type 
HA-tagged 5-HT2AR or HA-H452Y-5-HT2AR and FLAG-!-arrestin 2, stimulated 
with 10 µM 5-HT for 30 min, or not stimulated at all, before receptor 
immunoprecipitation with mouse monoclonal anti-HA antibody (12CA5) (2.4 µg/µl), 
or non-immune mouse IgG  (2.4 µg/µl) as control (Figure 4.7). Following the 
separation of immunoprecipitated proteins by gel electrophoresis, the amount of 
FLAG-!-arrestin 2 associated with the receptor pull-downs was assessed using rabbit 
polyclonal anti-FLAG (Affinity Bioreagents) and HRP-linked anti-rabbit antibody 
(Chemicon). Receptor input was determined with the use of rat monoclonal HRP-
linked anti-HA antibody (Roche, clone 3F10). FLAG-!-arrestin 2 bands (lower panel 
in Figure 4.7) could not be visualised due to the presence of heavy IgG antibody 
fragment bands which often appear at both ~25kDa and ~50kDa due to non-specific 
interactions encountered with particular detection antibodies. These results were 
typical of 2 independent experiments. Thus in an attempt to eliminate the non-
specific IgG bands, the same co-immunoprecipitation was performed, but using anti-
HA antibody that was previously covalently conjugated to the Protein G Sepharose 
beads, as outlined in section 2.9 (Figure 4.8). Again, despite an obvious decrease in 
bands at ~50kDa when using similarly conjugated non-immune IgG as a control, 
FLAG-!-arrestin 2 could not be clearly visualised. It was considered likely that 
available concentrations of pull-down antibody were decreased as a result of 




inefficient conjugation to the Protein G beads and thus did not capture sufficient HA-
5-HT2AR or HA-H452Y-5-HT2AR to provide detectable levels of associated FLAG-!-
arrestin 2. 





Figure 4.6 !-arrestin 2 binding to GST-fusion proteins of wild-type- and 
H452Y-5-HT2AR domains. In (a) GST-fusion proteins of the 5-HT2AR carboxy 
terminal tail (ct) and the third intracellular loop (i3) as well as unconjugated GST 
(running at approximately 40 kDa, 36 kDa and 29 kDa respectively) were used as 
potential bait for proteins in lysates of COS7 cells transfected with FLAG-tagged !-
arrestin 2. FLAG-!-arrestin 2 was found to preferentially bind to the 5-HT2ARct over 
the 5-HT2ARi3. In (b) FLAG-!-arrestin 2 binding was compared between GST-fusion 
proteins of the wild-type 5-HT2ARct, the corresponding H452Y construct and GST 
alone. The H452Y substitution conferred a marked increase in the binding of FLAG-









Figure 4.7 Investigation of co-immunoprepcipitation of !-arrestin 2 with wild-
type HA-5-HT2AR and HA-H452Y-5-HT2AR. COS7 cells were co-transfected with 
HA-tagged wild type or H452Y variant 5-HT2A receptor and FLAG-tagged !-arrestin 
2. Cells were either not stimulated or stimulated with 10 µM 5-HT for 30 min. Anti-
HA tag antibody was used to immunoprecipitate the receptor. Non-immune mouse 
IgG was used as a control. The figure shows levels of FLAG-!-arrestin 2 pulled 
down with both variants of receptor (Co-IP), levels of HA-5HT2A receptors recovered 
in the immunoprecipitates (IP) and FLAG-!-arrestin 2 inputs (lysate). The FLAG 
antibody used to detect receptor-associated FLAG !-arrestin 2 unfortunately 
showed substantial non-specific binding, probably to an interaction with IgG heavy 
chain which would run close to the position expected for arrestins. 





Figure 4.8 Investigation of co-immunoprepcipitation of !-arrestin 2 with wild 
type HA-5-HT2AR and HA-H452Y-5-HT2AR using HA-antibody conjugated to 
Protein G-Sepharose beads. COS7 cells were co-transfected with HA-tagged wild-
type or H452Y variant 5-HT2AR and FLAG-tagged !-arrestin2. Cells were either not 
stimulated or stimulated with 10 µM 5-HT for 30 min. Anti-HA tag antibody was 
conjugated to Protein G-Sepharose beads and used to immunoprecipitate the 
receptor. Similarly conjugated non-immune mouse IgG was used as a control. The 
figure shows levels of FLAG-!-arrestin 2 pulled down with both variants of receptor 
(Co-IP), levels of HA-5HT2AR recovered in the immunoprecipitates (IP) and FLAG-!-
arrestin 2 inputs (lysate). Unfortunately FLAG-!-arrestin 2 could not be clearly 
detected in the receptor pull-downs. 
 




4.2.3 Investigation of the potential significance of residue Ser 453 in the 5-HT2AR  
The H452Y polymorphism is situated adjacent to Ser 453, a potential GRK 
phosphorylation site. To investigate whether this site is involved in the functional 
influence of the H452Y substitution, new mutant variants of the 5-HT2AR were 
generated that substituted an Ala (A) for the usual Ser (S) 453, to produce S453A-5-
HT2AR and H452Y-S453A-5-HT2AR.  To assess any functional impact of the new 
mutation, COS7 cells were co-transfected with either wild-type -5-HT2AR, S453A-5-
HT2AR, or H452Y-5-HT2AR  or H452Y-S453A-5-HT2AR and the time-course of 5-
HT-induced PLC activation was assessed. Figure 4.9a illustrates the PLC responses 
of wild-type-5-HT2AR- and S453A-5-HT2AR-expressing cells stimulated with 10 µM 
5-HT for between 0-180 min. It can be seen that the S453A mutation does not have 
any discernable effect upon 5-HT2AR-mediated PLC activity, with the maximum 
PLC responses of 5-HT2AR and S453A-5-HT2AR reaching 8.70 ± 0.22 and 7.69 ± 
0.61 fold of basal respectively. Figure 4.9b illustrates PLC responses of H452Y-5-
HT2AR- and H452Y-S453A-5-HT2AR-expressing cells stimulated with 10 µM 5-HT 
for between 0-180 min. In contrast, the S453A mutation does appear to confer a 
significant increase to the time-dependent PLC responses of the H452Y variant 5-
HT2AR between time-points 100-180 min, with the maximum PLC response of the 
H452Y-5-HT2AR reaching 7.00 ± 0.21 fold of basal, but that of the H452Y-S453A5-
HT2AR reaching 10.97 ± 0.33 fold of basal. This difference was found to be 
statistically significant (p<0.05 by Wilcoxon test). The influence of the S453A 
mutation was further assessed on the concentration-dependence of PLC responses 
(Figure 4.10a & b). COS7 cells were transfected with wild-type -5-HT2AR, S453A-5-
HT2AR, or H452Y-5-HT2AR or H452Y-S453A-5-HT2AR and stimulated with 1-




10,000 nM 5-HT for 180 min. Again, as illustrated in Figure 4.10a, the S453A 
mutation did not have any discernable effect upon 5-HT2AR-mediated PLC activity 
with the maximum PLC response of the 5-HT2AR and S453A-5-HT2AR reaching 4.28 
± 1.87 and  4.33 ± 0.21 fold of basal, respectively. In contrast, in Figure 4.10b, PLC 
responses of the H452Y-S453A-5-HT2AR reached a maximum of  8.11 ± 1.45 fold of 
basal and were found to be significantly increased at concentrations 100-10,000 nM 
over those of the H452Y-5-HT2AR, which demonstrated maximum PLC responses of 
4.71 ± 0.31 fold of basal. There was no marked difference between EC50 values, 
which all lay within the range 9.23  ± 1.67 nM and 24.34  ±  2.21 nM respectively 
(p<0.05 by Wilcoxon test).  
 
We then asked whether the S453A mutation might disrupt the inhibitory effect of !-
arrestin 2 on PLC responses that is apparent only in the setting of the H452Y variant 
5-HT2AR. Figure 4.11 illustrates the PLC responses of COS7 cells co-transfected 
with either the H452Y-5-HT2AR or the H452Y-S453A-5-HT2AR and pcDNA3.1 or !-
arrestin 2, and stimulated with increasing concentrations of 5-HT (1-10,000 nM). 
Again H452Y-5-HT2AR-mediated PLC responses were enhanced in the case of the 
S453A mutation (as in Figure 4.10b) and !-arrestin 2 acted to decrease H452Y-5-
HT2AR-mediated PLC responses (as in Figure 4.5b). The addition of !-arrestin 2 also 
resulted in a significant decrease of S453A-H452Y-5-HT2AR-mediated PLC 
responses at 5-HT concentrations 10-10,000 nM, resulting in an approximate 46% 
loss of 5-HT-induced PLC responses and a maximum response value of 3.75 ± 0.60 
fold of basal compared to 7.8 ± 0.25 fold of basal in the absence of  !-arrestin 2 
(p<0.05 by Wilcoxon test).  








Figure 4.9 5-HT-induced PLC activation (time-course) in COS7 cells 
transfected with wild type, S453A, H452Y or S453A-H452Y variants of HA-
5HT2AR. Time-course of 5-HT-induced PLC activation in COS7 cells transfected with 
HA-tagged wild-type (!) or S453A (!) variants of the receptor (a) and H452Y (") or 
S453A-H452Y (") variants (b). Cells were stimulated with 10 µM 5-HT for 0-180 
min. PLC activity is measured as [3H]InsP production. PLC responses of the S453A-
H452Y variant 5-HT2AR were found to be significantly greater than for H452Y variant 
controls at time-points 100-180 min. Significance denoted by * (p<0.05 by Wilcoxon 
test).  The points plotted represent means ± SEM, n = 4. 
b 
a 









Figure 4.10 5-HT-induced PLC activation (concentration-dependence) in COS7 
cells transfected with wild-type, S453A, H452Y or S453A-H452Y variants of 
HA-5HT2AR. Concentration-dependence of 5-HT-induced PLC activation in COS7 
cells transfected with HA-tagged wild-type (!) or S453A (!) variants of the 5-HT2AR 
(a) and H452Y (") or S453A-H452Y (") variants (b). Cells were stimulated with 1-
10,000 nM 5-HT for 180 min. PLC activity is measured as [3H]InsP production. PLC 
responses  of the S453A-H452Y variant of the 5-HT2AR were found to be 
significantly greater than for H452Y variant controls at concentrations 100-10,000 
nM. Significance denoted by * (p<0.05 by Wilcoxon test).  The points plotted 
represent means ± SEM, n = 3. 
b 
a 












Figure 4.11 Concentration-dependence of 5-HT-induced PLC activation in 
COS7 cells co-transfected with H452Y or S453A-H452Y variants of HA-5HT2AR 
and pcDNA3.1 or !-arrestin 2. PLC responses of COS7 cells co-transfected with 
HA-tagged H452Y-5-HT2AR and pcDNA3.1 (!), HA-H452Y-5-HT2AR and !-arrestin 2 
(!), HA-H452Y-S453A-5-HT2AR and pcDNA3.1  (") or HA-H452Y-S453A-5-HT2AR 
and !-arrestin 2 ("). Cells were stimulated with 1-10,000 nM 5-HT for 180 min. PLC 
activity is measured as [3H]InsP production. PLC responses in cells transfected with 
the HA-H452Y-S453A-5-HT2AR variant and !-arrestin 2 were found to be 
significantly less than those in cells co-transfected with the HA-H452Y-S453A-5-
HT2AR and pcDNA3.1 at concentrations 10-10,000 nM. Significance denoted by * 
(p<0.05 by Wilcoxon test).  The points plotted represent means ± SEM, n = 3. 




To determine that the differences in PLC responses observed were not simply a 
consequence of differences in expression of 5-HT2AR variants, COS7 cells were 
transfected with either the wild-type, H452Y, S453A, or H452Y-S453A receptor 
variant and assayed for levels of receptor binding. In a pilot study, specific 5-HT2AR 
ligand-binding was determined by the incubation of membranes from appropriately 
transfected COS7 cells with the selective 5-HT2AR ligand [
3H]ketanserin, in the 
presence/absence of excess mianserin, to define non-specific binding. Table 4.1 
shows total and non-specific binding was at approximately similar levels for each of 
the four receptor variants suggesting that they were likely to be expressed at similar 
numbers of receptors. 
 






























437 ± 51 
 
 
515 ± 42 
 
432 ± 36 
 





198 ± 21 
 
174 ± 20 
 
215 ± 17 
 
178 ± 23 
 
 
Table 4.1 Ligand binding to wild type, H452Y S453A and H452Y-S453A variant 
constructs of the 5-HT2AR. Levels of expression of wild-type, H452Y, S453A and 
H452Y-S453A variant 5-HT2AR were assessed in a pilot study by binding of the 
selective 5-HT2AR ligand [
3H]ketanserin (0.8 nM) in the absence/presence of excess 
10 µM mianserin, to define non-specific binding. Values are means ± SEM, n = 5. 
There were no discernable differences between the receptor constructs in either 
total or non-specific binding. 




4.2.4 5-HT2AR activation of ERK MAP kinase, potentially downstream of arrestins 
Arrestins are well established to act as scaffolds for the components of signalling 
complexes, thereby facilitating the activation of various signalling molecules, 
including ERK 1/2. In a pilot study, we therefore assessed the time-course of 5-HT-
stimulated ERK activation in COS7 cells transfected with either wild-type 5-HT2AR, 
or H452Y-5-HT2AR. Cells were stimulated with 10 µM 5-HT for 0-120 min before 
lysis in Laemmli buffer, separation of proteins by SDS-PAGE and Western blot. 
ERK phosphorylation was subsequently assessed with the use of polyclonal rabbit 
anti-phospho ERK 1/2 antibody (Cell Signalling Technologies) and HRP-linked anti-
rabbit antibody (Cell Signalling Technologies) or polyclonal rabbit anti-pan ERK 1/2 
antibody (Cell Signalling Technology) and HRP-linked anti rabbit antibody (Cell 
Signalling Technologies). In these preliminary findings wild-type-5-HT2AR-mediated 
ERK activation was found to peak at approximately 30-60 min (Figure 4.12a). 
However, H452Y-5-HT2AR-mediated ERK activation appeared to be more robust 
and remained elevated from 10 min up to 120 min following 5-HT addition (Figure 
14.12b). Further work would be required to fully substantiate these preliminary 
findings. 











Figure 4.12 Time-course of 5-HT-induced ERK1/2 phosphorylation by the wild-
type 5-HT2AR and the H452Y-5-HT2AR. COS7 cells were transfected with the wild-
type 5-HT2AR (a) and either wild-type or H452Y-5-HT2AR (b) and stimulated with 10 
µM 5-HT for periods of time between 0-120 min. 1 µM forskolin and 300 nM 
pervanadate were used as positive controls. Proteins were separated by SDS-
PAGE and Western blot and ERK activation assessed with the use of phospho-ERK 
and pan-ERK antibodies.  
b 
a 




4.3 Discussion  
The first indication that there may be some change in the regulation of PLC 
signalling in the H452Y variant of the 5-HT2AR came from experiments on Ca
2+ 
mobilisation in platelets from heterozygous patients in which 5-HT-induced Ca2+ 
responses were attenuated or curtailed (308). These findings were followed up by 
Hazelwood et al, who determined the H452Y-5-HT2AR variant of the receptor to 
exhibit a significantly reduced ability to activate PLC in NIH3T3 cells (309). To 
further investigate the possible underlying basis for this we initially examined the 
time-course of [3H]InsP accumulation in COS7 cells expressing either wild-type-5-
HT2AR or H452Y-5-HT2AR and stimulated with 5-HT. Both receptor types were 
found to demonstrate a delayed time-dependent attenuation of the rate of [3H]InsP 
accumulation at 5-HT incubation times of >140 min. This appears to be generally in 
line with time-dependent desensitisation of PLC activity demonstrated by other class 
A receptors, such as the angiotensin II receptor and the FP prostaglandin F2! 
receptor, have been shown to desensitise between ~ 90 and >120  min ref (462,463). 
However, our current studies showed there to be no discernable differences in the 
time-course of wild-type- or H452Y-5-HT2AR-mediated PLC activation. Thus we 
repeated the assay in C6 glioma cells which endogenously express the 5-HT2AR, and 
have previously been demonstrated to rapidly desensitise following agonist-pre-
incubation (128). Endogenous 5-HT2AR-mediated PLC responses were again found 
to desensitise between ~ 140-180 min and again there were no discernable 
differences in the time-courses of PLC responses mediated by wild-type- or H452Y-
5-HT2AR additionally expressed in these cells (although desensitisation of these 
responses was less marked).  





To more directly assess any early phase of 5-HT-induced desensitisation of phospho-
inositide hydrolysis that may not have been clearly identifiable in the time-course 
assay, we examined wild-type- and H452Y-5-HT2AR-mediated phospho-inositide 
hydrolysis in COS7 cells that had been pre-incubated with 5-HT for periods of up to 
30 min. Again, in contrast to findings in NIH3T3 cells in which the H452Y-5-HT2AR 
demonstrated a significantly altered desensitisation profile to the wild-type-5-HT2AR 
(309), we found that in COS7 cells the H452Y substitution did not appear to confer 
any significant alteration to receptor desensitisation of PLC responses. Hazelwood et 
al described the wild-type-5-HT2AR to exhibit a biphasic mode of desensitisation, 
demonstrating a loss of ~ 40% phospho-inositide hydrolysis with 10 min 5-HT pre-
treatment whereas the H452Y-5-HT2AR desensitised in a monophasic fashion, 
demonstrating a significantly altered loss of only ~ 25% phosphoinostide hydrolysis 
with 10 min 5-HT pre-treatment but apparently being already in a partially 
desensitised state (309). Our results in COS7 cells, however, did not indicate any 
discernable loss of responses following pre-incubation with 5-HT for between 0-30 
min. 5-HT2AR desensitisation has been reported in various cell models, including in 
PS200 hamster fibroblast cells, in which desensitisation was found to occur relatively 
slowly, with an initial loss of ~ 25% [H3]InsP formation by 12 minutes, and an ~ 
50% loss of response by 1 hour (454) and in HEK293 cells stimulated with 
quipazine, in which phospho-inositide hydrolysis was determined to decrease by ~ 
20% at 10 min, ~ 40% at 1 h and ~ 60 % at 240 min of agonist pre-treatment (130). 
Studies examining the endogenous expression of !-arrestins in a variety of cell-types 
determined COS7 cells to express very low levels of endogenous !-arrestin, the 




lowest of all cell-types studied, and HEK293 cells the highest (although Gray et al 
report arrestin-independent 5-HT2AR desensitisation in HEK293 cells) (130)), which 
could be a factor in the differing 5-HT2AR desensitisation profiles (464).  
 
Due to the very low endogenous levels of !-arrestin expression in COS7 cells we 
investigated the possible role of !-arrestin 1/!-arrestin 2 by co-transfecting these 
with wild-type or H452Y-variant 5-HT2AR in order to assess their influence on PLC 
responses. Although !-arrestin 1 had no effect upon wild-type- or H452Y-5-HT2AR-
mediated [3H]InsP production, !-arrestin 2 induced a significant decrease in both 
time-dependent and dose-dependent H452Y-5-HT2AR-mediated PLC responses. It 
was confirmed by Western blot that both arrestin isoforms were being adequately 
expressed. In addition to arrestins preferentially binding particular GPCRs over 
others (465), many GPCRs have been shown to selectively bind specific arrestin 
isoforms, and the arrestin isoform-specificity is thought to be largely dependent on 
C-terminal residues (437,438). Our studies do not demonstrate any isoform-
dependent !-arrestin effect on wild-type-5-HT2AR-mediated [
3H]InsP production, but 
do suggest that the H452Y substitution confers selectivity for the !-arrestin 2 
isoform. To investigate this effect further we assessed the physical interaction of the 
!-arrestin 2 isoform with the receptor. Although previous studies have demonstrated 
an isoform-non-selective binding of arrestins to the 5-HT2ARi3 they did not 
investigate binding to the 5-HT2ARct (186). When using GST-fusion proteins of the 
5-HT2ARi3 and 5-HT2ARct domains, we found that !-arrestin 2 bound with clearly 
much greater affinity to the 5-HT2ARct. Furthermore, GST-fusion proteins of wild-
type- and H452Y-5-HT2ARct were used to compare levels of captured !-arrestin 2 




and identified interaction with the H452Y-5-HT2ARct to be distinctly greater than 
that with wild-type-5-HT2ARct. Attempts to investigate these interactions in a cellular 
setting by co-immunoprecipitation and Western blot were  not successful due to the 
proximity of non-specific IgG bands (~ 50 kDa) to !-arrestin 2 bands (~ 52 kDa), 
thereby obscuring any !-arrestin 2 protein which may have been 
immunoprecipitated.   
 
Thus these data suggest that the presence of the H452Y substitution results in both 
increased !-arrestin 2 binding by the 5-HT2ARct, and the conferment of !-arrestin 2-
dependent “desensitisation” to 5-HT2AR-mediated PLC responses. The H452Y 
polymorphic residue is adjacent to a Ser residue (S453), a potential site for Ser/Thr 
kinases such as GRKs. Putative phosphorylation sites required for desensitisation in 
the wild-type-5-HT2AR were previously determined by sequential mutagenesis of all 
5-HT2AR intracellular Ser/Thr residues, with the finding that only Ser 188 and Ser 
421 were thought to be involved, in HEK293 cells at least (455).  However, the 
consensus targeting sites for GRKs 1, 2 and 3 are thought to often involve 
serine/threonine residues in acidic environments (466), and residues 454 and 455 of 
the 5-HT2AR (adjacent to S453) are both glutamate. We hypothesised that the 
presence of a tyrosine at position 452 in place of the usual histidine makes the 
adjacent serine more susceptible to phosphorylation by Ser/Thr kinases. Single point 
mutagenesis was used to generate S453A 5-HT2AR constructs and assess any 
evidence for a role of this residue in desensitisation/attenuation of PLC signalling by 
!-arrestin 2. The new mutation was not found to affect wild-type-5-HT2AR-mediated 
PLC responses, although it appeared to significantly increase H452Y-5-HT2AR-




mediated PLC activity. Whether this might be due to attenuation of an event 
contributing to endogenous desensitisation of PLC signalling by this receptor variant 
is a possibility, but could not be explicitly proved in the present study. Radio-ligand 
binding showed that the affinity and number of binding sites were very similar 
between the wild-type and H452Y-5-HT2AR (Chapter 3) and that addition of the 
S453A mutation to these did not appear to modify the levels of expression of these 
constructs. However, the addition of !-arrestin 2 resulted in a significant decrease in 
H452Y-S453A-5-HT2AR-mediated PLC activity below control H452Y-S453A-5-
HT2AR responses, suggesting that the increase in H452Y-S453A-5-HT2AR-mediated 
PLC responses in the absence of !-arrestin 2 is not subsequent to the loss of a 
Ser/Thr kinase site which may be a GRK target and a resulting resistance to !-
arrestin 2. These results suggest that increased susceptibility of the H452Y variant 
receptor to !-arrestin 2 is potentially a direct result of the H452Y mutation, as 
opposed to its influence on the putative Ser/Thr kinase target site at residue 453. 
 
!-arrestins are well established to act as scaffolds for MAP kinase signalling 
complexes, thereby facilitating agonist-induced activation of MAP kinases. Thus in 
pilot studies we assessed time-course of 5-HT-induced ERK 1/2 phosphorylation in 
both wild-type- and H452Y-5-HT2AR-expressing COS7 cells. The preliminary 
findings appeared to indicate that H452Y-5-HT2AR-mediated ERK 1/2 
phosphorylation did appear to be both stronger and to occur earlier. This could 
possibly be as a result of increased !-arrestin 2 interactions with the H452Y variant 
receptor, hence increased scaffolding of  MAP kinase signalling components. These 
observations would be consistent with the idea that the H452Y substitution leads not 




only to enhanced binding of  !-arrestin 2 at the receptor, and desensitisation-like 
attenuation of PLC signalling, but may also facilitate arrestin-dependent signalling. 
Extensive further study with a range of techniques; including siRNA knockdown of 
endogenous arrestin isoforms, would be needed to establish and reveal the extent of 
































An independent proteomic study performed in the lab resulted in the identification of 
several previously non-recognised 5-HT2ARct binding partners which have been 
further investigated here. In that study, GST-fusion protein constructs of the 5-
HT2ARct were incubated with rat brain cytosol, and specifically bound proteins were 
separated by SDS-PAGE and identified using Matrix-Assisted Laser 
Desorption/Ionization-Time-Of-Flight (MALDI-TOF) mass spectrometry. Two such 
detected proteins were the Ca2+-binding proteins annexin A2 and S100B.  
 
5.1.1 Annexin family 
Ca2+ binding proteins are classified on the basis of the structure of their Ca2+ binding-
domains, into EF-hand proteins, C2-domain proteins and annexin-related, or type-II 
Ca2+ binding-site proteins (467). The annexin superfamily is sub-categorized into 
family A (vertebrate annexins), family B (invertebrate annexins), family C (fungi 
and unicellular eukaryote annexins), family D (plant annexins) and family E (protist 
annexins) (467,468). The vertebrate annexin family comprises 12 annexin proteins, 
annexins A1-A11 and A13 (469). All vertebrate annexin proteins are composed of a 
conserved C-terminal protease-resistant core, and a divergent amino-terminal region. 
The N-terminus varies widely in both size and amino acid composition and is 
thought to influence function, thereby conferring specificity within the annexin 
family (470). The Ca2+/phospholipid binding C-terminal core domain is composed of 
four 70-75 residue homologous repeats (except in annexin A6, which contains eight) 




(469,471-473).  X-ray crystallographic data suggests that in the case of annexin A2, 
each of the four repeating regions comprises five !-helices that are arranged into 
similar structures (472). Additionally, hydrophobic interactions occur between 
residues of the repeating units and the core domain forms a tightly packed, curved 
disc, to produce what is known as the ‘annexin fold’ (472). The concave side of the 
annexin core, which is orientated away from the membrane, forms interactions with 
the N-terminal domain and cytosolic signalling molecules (471,474). The convex 
side of the disc, which faces the membrane, contains binding sites for actin, 
phosphoinositide and Ca2+ (471,474). The binding of Ca2+ by annexin, creates a 
bridge between the negatively charged carbonyl/carboxyl groups of annexin and 
phosphoryl groups of membrane phospholipids, thereby facilitating the reversible 
association of the annexin core domain at the negatively charged phospholipid 
membrane surface (475). This Ca2+-induced bridging mechanism may facilitate 
further direct annexin-phospholipid interactions that contribute to membrane binding 
(476).  
 
5.1.2 Annexin A2 
Annexin A2 exists both as a soluble monomeric form (annexin A2 ~ 36kDa), and as 
a heterotetramer (annexin A2t ~ 90 kDa), that is composed of two annexin A2 
molecules and a dimer of the annexin binding partner and regulatory subunit 
S100A10 (alternatively known as p11) (477). p11, an 11kDa EF-hand protein, forms 
a Ca2+-independent interaction with the N-terminal region of annexin A2, to form 
this heterotetramer consisting of a central p11 dimer, linked to two annexin 
protomers (478). Formation of annexin A2t enables an increased association of the 




annexin A2 amino-terminus with the membrane, allowing annexin A2 to aggregate 
membranes at micromolar Ca2+ concentrations (467,479).  Annexin monomers and 
complexes are involved in a diverse array of physiological processes, many of which 
are attributed to their ability to bind phospholipids in a Ca2+-dependent manner. 
Annexins typically associate with negatively-charged phospholipids, but annexin A2 
is known to specifically interact with the plasma membrane component 
phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P2) (480,481). The affinity of 
annexin A2 association with the membrane is also reguated by cholesterol and pH; 
annexin A2 can undergo cholesterol-mediated association with endosomal 
membranes in a Ca2+-independent manner (482), and the annexin A2 monomer has 
been demonstrated to form Ca2+-independent plasma membrane interactions at mild 
acidic pH (pH levels 6.6-6.8), whilst at the same pH, annexin A2t appears to undergo 
conformational changes comparable to those induced by Ca2+ (483). Furthermore, 
annexin A2 undergoes modification by both Tyr and Ser/Thr kinases. Nicotine 
stimulation has been demonstrated to promote PKC-mediated annexin A2 
phosphorylation in chromaffin cells(484), and annexin A2 has additionally been 
shown to undergo insulin-triggered tyrosine phosphorylation subsequent to insulin 
receptor activation(485). The latter phosphorylation event has recently been 
demonstrated to be important for promoting Rho/Rho kinase-dependent and actin-
mediated changes in cell morphology (486). Phosphorylation of annexin A2 
regulates its function, reducing its affinity for phospholipids and interfering with the 
ability of annexin A2t to aggregate chromaffin secretory granules at micromolar Ca2+ 
concentrations (487,488).  
 




5.1.3 Annexin A2 in vesicular trafficking 
Annexin A2 is also capable of binding to F-actin and there is strong evidence to 
support the involvement of annexin proteins in intracellular trafficking (489,490). 
Annexin A2t is reportedly required for Ca2+-dependent exocytosis and influences the 
aggregation and fusion of lipid vesicles in chromaffin cells (484,491); it is also 
reported to induce the formation of plasma membrane cholesterol-rich microdomains 
(lipid rafts), essential for exocytosis (492,493). The localisation of annexin A2t 
within plasma membrane lipid rafts that also contain transmembrane receptors such 
as CD44, Src-related kinases and caveolins indicates that annexin A2 may also play 
an important role in the recruitment and arrangement of signal transduction 
components (493,494). Annexin A2t also appears to localize between intracellular 
secretory granules and the plasma membrane in chromaffin cells, and has been 
demonstrated to undergo conformational changes to form cross-links between the 
vesicles and the plasma membrane, following cellular stimulation (495,496). 
Annexin A2 is additionally found to be associated with endosomes within Baby 
Hamster Kidney (BHK) cells  (497). Furthermore, annexin A2t is implicated in the 
recycling of receptor complexes such as the transferrin receptor and the epidermal 
growth factor receptor (EGFR) (498,499), and is demonstrated to be important for 
the uptake of the transferrin receptor via clathrin-coated pits (498). 
 
5.1.4 Trafficking of   ion channels 
Additionally, annexin A2 is known to be involved in modulation of ionotropic 
signalling pathways; it is demonstrated to regulate the functional expression of 
transient receptor potential calcium channels TRPV5 and TRPV6 in kidney and 




intestinal epithelial cells (500,501), the cystic fibrosis transmembrane conductance 
regulator (CFTR) chloride channel in epithelial cells(502), and volume-activated 
chloride currents in vascular endothelial cells (503). Furthermore, the annexin A2 
binding partner p11 is also implicated in the targeting of several ion channels to the 
plasma membrane, including the Nav 1.8 ion channel (504), acid-sensing ion channel 
(ASIC1a channel) (505), as well as TRPV5 and TRPV6, and was recently identified 
to act as a mediator in the upregulation of 5-HT1B receptor movement to the plasma 
membrane surface (506). 
 
5.1.5 Annexin A2 activity at the nucleus 
Monomeric annexin A2 is also capable of localising at, and entering the nucleus. It is 
suggested that monomeric annexin A2 may be involved here together with protein 
kinases, in regulating DNA replication and cellular proliferation (494). Reports have 
suggested that it forms part of a primer recognition complex that increases DNA 
polymerase-! catalytic activity on DNA substrates (507), is able to bind mRNA 
thereby promoting its association with the cytoskeleton and perinuclear localisation 
(508), and has been identified to associate with PKC" undergoing phorbol ester-
induced translocation to the nucleus in NIH3T3 fibroblast cells (509). 
 
5.1.6 S100B 
S100B is a member of the S100/calmodulin/troponin C Ca2+-binding protein 
superfamily. Members of this family are EF-hand proteins, thus they contain a helix-
loop-helix domain, consisting of two !-helices, linked by a short loop region that 
typically binds Ca2+ ions. It has a moleular mass of 21kDa, and exists in various 




forms; as a monomer, as a homodimer linked via disulphide bonds, and as a 
heterodimer attached to the S100A1 protein (510-512). S100B is distributed 
throughout the central and peripheral nervous systems and is primarily produced by 
astrocytes (513). It is implicated in a variety of cellular functions, such as cellular 
communication, growth, signal transduction and energy metabolism (514), but is 
primarily thought to act as a Ca2+ sensor. Following the binding of Ca2+ by the four 
binding sites of the EF hand domain, S100B undergoes a conformational change and 
exposes key residues involved in interactions with various target proteins (515). This 
enables the protein to convey signals to intracellular proteins such as the tumour 
suppressor protein p53 (516), in a Ca2+-dependent manner, (515,517). Furthermore, 
increased levels of S100B have been associated with neurodegenerative disorders 
such as Alzheimer’s Disease (518) and neuropsychological disorders such as 
schizophrenia (519).  






5.2.1 Physical interactions of Ca2+-binding proteins with the 5-HT2AR 
In order to further assess interactions of the 5-HT2AR with annexin A2, COS7 cells 
were co-transfected with HA-5-HT2AR and annexin A2, and the receptor was 
immunoprecipitated in a nominally Ca2+-free environment with anti-HA antibody, or 
non-immune IgG as a control.  Annexin A2 was identified by Western blot analysis 
with anti-annexin A2 rabbit polyclonal (H-50; Santa Cruz) and polyclonal anti-rabbit 
HRP-conjugated antibody (Chemicon).  It is evident from Figure 5.1 that annexin A2 
demonstrates a specific association with the HA tagged-5-HT2AR; annexin A2 pull-
down is illustrated in the bottom panel. In lane 1, annexin A2 immunoreactivity is 
clearly associated with anti-HA antibody-directed immunoprecipitation of the 
receptor, whereas in lane 2, barely detectable quantities of annexin A2 were co-
immunoprecipitated with the control non-immune IgG. 
 
To broadly isolate the region of the receptor that annexin A2 preferentially interacts 
with (Figure 5.2), rat brain cytosol was incubated with GST-fusion proteins of the 5-
HT2ARct or i3 immobilised on glutathione Sepharose-4B matrix. Following exposure 
to brain proteins, the samples were washed and bound proteins were eluted from the 
matrix columns. Annexin A2 was detected and identified by Western blot and 
antibody analysis. Annexin A2 was found to interact strongly with the C-terminal 
construct of the receptor, whereas binding to the i3 construct appeared minimal. In 
both cases the extent of annexin A2 binding was increased in the presence of added 1 
mM Ca2+. This would be consistent with the idea that conformational changes within 




annexin A2 upon Ca2+-binding  may facilitate its binding to the 5-HT2AR, which 
appears to involve predominantly the c-terminal domain of the receptor. 
 











Figure 5.1 Co-immunoprecipitation of annexin A2 with HA-tagged 5-HT2AR. 
Solubilised extracts from COS7 cells co-transfected with annexin A2 and sHA-5-
HT2AR (signal sequence and HA-tagged 5-HT2AR) were co-immunoprecipitated with 
anti-HA antibody or non-immune IgG control and proteins were visualised by 
Western blot and enhanced chemiluminescence. Annexin A2 was found to 
associate specifically with the receptor. 








Figure 5.2 Capture of annexin A2 from rat brain cytosol by GST-fusion 
proteins of the 5-HT2ARct and i3, in the presence and absence of Ca
2+. Annexin 
A2 captured by GST-fusion proteins of 5-HT2AR domains of interest was revealed by 
Western blot and antibody analysis. Annexin A2 was found to associate selectively 
with the c-terminus of the receptor in a Ca2+-facilitated manner (construct ~ 40kDa), 
to a greater extent than the i3 domain (construct ~36 kDa). This figure was provided 
by Derek Robertson.  




5.2.2 Functional influences of Ca2+-binding proteins on 5-HT2AR signalling 
To establish potential functional consequences of 5-HT2AR interactions with annexin 
A2 (and also S100B), the effects of annexin A2 and S100B upon the conventional 
signalling pathway of the 5-HT2A receptor, Gq/11-mediated activation of PLC, were 
investigated in COS7 cells. Figure 5.3a illustrates the effects of annexin A2 and 
S100B expression upon the time-course of 5-HT2AR-mediated PLC responses to 5-
HT.  Annexin A2 was found to evoke an increase in 1 µM 5-HT-induced PLC 
activation which was statistically significant over a time-period of 100-180 min, to 
approximately 6-fold of basal at 180 min. This represents an increase of 
approximately 33% in maximal PLC responses at 180 min compared to control 
responses, which were approximately 4-fold over basal. Conversely, expression of 
S100B did not cause any discernable changes in PLC responses, with the maximal 
response to 5-HT at 180 min being within 5% of the control response.  The influence 
of annexin A2 upon PLC responses was further investigated in the presence of the 
annexin A2 regulatory subunit p11 (Figure 5.3b).  Again, expression of annexin A2 
induced a significant increase in 5-HT-induced PLC responses compared to control 
(at 100-180 min). However, co-expression of p11 with annexin A2 did not induce 
any further increase in PLC activity; in fact, PLC responses appeared slightly (but 
not significantly) reduced, with maximal PLC responses at 180 min reaching 
approximately 5.75-fold of basal responses, compared to approximately 6.4-fold of 
basal PLC activity seen with annexin A2 plus empty vector. Furthermore, 
transfection of COS7 cells with p11 plus empty vector did not induce any 
discernable increase in PLC responses over control, with maximal PLC responses at 
180 min of approximately 4.85- and 4.72-fold of basal, respectively. 








Figure 5.3 Effects of annexin A2, S100B and p11 on the time course of 5-HT 
PLC activation in COS7 cells transfected with 5-HT2AR. PLC activation  
responses elicited by  1 µM 5-HT were measured by [3H] labelled inositol phosphate 
production. a. Cells were additionally transfected with empty pcDNA3.1 vector (!), as 
control,  annexin A2 (!), or S100B ("). Annexin A2, but not S100B caused a 
significant upregulation of the 5-HT2AR time-dependent signalling response. b. Cells 
were transfected with empty pcDNA3.1 vector (!), as control,  annexin A2 and 
pcDNA3.1 (!), annexin A2 and p11 ("), or p11 and pcDNA3.1 (!). p11 failed to 
elevate PLC responses above control and co-transfection of S100A10 with annexin 
A2 did not induce any further increase in PLC responses than that evident with 









Further experiments were also carried out in order to evaluate any effects of the Ca2+-
binding proteins on the concentration-dependence of 5-HT2AR-mediated PLC 
activation. COS7 cells overexpressing control pcDNA3 vector, annexin A2 (Figure 
5.4a), or S100B (Figure 5.4b) were stimulated with increasing concentrations of 5-
HT, from 1 nM - 10,000 nM for 30 min, and PLC responses measured (Figure 5.4a). 
Annexin A2-expressing COS7 cells demonstrated an increase in the amplitude of the 
5-HT concentration-response curve. Levels of PLC activity at 5-HT concentrations 1 
nM – 10,000 nM in annexin A2 cells were found to be significantly increased above 
control (p<0.001 by Wilcoxon test in each case). The EC50 for 5-HT in 5-HT2AR plus 
pcDNA3 cells was 4.41 nM ± 1.36 nM, which was slightly, but not significantly, 
decreased to 2.02 nM ± 0.92 nM with the addition of annexin A2, in the 5-HT2AR 
plus annexin A2-transfected cells. However, the Emax of 5-HT2AR plus annexin A2 
cells was found to be significantly higher, at 3.49 ± 0.18 (fold of basal) than that 
demonstrated by control cells, at 2.37 ± 0.11 (p<0.001 by Wilcoxon test). In contrast, 
Figure 5.4b shows that S100B-expressing cells did not appear to demonstrate any  
upregulation of PLC responses. There were no significant changes to either EC50 
values, or Emax, which were 4.73 nM ± 1.40 nM and 6.90 nM ± 1.70 nM, or 2.93 ± 
0.15 and 3.04 ± 0.23 fold of basal, respectively. 









Figure 5.4 Effect of annexin A2 and S100B on the concentration-dependence 
of 5-HT-induced PLC activation in COS7 cells transfected with the 5-HT2AR. 
Responses were measured by [3H] labeled inositol phosphate production over 30 
min. The cells were transfected with the 5-HT2AR and either empty vector as control 
(!), annexin A2 (!) (Figure 5.4a), or S100B (") (figure 5.4b). Annexin A2 caused a 
significant upregulation of the 5-HT2AR signalling response with asterisks denoting 
significance (! p <0.001, Wilcoxon test). S100B had no discernable effect on the 








5.2.3 Interaction between annexin A2 and arrestin - influences on 5-HT2AR 
signalling  
In Chapter 4 it was shown that !-arrestin 2 expression consistently attenuated 5-HT-
induced PLC activation mediated by the H452Y-5-HT2AR, although such an effect 
was not detectable with the wild-type-5-HT2AR. The enabled influence of !-arrestin 
2 in the H452Y variant would be consistent with the idea that !-arrestin 2 may 
interact with the receptor domain. As the c-terminal domain is also the site of 
interaction of annexin A2, experiments were carried out to investigate whether there 
was any functional interaction between the influence of annexin A2 and !-arrestin 2  
on PLC responses of the H452Y-5-HT2AR. COS7 cells were triple-transfected with a 
complement of H452Y-5-HT2AR and either double quantities of pcDNA3.1, 
pcDNA3.1 plus annexin A2, pcDNA3.1  plus !-arrestin 2, or annexin A2 plus !-
arrestin 2, and assessed for PLC responses upon stimulation with 3 µM 5-HT for 180 
min (Figure 5.5). The H452Y-5-HT2AR-mediated PLC activity of annexin A2 plus 
pcDNA3.1-expressing cells was found to be significantly greater than control cells, 
with mean [
3
H]InsP production (dpm/assay) in response to 5-HT reaching 1322 ± 58, 
as opposed to 1012 ± 66 for control cells. Expression of !-arrestin 2 resulted in a 
significant reduction of 5-HT-induced PLC responses to 806 ± 72 (dpm/assay). 
However, cells expressing receptor, !-arrestin 2  and annexin A2 were still found to 
yield significantly elevated 5-HT-induced PLC responses with [
3
H]InsP production 
activity reaching 1214 ± 54 (dpm/assay) (p <0.05, in each case). The apparent ability 
of annexin A2 to abrogate the inhibitory influence of !-arrestin 2 on signalling by the 
H452Y-5-HT2AR would be consistent with the idea that annexin A2 binding to the 
receptor c-terminal domain may prevent the docking of !-arrestin 2. Interestingly 




this would appear to represent a secondary level modulatory influence on signalling 
that further distinguishes the H452Y variant from the wild-type receptor, but time 
was not available to extend the investigation. 








Figure 5.5 5-HT-stimulated PLC responses of COS7 cells co-transfected with 
the H452Y-5-HT2AR and complements of annexin A2, !-arrestin 2 and 
pcDNA3.1. Bar graph illustrating H452Y-5-HT2AR-mediated PLC responses of COS7 
cells triple-transfected with H452Y-5-HT2AR and double quantities of pcDNA3.1, or 
pcDNA3.1 plus annexin A2, pcDNA3.1  plus !-arrestin 2, or annexin A2 plus !-arrestin 
2, and stimulated with 3 µM 5-HT for 180 min. Annexin A2 plus pcDNA3.1 cells 
demonstrated significantly greater PLC responses than control cells, denoted by (" 
p <0.05, unpaired t-test)  and !-arrestin 2 plus pcDNA3.1 cells demonstrated 
significantly decreased PLC responses compared to control cells, denoted by (! p 
<0.05, unpaired t-test). However, annexin A2 and !-arrestin 2 PLC responses were 
still significantly greater than control, denoted by (" p <0.05, unpaired t-test). All 
values are the mean ± SEM for n = 4 measurements. 






Previous work in the laboratory suggested that annexin A2 physically associates with 
the c-terminal region of the 5-HT2AR. In the current series of experiments, co-
immunoprecipitation studies clearly demonstrated an association with the receptor 
and this was confirmed by results from GST-fusion protein experiments that suggest 
that the interaction site (which may or may not involve other proteins) was in the c-
terminal domain of the receptor. Another Ca2+-binding protein, calmodulin, has been 
identified to bind both the 5-HT2ARi2 and the 5-HT2ARct between residues 378 to 
395, which are positioned close to tm7 and the NPxxY domain (520). It is possible 
that annexin A2 may bind to a similar region of the receptor ct. The exact annexin 
A2 binding site could be further investigated with the expression of the 5-HT2AR 
serially truncated or mutated at the suspected annexin interaction site, and observing 
the effect on the physical associations and signalling responses of the receptor.  
 
When experiments were carried out to explore any functional impact of this 
interaction, annexin A2 was demonstrated to act as a novel modulator of  5-HT2AR-
mediated PLC activation. However, neither S100B, a further calcium-binding protein 
found to interact with the 5-HT2Act, or the annexin A2 binding subunit, p11, induced 
a similar modulation of 5-HT-induced PLC activation. Evidence for an extensive role 
of annexin A2 and p11 within cellular trafficking (480), provides support for a 
putative similar role in the transport of the 5-HT2AR, which could explain the 
increase in 5-HT-induced signalling that was seen. It is thus possible that annexin A2 
could facilitate the expression of the receptor at the plasma membrane, potentially 
either by anchoring the receptor at the appropriate plasma membrane microdomain or 




alternatively, by acting as a chaperone and increasing the delivery of the receptor 
from the endoplasmic reticulum to the plasma membrane. A subsequent increase in 
plasma membrane 5-HT2AR expression would thus result in increased 5-HT2AR-
mediated signalling, such as an enhancement of PLC activation. However, unlike the 
present findings, previous studies have determined annexin A2 involvement in 
receptor membrane targeting and trafficking to be p11-dependent, or to involve the 
heterotetrameric form of annexin A2 bound to p11 (484,493). The apparent p11-
independent annexin A2-mediated increase in PLC signalling could be explained by 
a reliance upon endogenous levels of p11. If basal p11 levels were sufficient for 
hetero-tetramer formation, the further addition of p11 may not induce any further 
facilitation of signalling.  
 
It is also possible that annexin A2 might promote allosteric modulation of the 5-
HT2AR, thereby inducing a more active receptor conformation.   For instance, the 
direct interaction of annexin A2 with the receptor could induce conformational 
changes that improve receptor and Gq/11 coupling, thereby increasing the efficiency 
of functional receptors at the membrane. A further possibility is that annexin A2 
could function as a scaffold for the necessary protagonists of 5-HT2AR-mediated PLC 
activation: annexin A2t has previously been suggested to act as a scaffold for the 
CD44 receptor and various signal transduction components when localised within 
lipid rafts (493). Additionally, annexin A6, which is not a PKC! phosphorylation 
target (467), has been found to associate with PKC! following PKC! activation and 
subsequent translocation to lipid raft microdomains (521,522), forming a basis for 
the hypothesis that annexin A6 may function as a scaffold for PKC (467). 




Furthermore, PSD-95, a PDZ-domain binding protein that interacts with the 5-
HT2ARct, has been shown to increase 5-HT2AR-mediated PLC signalling, reportedly 
by acting as a scaffold to organise the necessary components of the PLC signalling 
pathway, thereby increasing PLC activity (191). Thus it could be conjectured that by 
acting in a similar manner, annexin A2/A2t could cause an increase in 5-HT2AR-
mediated PLC signal transduction.      
 
As previously mentioned, calmodulin is known to associate with residues 378-395 of 
the 5-HT2ARct. Within this region is both a putative PKC target motif (
384NKTYR388) 
(520), and the (376NPxxY380) motif, which as well as being involved in PLD 
signalling is known to act as an internalisation sequence for many class A GPCRs 
(47,374,523). It is theoretically possible that association of annexin A2 with the 
former motif could interfere with PKC association with the receptor, thereby 
inhibiting PKC-mediated 5-HT2AR phosphorylation and subsequent desensitisation. 
Such a mechanism could allow for the increased expression of active receptors at the 
plasma membrane surface.  However, annexin A2 appears to increase 5-HT-induced 
PLC responses at low agonist concentrations, at which point it may be less likely that 
desensitisation would be playing a major role. The binding of annexin A2 to the 5-
HT2ARct could also theoretically act to hinder NPxxY-dependent internalisation. 
Although the mechanism by which various GPCRs are dependent upon this motif for 
efficient internalisation is not yet fully understood, interruption of the sequence by 
point mutagenesis has been demonstrated to inhibit internalisation (47,523). Thus, 
shielding of these residues could potentially result in an increase of receptor 
population at the cell surface. As previously mentioned, the NPxxY motif has 




previously been demonstrated to be involved in ARF-mediated activation of PLD 
(274), thus it would also be of interest to investigate any possible effects of annexin 
A2 on receptor mediated-PLD responses. 
 
Recent studies demonstrated that p11 acts to chaperone the translocation of the 5-
HT1B receptor to the plasma membrane (506). It was also noted that levels of p11 in 
rodent brain are increased following administration of antidepressants, and decreased 
in both animal models of depression and in brain tissues taken from patients 
suffering from depression (506). Furthermore, p11 knockout mice were found to 
exhibit depression-like behaviour, and following the induction of p11 overexpression 
in mice, specific behaviours were noted that mimicked those seen following 
treatment with antidepressants (506). The p11 partner annexin A2 is known to exist 
within lipid raft fractions of both the hippocampus and the cerebral cortex of rat 
brain and is putatively involved in learning processes (524). Additionally, as 
previously discussed, 5-HT2AR activity is also strongly implicated in a wide range of 
neuropsychiatric disorders. Thus, it is possible that the increase in 5-HT2AR-mediated 
PLC signalling seen with the addition of annexin A2 could have biological 
significance to psychotropic roles within the CNS. Annexin A2 is additionally 
expressed in high levels within lung, intestine, kidney, muscle, epithelial and 
fibroblast cells (525), and the 5-HT2AR is known to be expressed in various 
peripheral regions, including platelets where it induces aggregation and smooth 
muscle where it promotes contraction (168), thus annexin A2-5-HT2AR interactions 
could also be of importance within peripheral systems. 
 




In experiments to investigate the functional interaction of two putative c-terminal 
domain interacting proteins we found that annexin A2 can abrogate the inhibitory 
effect of  !-arrestin 2 on PLC signalling at the H452Y variant receptor (where the 
influence of !-arrestin 2 is more marked compared to the wild-type receptor). This 
suggests that annexin A2 docking to the receptor may intefere with arrestin-mediated 
processes such as desensitisation and internalisation (at the H452Y variant at least) 
and may be consistent with an interaction, at least in part, with a more distal region 
of the c-terminal domain. These observations suggest that association of the Ca2+-
binding protein annexin A2 with the 5-HT2AR may have functional relevance not 
only to its signalling abilities but also to its secondary level modulation by other 
proteins such as arrestins. Furthermore it appears that the H452Y variant form of the 
5-HT2AR may differ in its susceptibility to some of these influences compared to the 





























6.0 Final Discussion 
 
The 5-HT2AR is widely implicated to be involved in a range of psychiatric disorders, 
including bipolar disorder (306), obsessive compulsive disorder (526), alcoholism 
(304), personality disorders (527) and schizophrenia (172). Psychiatric disorders 
such as schizophrenia can not only be severely disabling for the individual, but also 
profoundly affect associated family and friends, and present a significant impact 
upon society and the economy. Treatment for schizophrenia is often open-ended: the 
majority of sufferers continue to be affected throughout their lives, and face the 
likelihood of chronic unwanted side-effects associated with ongoing pharmacological 
treatment. A multi-factorial disease-state such as schizophrenia is so complex in 
terms of its etiology that it is very difficult to target specifically and effectively. It is 
therefore very important to study the pharmacological and biochemical mechanisms 
of any associated signalling pathways, in an attempt to develop a more sophisticated 
model of this disease process and its treatment. Thus this thesis has focussed on 
signalling by the 5-HT2AR and the impact of an H452Y receptor polymorphism, 
exploring downstream PLD activity, desensitisation of PLC responses and the effects 
of Ca2+-binding proteins. 
 
5-HT2AR-mediated PLD activation has not been widely studied in comparison to the 
more conventional signalling pathways, thus we were able to identify some 
fundamental determinants of 5-HT2AR-mediated PLD activity in COS7 cells. We 
employed co-immunoprecipitation and functional PLD assay to identify PLD1 as the 
active isoform, and determined the activation of PLD1 by the 5-HT2AR to be 




primarily ARF-mediated. Due to the potentially cell-specific nature of 5-HT2AR-
mediated PLD activation, it would be of interest to perform parallel studies in 
alternative cell-types to elucidate whether this is a typical pattern of PLD activity 
downstream of the 5-HT2AR.  We further determined the probable locus of PLD1 
binding to be between residues 438 and 471 within the distal region of the receptor 
C-terminus, distinct to the ARF1 binding site at the beginning of the C-terminus. The 
agonist-stimulated activation of the 5-HT2AR is known to be swiftly followed by the 
recruitment of ARF1 to the 5-HT2ARct (274) and, as presented in this thesis by the 
time-course of 5-HT-stimulated co-immunoprecipitation of PLD1 with the PrC-5-
HT2AR, we found that PLD1 was likely to be associated with the receptor prior to 
agonist-stimulation. Thus a likely model of ARF-mediated PLD activation would be 
the direct association of ARF1 with PLD1 following the recruitment of ARF1 to the 
receptor. This could be facilitated by conformational changes of the receptor 
bringing ARF1 and PLD1 into contact, the dissociation of activated ARF1 from the 
receptor and its subsequent association with PLD1 or, alternatively, despite binding 
at a site in the distal regions of the receptor, PLD1 could overlap the ARF1 binding 
region, thus ARF1 and PLD1 could interact upon the recruitment of ARF1 to the 
receptor. An appropriate extension of these studies would be to analyse the time-
course of agonist-induced ARF1 and PLD1 association at the receptor with the use of 
fluorescence techniques such as fluorescence resonance energy transfer (FRET).   
 
PLD activation was then investigated downstream of a physiologically relevant 
H452Y polymorphic variant of the receptor, and compared to wild-type 5-HT2AR-
mediated PLD activation. The H452Y polymorphic variant was found to evoke a 




significantly decreased facilitation of PLD1 responses and association with the 5-
HT2ARct. As previously discussed, the H452Y polymorphism is associated with a 
resistance to the atypical antipsychotic clozapine (301), as well as with bipolar 
disorder (306), ADHD (305) and poor memory (307). Clozapine acts as an 
anatognist of 5-HT2AR signalling, thus it would be of particular interest to explore the 
effects of clozapine upon 5-HT-induced PLD1 activation downstream of both 
receptor variants. A pertinent extension of these studies would involve the 
pharmacological assessment of a further range of atypical antipsychotics, such as 
risperidone, olanzapine and ziprasidone, upon 5-HT2AR-mediated PLD1 activation 
and any effects of the H452Y polymorphism.   
 
The influence of the H452Y polymorphism was further explored with regard to 5-
HT2AR-mediated PLC activity. There did not be appear to be any discernable 
alteration of 5-HT-induced PLC responses as a result of the introduction of the 
H452Y polymorphism to the 5-HT2AR. However, in the presence of !-arrestin 2, 
H452Y-5-HT2AR-mediated PLC responses were significantly reduced below that of 
the wild-type receptor. Furthermore, GST-fusion protein studies revealed a 
substantial increase in !-arrestin 2 binding by the H452Y variant receptor when 
compared to wild-type. !-arrestin isoforms are now well-accepted to independently 
facilitate G protein-independent signalling, by acting as scaffolds of multi-signalling 
protein complexes (135). One well-studied consequence of !-arrestin-dependent 
signalling is the phosphorylation and subsequent activation of Map kinases, such as 
ERK1/2 (137). We explored the hypothesis that the increased binding of !-arrestin 2 
seen with the H452Y-5-HT2AR might also result in changes to potential 5-HT2AR-




mediated G protein-independent ERK1/2 activation. Preliminary studies suggest that 
5-HT-induced ERK1/2 phosphorylation is increased as a consequence of the H452Y 
polymorphism. The recent discovery that ‘biased ligands’ can act as differential 
activators of !-arrestin or G protein signalling (528,529), to selectively favour the 
activation of one pathway over the other, has generated further possibilities for the 
pharmacological targeting of certain GPCRs. Thus, it would be of much interest to 
further investigate H452Y- and wild-type 5-HT2AR-mediated ERK1/2 
phosphorylation in the presence of a greater array of ligands including, as discussed 
above, clozapine and a further range of atypical antipsychotics. To further 
substantiate the impact of !-arrestin 2 on both H452Y-5-HT2AR-mediated PLC 
responses and ERK1/2 phosphorylation, it would be appropriate to knock down any 
endogenous arrestin using siRNA and evaluate any difference in PLC and ERK1/2 
responses. A relatively new technique that could be utilized to quantify the agonist-
induced recruitment of !-arrestin to both receptor variants involves using receptor 
and !-arrestin isoforms complementarily tagged with R-luc and YFP, which allows a 
BRET signal to be calculated following the recruitment of !-arrestin to within a 
100Å distance of the receptor.   
 
Finally, this thesis illustrates the ability of the Ca2+-binding protein, annexin, to 
increase the facilitation of 5-HT2AR-mediated PLC responses. To investigate further, 
it would be appropriate to explore the effects of annexin on the trafficking of the 
receptor to the cell surface. Various techniques could be employed to study this, 
including the quantification of membrane-expressed receptor by radioligand-binding 
studies, and protein localisation studies using confocal/fluorescent microscopy. 





In conclusion, this thesis presents new insights into the signalling mechanisms of the 
5-HT2AR and its H452Y receptor variant, that are of potential value to the further 
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